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Abstract 
Juan Antonio Jiménez 
 
ANTI-TUMOR AND RADIO-SENSITIZING PROPERTIES OF AD-IU2, A PROSTATE-
SPECIFIC REPLICATION-COMPETENT ADENOVIRUS ARMED WITH TRAIL 
 
 In this thesis, I investigated the preclinical utility and antitumor efficacy of 
TRAIL delivered by Ad-IU2, a prostate-specific replication-competent adenovirus 
(PSRCA), against androgen-independent prostate cancer.  Through 
transcriptional control of adenoviral early genes E1a, E1b and E4, as well as 
TRAIL by two bidirectional prostate-specific enhancing sequences (PSES), 
expression of TRAIL as well as adenoviral replication was limited to prostate-
specific antigen and prostate-specific membrane antigen (PSA/PSMA)-
expressing cells.  Ad-IU2 replicated efficiently in and was restricted to 
PSA/PSMA-positive prostate cancer cells and induced 5-fold greater apoptosis in 
androgen-independent CWR22rv and C4-2 prostate cancer cells than the 
PSRCA control not expressing TRAIL.  Ad-IU2 exhibited superior killing efficiency 
in PSA/PSMA-positive prostate cancer cells at doses 5 to 8-fold lower than that 
required by a non-TRAIL expressing PSRCA to produce a similar effect.  This 
enhanced cytotoxic effect was not observed in non-prostatic cells, however.  As 
an enhancement of its therapeutic efficacy, Ad-IU2 exerted a bystander effect 
through either direct cell-to-cell contact or soluble factors present in conditioned 
media from Ad-IU2-infected cells.  In vivo, Ad-IU2, as compared to a control 
PSRCA, markedly suppressed the growth of subcutaneous CWR22rv xenografts 
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at six weeks post-treatment (3.1 vs. 17.1-fold growth of tumor).  The treatment of 
androgen-independent prostate cancer with Ad-IU2 prior to external beam 
radiation therapy (EBRT) significantly reduced clonogenic survival with dose 
reduction factors of 4.91 and 2.43 for CWR22rv and C4-2 cells, respectively.  
Radio-sensitization by Ad-IU2 was restricted to PSA/PSMA-positive cells.  
Combinatorial radio-gene therapy resulted in accumulation of cells in G1 phase 
and a perturbation of the radiation-induced G2 phase arrest.  This multi-modal 
approach combining viral lysis, apoptosis-inducing gene therapy, and radiation 
therapy could have great impact in achieving complete local tumor control while 
reducing radiation dose and associated treatment morbidities.  This would result 
in improvement of the clinical outcome of patients with high risk prostate cancer.  
 
 
Thomas A. Gardner, M.D., Chair   
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Introduction 
 
Clinical Significance of Prostate Cancer 
In 2008, it is estimated that prostate cancer will account for the most new cancer 
diagnoses, aside from skin cancer, at 186,320 men in the United States and will be the 
second most common cause of cancer-specific mortality at 28,660 men.  The incidence 
of locally advanced or high risk prostate cancer has decreased since the advent of 
prostate-specific antigen (PSA) screening; however 9% of newly diagnosed men will 
present initially with locally advanced or metastatic disease (1).  For American men, the 
overall lifetime risk of developing clinically-detectable prostate cancer is 1 in 6; however, 
post-mortem examination of men above the age of 80 reveals a prevalence of greater 
than 80%, indicating that most men die with the disease rather than of prostate cancer.  
In addition, microscopic foci of disease can be found incidentally in surgical specimens 
from transurethral resections of the prostate for benign prostatic hyperplasia (BPH); 
however, approximately 90% of these lesions remain sub-clinical throughout the entire 
lifetime of the patient (2).  The hallmarks of this disease include an initially indolent and 
multi-focal cancer, temporary response to androgen depletion by growth suppression 
and apoptosis, development of androgen-independent tumors and distant metastasis to 
bone in late stages of the disease, resulting in the demise of the patient. 
Significant risk factors for developing prostate cancer include age, race and 
family history.  Prostate cancer is rare in men below the age of 50, with an incidence of 
only 1%.  The risk of developing cancer of the prostate increases with advancing age, 
from 20% in men in their fifties to 70% in men in their seventies (3).  Drastic differences 
in incidence occur among men of different races as well.  Men of Asian descent in China 
and Japan have an age-adjusted incidence of 2 and 9 per 100,000, respectively, 
compared to 101 for whites in the United States.  The greatest risk of developing 
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prostate cancer and disease-specific mortality is among African-Americans, with an age-
adjusted incidence of 137 per 100,000 (4).  Interestingly, when Japanese men immigrate 
to the United States, their incidence of prostate cancer increases; however, not to the 
extent of Caucasian-American men, implicating a role for environmental and lifestyle 
factors.  For example, obesity is associated with higher grade prostate cancer and local 
or biochemical recurrence following radical prostatectomy (5, 6).  Furthermore, a study 
involving 46,786 men found that higher caloric intake was associated with increased risk 
of metastatic prostate cancer and mortality, especially in young men and men with a 
family history of prostate cancer (7).  Higher risk of advanced prostate cancer was also 
associated with diets high in red meat, saturated fats, dairy products and beer (8-11).  
Heredity plays a major role in determining risk for the development of prostate cancer.  
Nearly 10% of cases world-wide are attributable to inheritance, while the remainder 
appear to be sporadic and influenced by other factors (12).  Several autosomal dominant 
and X-linked alleles have been identified through segregation analysis and linked to 
prostate cancer risk. The best described susceptibility locus, hereditary prostate cancer 
(HPC1) is found on the chromosomal region 1q24-25 (13).  Polymorphic variations of the 
gene encoding the androgen receptor (AR), specifically polyglutamic repeats (CAG), 
have been described in which the length of the repeat is inversely proportional to AR 
transcriptional activity (14, 15).  Finally, certain polymorphisms of SRD5A2, the gene that 
encodes 5-α-reductase-2 which is responsible for activating androgens within the 
prostate, have been shown to have increased enzymatic activity and linked to a 2-fold 
increase in risk of prostate cancer and disease progression (16). 
The majority of cases of adenocarcinoma of the prostate develop in the 
peripheral zone, along the posterior aspect of the prostate, which is palpable on digital 
rectal examination.  Spread of the disease occurs by local extension beyond the capsule 
into the seminal vesicles or the bladder neck.  Hematogenous spread occurs primarily as 
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osteoblastic lesions to the lumbar spine, femur and pelvis, although dissemination 
occurs rarely to other organs, including the lungs and brain.  Lymphatic spread often 
precedes osseous metastases and occurs initially in the obturator fossa.  Grading of 
prostatic tumors is critical, as a correlation exists between high Gleason score and poor 
prognosis (17).  Tumors are graded on the basis of glandular pattern and differentiation 
under low-power magnification and are given a score of 1 for well differentiated glands 
or 5 for poor differentiation.  Because prostatic adenocarcinoma is heterogeneous and 
multi-focal, the Gleason score is comprised of the sum of the primary and secondary 
patterns observed.  Tumor staging is classified using the TNM system where T 
represents the size of the primary tumor, N represents spread to lymph nodes, and M 
represents evidence of metastatic spread.  T stage ranges from 1 for tumors that cannot 
be palpated and are incidental findings to 4 for tumors that have spread to adjacent 
tissues beyond the seminal vesicles.  Elevation of PSA can occur with cancer of the 
prostate; however, this is not a cancer-specific marker, and other conditions such as 
prostatitis and benign prostatic hyperplasia (BPH) can also elevate this serum marker.  
Of greater prognostic utility is PSA velocity (rate of change in serum PSA values with 
respect to time), which predicts the aggressiveness of the cancer (18), and PSA 
doubling time, which is the best surrogate marker for survival in metastatic disease (19).  
Historically, the extent of disease was established on clinical staging alone; 
however, because most prostate cancer diagnosed today is nonpalpable, more 
quantitative tests are performed to characterize tumors as low, intermediate or high risk 
of treatment failure.  High risk stratification criteria include patients with a single 
parameter of cT3 disease, Gleason score >7, baseline PSA >20 ng/ml or pretreatment 
PSA velocity >2 ng/ml per year (20).  Although these criteria aid in clinical decision 
making for the urologist, the management of prostate cancer remains challenging given 
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the fact that as many as 15% of men with prostate cancer-specific mortality (PCSM) 
initially may have had low risk prognostic factors (21).       
 
Molecular Pathogenesis of Prostate Cancer 
 Most prostate cancers are sporadic in nature and result from numerous somatic 
mutations, DNA hypermethylations, chromosomal rearrangements and gene 
amplifications.  Accumulation of genomic insults is responsible for progression from 
normal prostatic epithelium to high-grade prostatic intraepithelial neoplasia (PIN) to 
malignancy, as outlined in Figure 1.  Inflammation plays an early role in the development 
of prostate cancer, especially high-grade PIN (22), and the reactive oxygen species 
 
 
Figure 1.  Molecular 
pathogenosis and 
progression of prostate 
cancer.  As with most 
cancers, a prostate 
epithelial cell must 
receive several genetic 
mutations before it 
becomes cancerous, 
which is often preceded 
by a condition called 
prostatic      intraepithelial 
neoplasia (PIN).  Aditional mutations are required for a tumor to metastasize and 
become hormone refractory. 
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produced by inflammatory cells cause both cellular and genomic damage.  Glutathione 
S-transferase (GST) is an enzyme produced within the prostate that protects cells 
against oxidative DNA damage (23), and this house-keeping gene is inactivated in 
greater than 90% of cases of PIN and tumors of the prostate by hypermethylation of 
CpG islands within the promoter region of GSTP1 (24, 25).  Loss of chromosome 8p21, 
and specifically loss of the tumor suppressor gene NKX3.1, occurs early during the 
progression from high-grade PIN to prostate cancer.  This prostate-specific homeobox 
gene is essential for normal prostate development (26) and represses activity of the PSA 
promoter (27).  Haploinsufficiency of NKX3.1 appears to be correlated to progression of 
disease, as one study found NKX3.1 expression to be absent in 20% of PIN lesions, 6% 
of T1a/b tumors, 22% of T3/4 samples, 34% of androgen-independent tumors and 78% 
of cancer metastases (28).  Recently, chromosomal translocations and gene fusions 
have been identified involving ETV1 (7p21.2) and ERG (21q22.3), two members of the 
erythroblastosis virus E26 transforming sequence (ETS) family of transcription factors, 
and the 5’ untranslated region of the prostate-specific transmembrane protease serine 2 
(TMPRSS2, 21q22.2) (29).   TMPRSS2:ETS fusions act as oncogenes, and because 
TMPRSS2 is induced by androgen stimulation, ETS genes are overexpressed in 
prostate cancer, resulting in the progression from PIN and the ability to invade (30).  
Another tumor suppressor associated with cancer progression is phosphatase and 
tensin homologue (PTEN), whose somatic mutation was correlated with high grade and 
stage of prostate cancer (31) and particularly with metastatic disease (32). 
Finally, systemic disease is usually treated with androgen deprivation therapy 
(ADT); however, despite an early response, most advanced tumors will progress to a 
hormone-refractory state where cell proliferation occurs in the absence of androgens.  
This occurs through somatic mutations in the gene for AR.  Gene amplification allows 
overexpression of AR, and thereby enhances the sensitivity of tumor cells to lower levels 
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of circulating androgens (33).  Also, somatic mutations within the ligand-binding domain 
of AR allow constitutive activation or activation by estrogens and anti-androgens (34-36).  
Treatment of androgen-independent metastatic prostate cancer remains challenging and 
ultimately leads to poor outcomes. 
 
Current Therapy for Locally Advanced Prostate Cancer 
In two large clinical studies, despite definitive treatment with radical 
prostatectomy, at least 56% of patients with cT3 disease experienced biochemical 
disease recurrence at 10 years, with the development of local and systemic disease 
recurrence in 27% of patients (37, 38).  In a study evaluating the benefit of postoperative 
irradiation, the addition of adjuvant external beam radiation therapy (EBRT) significantly 
decreased biochemical failure at 5 years to 26% vs. 47.4% compared to the surgery 
alone group, and the rate of local failure decreased from 19% to 8.8%; however, 
because follow-up was only for 5 years, no impact was observed on the rate of distant 
metastasis formation or PCSM (39).  Given that prostate cancer is dependent on 
activated androgens and the AR for growth (40), adjuvant androgen deprivation therapy 
(ADT) is well established as standard of care for high risk prostate cancer to slow the 
growth and dissemination of undetectable residual cancer cells at local or distant sites.  
Primary hormonal therapy involves surgical castration or medical castration with 
gonadotropin-releasing hormone (GnRH) agonists such as leuprolide and AR 
antagonists such as bicalutamide.  Nearly all advanced prostate cancers will become 
hormone refractory within 14 to 20 months of initiating ADT (41, 42), and secondary 
hormonal therapy with ketoconazole and GnRH antagonists such as abarelix merely 
provide palliation without survival benefit for this fatal disease phenotype.  Most patients 
die within 3 to 5 years of developing osseous metastases.  While there is a pressing 
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need to develop better systemic therapies to treat or prevent disseminated disease, 
there also exists an urgent need to develop more effective local treatment modalities. 
EBRT for prostate cancer can take the form of electromagnetic (X-ray) or particle 
(proton) beams focused directly onto the patient’s tumor.  Regardless of the mode of 
EBRT, its therapeutic effect may occur directly from ionization of DNA resulting in lethal 
strand breakage or indirectly from the interaction between the oxygen radical species 
produced and DNA or a perturbation of cellular homeostasis regulators which are 
responsible for control of the cell cycle, DNA repair and apoptosis (43).  EBRT can be 
prescribed as definitive treatment for advanced prostate cancer, where a 70 to 80 Gy 
total dose is administered to the prostate, seminal vesicles and pelvic lymph nodes in 
1.8 to 2 Gy fractions, or as palliative treatment of vertebral osseous metastases that 
compress the spinal cord, where a 30 Gy total dose is administered in 3 Gy fractions 
(44).  Multiple clinical studies have demonstrated that tumor eradication is directly 
proportional to the dose of radiation given.  Hanks et al recently reported significant 
improvement in biochemical disease-free survival with EBRT dose escalation in high risk 
patients with pretreatment serum PSA levels of 10 to 20 ng/ml.  Patients receiving <71.5, 
71.5 to 75.6 or >75.6 Gy experienced 19%, 31% and 84% biochemical free survival, 
respectively at 8 years.  Likewise, increased radiation dose enhanced freedom from 
distant metastases in this patient population (45).  These data confirmed the results from 
a case-matched retrospective study in which a dose increase from 72 to >76 Gy for 
patients with intermediate to high risk prostate cancer resulted in significant 
improvement in biochemical disease-free survival, freedom from distant metastases and 
PCSM (46).  However, as the radiation dose is elevated, the incidence of moderate to 
severe adverse effects also increases.  Acute reactions are the result of damage to 
rapidly dividing mucosal cells and include cystitis, hematuria, dysuria, nocturia (from 
urinary flow obstruction due to an inflamed prostate), proctitis, diarrhea, rectal bleeding 
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and tenesmus.  Late or chronic reactions are caused by irreversible damage to slowly 
proliferating cells such as fibroblasts and endothelial cells and include vascular damage, 
fibrosis, urethral strictures, impotence, vesicorectal fistulas and spinal cord necrosis (in 
the case of palliative irradiation) (47, 48).  To overcome these adverse events, 3-
dimensional conformal radiation therapy (3D-CRT) was developed to accurately limit and 
shape the radiation field to the target tissue through the use of image-guided beam 
alignment.  A further enhancement of this technology is intensity-modulated radiation 
therapy (IMRT), where steep intensity gradients are created within the tumor by 
modulating the intensity of the radiation beam within each field.  Despite these 
advancements, toxicity to adjacent tissues remains the dose-limiting factor resulting in 
incomplete tumor eradication and poor clinical outcomes.   
Clinical evidence supports the hypothesis that poor local control of the primary 
tumor leads to the development of distant metastases, increased morbidity and ultimate 
demise of the patient.  Fuks et al. documented a 4-fold increase in the relative risk of 
developing distant metastases in patients with local failure following pelvic lymph node 
dissection and I125 brachytherapy compared to the risk in patients without local failure.  
The relationship between distant metastases and local control was seen regardless of 
tumor stage or grade.  The actuarial freedom from distant metastases at 15 years was 
77% in the 351 patients with local control vs. 24% in 328 patients with local failure.  Most 
importantly, patients who developed distant metastases despite adequate local control, 
failed sooner (37 months) than patients who experienced local recurrence (54 months).  
These data suggest that distant metastases in patients with local control preexisted as 
micrometastases prior to the initiation of therapy (49).  In a larger study involving EBRT 
without adjuvant ADT, local failure was independently and strongly associated with 
distant failure.  The 10-year freedom from distant metastases was 77% in the locally 
controlled group vs. 61% in the local failure group.  As in the previous study, the median 
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time to distant metastasis detection was longer in patients with locally controlled disease 
(54 months) as compared to patients with local failure (34 months).  The initial hazard 
rate of developing distant metastases was higher in patients with local failure (3.6% vs. 
3.0%), suggesting that a more aggressive and malignant tumor may present with a 
higher incidence of micrometastases at the time of diagnosis.  However, the hazard rate 
for the development of distant failure increased over time, while the risk of distant 
metastases decreased in the locally controlled group (9.1% vs. 0.8% at 12 to 15 years), 
supporting the theory that persistent local disease may embolize tumor cells to distant 
sites (50).  These studies provide evidence that early and complete eradication of all foci 
of prostate cancer is necessary to achieve a long-term cure and reduce the need for 
salvage ADT, which is associated with significant morbidity.  Therefore, the combination 
of a radiation sensitizer with EBRT will allow for RT dose reduction, resulting in less 
acute toxicity and enhanced therapeutic efficacy, resulting in better patient outcomes. 
 
The Development of Molecular Therapy for Prostate Cancer 
Gene Delivery Vectors 
 The antitumor effect of gene therapy for prostate cancer is achieved when a 
therapeutic gene expression cassette is delivered directly to a target cancer cell by a 
viral vector.  The ideal vector would be specific for prostate cancer cells, have high 
transduction efficiency and be nonmutagenic.  Furthermore, a vector should be 
inexpensive to produce and administer to the patient.  Much research is underway to 
improve the specificity, transduction efficiency, and safety of gene therapy vectors.  The 
route of administration of the therapeutic agent depends by and large on the vector 
employed.  At the present time, most prostate cancer gene therapy trials entail the 
intralesional administration of the vector, which is quite suitable given the ease with 
which to visualize the prostate using transrectal ultrasound (TRUS) and its convenient 
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transrectal or transperineal access.  Ultimately, the desired route of administration is 
intravenous infusion of the vector.  This approach would seek and destroy all foci of 
cancer, regardless of their location; however, limiting factors include vector half-life, 
immunologic clearing of the vector and the infection of non-target organs.  Recent 
improvements in prostate-specific promoter systems and viral targeting have allowed 
this approach to be used in human prostate cancer clinical trials.  The viral vectors 
currently available for use in gene therapy clinical trials are listed in Table 1; however, 
only adenoviral vectors will be discussed, as this is the viral vector currently under 
development in our laboratory.  
 
Table 1.  Characteristics of vector systems commonly used for molecular therapy.  This 
table lists the key attributes of the vectors used previously in gene therapy clinical trials 
for prostate cancer. 
 
Adenovirus 
Adeno-
associated 
virus 
Retrovirus Vaccinia 
virus 
   
 
 
Maximum insert size 10 – 35 kb 2.4 / 4.8 kb 8 kb >30 kb 
In vivo gene delivery High High Low High 
Gene expression  Transient Stable Stable Transient 
Cell cycle dependent No No Yes No 
Genome integration No Site-specific Random No 
Immunoreactive Yes / No No No Yes 
     
 
 
 
Adenovirus.  The most commonly used viral vector in human gene therapy 
clinical trials is adenovirus, a non-enveloped, icosahedral virus containing a double-
stranded linear DNA genome 36 kb in size.  This non-integrating virus has a wide safety 
profile and is advantageous over many vectors in part due to its ability to carry a large 
insert and infect any cell, regardless of its cell cycle status.  In addition, its genome is 
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easily manipulated in the laboratory, and it is readily produced in high titers with 
relatively minimal expense.  Early-generation adenoviral vectors induced strong innate 
and adaptive immune responses, thereby limiting their gene delivery potential (51).  
Furthermore, it has been shown that nearly all humans have developed humoral 
immunity to adenovirus due to previous exposure; however, only 55% of the detected 
immunoglobulins are neutralizing antibodies (52).  Recently, adenoviral vectors have 
been modified to reduce immunogenicity, reinstating their hope for clinical utility (53). 
The adenoviral genome, as depicted in Figure 2, is flanked on both ends by short 
inverted terminal repeats (ITRs) which contain identical origins of replication.  Near the 5’ 
end is a short packaging signal (ψ) which is required for proper association of the viral 
genome with the capsid proteins (54).  Its transcription units are divided into two groups, 
early and late genes.  The viral genome carries six early units (E1a, E1b, E2, E3 and  
 
 
Figure 2.  Organization of the adenoviral genome.  Adenovirus contains a double-
stranded genome that is 36 kb in length.  Transcription occurs from both ITRs and uses 
alternative splicing to take advantage of overlapping sequences.  This transcription map 
depicts the early adenoviral transcription units with thin arrows, late transcripts in heavy 
arrows, and delayed mRNAs in italics.  Encoded within the E3 region and under the 
control of the major late promoter is a late transcript which includes adenovirus death 
protein (ADP).  Map units are indicated by the hashes.  Products of the late transcripts 
contribute to the structure of adenovirus. 
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E4), two delayed early units (IVa2 and IX), and two late units, one that is processed into 
five mRNAs (L1-L5) and one in the E3 region that is controlled by the major late 
promoter (MLP).  In addition, either one or two copies of virus-associated (VA) genes are 
encoded and transcribed by RNA polymerase III.  As shown in Figure 2, the transcription 
of adenoviral genes occurs from both strands and uses alternative splicing and multiple 
poly(A) sequences. 
E1a is the first sequence transcribed in the adenoviral genome.  Controlled by a 
constitutively active promoter, the E1a transcription unit encodes up to five polypeptides, 
of which only two, E1a 12S and E1a 13S, have known functions.  E1a proteins 
transactivate the promoters of other adenoviral genes (55).  Expression of E1a is critical 
to the virus.  In fact, deletion of the E1 region of the genome results in a replication-
deficient adenovirus (56).  E1a proteins also stimulate viral DNA synthesis by preventing 
G1 arrest and advancing the host cell into S-phase.  This is accomplished by binding 
pRB and releasing the associated transcription factor E2F (57), antagonizing the cyclin-
dependent kinase inhibitory protein p27kip1 (58), or inhibiting the transactivation of p53 by 
p300/CBP (59).  Furthermore, E1a proteins induce apoptosis of infected cells through 
p53-dependent and p53-independent pathways (59), both of which are blocked through 
the action of E1b proteins (60).  Acting in concert, E1b and E4 proteins shut-down host 
cell protein synthesis by blocking the cytoplasmic accumulation of cellular mRNAs, while 
stabilizing and exporting viral mRNAs from the nucleus to the cytoplasm (61, 62).  
Although adenovirus is not responsible for human malignancies, the products of the E1a, 
E1b and E4 genes transform cells in vitro (63); however, Ad5, the adenoviral serotype 
used mostly in prostate cancer gene therapy belongs to a non-oncogenic subgroup.  
Viral DNA synthesis occurs as E2 gene products accumulate.  The E2 region encodes a 
DNA polymerase that is essential for viral DNA replication (64) and the terminal protein 
(TP) which is covalently bound to the 5’ ends of the viral chromosome and serves as a 
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primer for DNA synthesis (65).  The expression of E3 is not essential for viral replication; 
however, it protects virally infected cells from lysis by cytotoxic T-lymphocytes (CTLs) by 
downregulating the expression of MHC class I antigen (66) and Fas receptor (67) on the 
infected cell surface.  Further protection from the body’s antiviral defense system is 
provided by VA RNA which forms a hairpin-loop structure and inhibits the activation of 
interferon-induced RNA-dependent protein kinase (PKR) (68).     
 Late gene products include ten structural proteins, of which seven (II, III, IIIa, IV, 
VI, VIII and IX) form the capsid and two (V and VII) are involved with the DNA-containing 
core.  Figure 3 depicts the structure of the adenovirus particle.  The most abundant 
protein on the capsid surface is the trimeric hexon (II), whose assembly requires the 
assistance of the L4 100-kd scaffold protein (69).  Neutralizing antibodies to the capsid 
 
are formed against surface loops of the hexon structure.  Polypeptides IIIa, VI, VIII and 
IX stabilize the hexon capsid structure and form a bridge with the adjacent core proteins.  
 
Figure 3.  Structure of the adenoviral 
virion.  Adenovirus is a non-enveloped 
icosahedral virus that is 1,500 Å in 
diameter.  Projecting from the vertices 
of the virus are twelve fiber knobs, 
which aid in host cell entry.  Proteins 
II, III, IIIa, IV, VI, VIII and IX form the 
viral capsid.  Proteins V, VII, X and TP 
associate  with the adenoviral genome 
and form the viral core.  Protease is responsible for the maturation of proteins IIIa, VI, 
VII, VIII and TP. 
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The penton base (III) forms at the twelve vertices of the capsid structure, with a trimeric 
fiber and distal knob (IV) projecting from each base.  Together, polypeptides III and IV 
form the penton complex and mediate host cell binding.  Initially, the knob domain of 
polypeptide IV binds to its cellular receptor, the coxsackie and adenovirus receptor 
(CAR) (70), followed by binding of an arg-gly-asp (RGD) motif in the penton to αvβ3 and 
αvβ5 integrins on the cell surface, stimulating internalization (71).  The E3 region 
encodes one late protein called adenovirus death protein (ADP) which is controlled by 
the major late promoter and is responsible for cell lysis and release of viral progeny (72).  
Recently, vectors have been constructed that overexpress ADP, leading to enhanced 
viral spread and oncolysis (73). 
While the majority of prostate cancer cells upregulate CAR expression (74), 
actual tumors may vary in adenoviral susceptibility.  For this reason, efforts have been 
made to retarget the virus, thereby enhancing its ability to infect prostate cells.  
Furthermore, the retargeting of adenovirus has narrowed its expansive tropism, allowing 
for safer systemic delivery without infection of non-target tissues such as liver and 
respiratory epithelium.  Early studies in adenoviral retargeting employed bispecific 
antibodies which cross-linked the virus to alternative cellular receptors (75, 76).  This 
has been applied to prostate cancer with a bifunctional antibody to the adenoviral fiber 
knob and prostate-specific membrane antigen (PSMA) (77).  Perhaps a more clinically 
feasible approach to prostate-specific retargeting of adenovirus is the genetic 
modification of the fiber knob.  Cell-binding peptides have been displayed on the 
carboxyl terminus of the fiber knob (78); however, this approach is unfavorable due to 
size constraints and structural hindrance.  Larger peptides can be incorporated into the 
HI loop of the fiber knob without structural consequences (79).  Lupold et al. identified 
two candidates for prostate-targeting peptides by phage display library which bind to 
PSMA (80); however, there exist no reports of its use for the transductional targeting of 
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adenovirus.  A final approach to the retargeting of adenovirus was devised by 
Shayakhmetov et al. in which the Ad5 fiber was replaced by the short-shafted Ad35 fiber 
(81).  This chimeric Ad5/35 uses CD46 as its cellular receptor (82) which is upregulated 
on the surface of many cancer cells.  Most importantly, systemic administration of these 
vectors does not result in hepatic infection, and Ad5/35 has demonstrated prostate 
cancer tropism (83).  In combination with transcriptional targeting, the transductional 
retargeting and detargeting of adenoviral vectors will increase the safety and efficacy of 
systemically-delivered molecular therapies for prostate cancer. 
 
Gutless adenovirus.  Although adenoviral vectors are attractive gene transfer 
agents, the presence of adenoviral genes within infected cells triggers an adaptive 
cellular immune response which produces cytotoxic T lymphocytes (CTLs), resulting in 
the elimination of transduced cells and shorter transgene expression (84).  To overcome 
this, gutless or helper-dependent adenoviral vectors were developed.  These high-
capacity vectors (up to 36 kb insert size) are devoid of all adenoviral coding sequences, 
resulting in little to no CTL immune response and long-term transgene expression.  
Therefore, this vector serves best for corrective gene therapy, immunotherapy and the 
delivery of anti-angiogenic factors.  Because gutless vectors only retain the 5’ and 3’ 
ITRs and the packaging signal, genomic space not occupied by the therapeutic 
expression cassette must be filled with stuffer DNA from human introns and non-coding 
sequences (85, 86).  To allow for gutless adenoviral genome replication, capsid 
formation and packaging, wild-type proteins must be provided in trans by co-infection of 
packaging cells with both a gutless and helper adenovirus.  However, the packaging 
efficiency of the helper virus must be reduced to prevent contamination of the gutless 
vector sample with replication-competent adenovirus.  This was achieved by Parks et al. 
through the use of a packaging signal flanked by two loxP sequences.  When amplified 
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in 293Cre cells, a packaging cell line that expresses the Cre recombinase, the 
packaging sequence is excised, preventing encapsidation of the helper genome (87).  
Employing this system, contamination levels of 0.1 to 10% are achieved, which is not 
acceptable for clinical applications.  One possible mechanism for such a high level of 
contamination is homologous recombination between the helper vector and adenoviral 
E1 sequences in HEK293 cells.  To circumvent this, PER.C6 packaging cells, in which 
no recombination occurs, can be used for co-infection to achieve contamination levels 
under 1% (88).  Currently, due to multiple and tedious vector co-infections, large-scale 
gutless virus production efficiency is limited.  This must be improved before helper-
dependent vectors can be widely deployed for therapeutic applications. 
 
Adeno-associated virus.  Adeno-associated virus (AAV), a member of the 
parvovirus family, is a small single-stranded DNA virus that is dependent on a helper 
virus, such as adenovirus, for replication.  AAV is an attractive vector for gene therapy 
because it elicits nearly no immune response, is known to cause no disease in humans, 
and integrates stably and site-specifically in a region on chromosome 19 (89).  The 
genome consists of two ITRs, which encode a packaging signal and the origin of 
replication, and two genes, rep and cap.  Cap encodes the viral capsid proteins while rep 
encodes four products of alternative splicing, Rep40, Rep52, Rep68 and Rep78, of 
which only Rep68 or Rep78 are necessary for replication and site-specific integration 
(90).  Recombinant AAV vectors are made by deleting rep and cap and inserting ~4.7 kb 
of therapeutic DNA; however, it has been observed that deletion of rep results in non-
specific integration of the virus (91).  Nonetheless, the majority of AAV vectors used 
today are rep-deleted.  Recombinant AAV is produced in HEK293 cells by co-
transfecting a plasmid containing the therapeutic DNA cloned between two ITRs and a 
plasmid containing the rep and cap genes.  Subsequently, the cells are infected with 
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adenovirus or transfected with a plasmid containing the adenoviral genes required for 
AAV replication (92).  Recently, methods have been devised to produce higher AAV 
titers, necessary for large-scale production for gene therapy applications (93).  Following 
infection, the rate-limiting step in gene expression appears to be the synthesis of the 
second strand (94).  This has been overcome by the recent development of self-
complementary, double-stranded AAV vectors which carry half the insert size of the 
single-stranded virus (95).  Similar to adenovirus, peptides can be inserted into the AAV 
capsid to retarget the vector specifically to receptors on the surface of prostate cancer 
cells (96).  To achieve site-specific integration of a transgene with the targeting capability 
of an adenoviral vector, Recchia et al. developed a hybrid Ad/AAV vector which carries a 
drug-inducible rep expression cassette and a transgene cassette flanked by two AAV 
ITRs.  Site-specific integration of the ITR-flanked transgene cassette was observed in a 
rep-dependent fashion (97). 
 
Prostate- and Tumor-Specific Promoters 
Recently, much effort has been made to develop tissue-specific delivery systems 
that reduce the risk of harming the patient.  Several studies have demonstrated the 
importance of tissue-specific vectors, revealing systemic toxicity with the administration 
of high doses of nonspecific vectors (98, 99).  Viral vectors with broad tropisms can 
transduce any cell in the body, provided that the cell expresses the correct receptor for 
the virus.  Through the use of tissue-specific promoters and enhancers, the expression 
of a therapeutic gene can be limited to prostate cells.  To date, several prostate-specific 
genes have been identified and their promoters have been well characterized.  Because 
no promoter is prostate cancer-specific, the entire prostate epithelium is susceptible; 
however, this poses no risk, as the prostate is a non-vital organ in the post-reproductive 
population. 
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Prostate-specific antigen promoter.  PSA is released into the bloodstream 
when the prostatic basement membrane is compromised, such as occurs in prostate 
cancer and therefore is used as a sensitive serum marker for the diagnosis and 
progression of prostate cancer (100).  PSA, a serine protease, is encoded by the human 
kallikrein-3 (hK3) gene (101).  PSA expression is AR-dependent, and its transcript levels 
are significantly reduced in the absence of androgen (102).  AR regulates PSA 
expression by binding to a 440 bp androgen-responsive enhancer core (AREc) in the 
upstream 5’ flanking region of the PSA gene (103, 104).  In vitro experiments have 
confirmed the tissue-specificity and androgen-dependency of this promoter (105).  In 
addition, this promoter has been used in multiple gene therapy studies (106, 107).  
Although this promoter confers high tissue-specificity, its utility in men undergoing 
androgen ablation therapy is limited.  To circumvent this problem, Gotoh et al. 
characterized the long (5,837 bp) PSA promoter as less dependent on androgen and 
therefore, more active than the short (631 bp) PSA promoter in the absence of androgen 
(106).  Two cis-acting elements within the long PSA promoter, a 440 bp AREc and a 150 
bp pN/H androgen-independent positive regulator, are responsible for this androgen-
independent activity.  A chimeric promoter with three-fold higher activity than the native 
PSA promoter has been produced by juxtaposing both elements (108).  Further attempts 
to enhance the activity while retaining the specificity of the PSA promoter in adenoviral 
vectors include duplication of the AREc, which led to a twenty-fold increase (109) or 
tandem duplication of the PSA promoter, which led to a fifty-fold increase above basal 
promoter activity (110).     
 
Prostate-specific membrane antigen promoter.   PSMA was discovered by 
Horoszewicz et al. by a monoclonal antibody produced in mice immunized with cell 
membranes from LNCaP cells (111).  PSMA is a type II integral membrane glycoprotein 
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with folate hydrolase (112), N-acetylated alpha-linked acidic dipeptidase (113) and 
glutamate carboxypeptidase (114) activities.  PSMA is expressed predominantly in 
prostate tissue and tumor neovasculature, with low levels detected in the gastrointestinal 
tract, salivary glands, kidney and brain (115).  Its expression is elevated higher in 
prostate cancer than in benign hyperplastic or normal prostate epithelium (116).  In 
addition, serum PSMA levels are highest in patients with metastatic disease, suggesting 
enhanced PSMA expression as prostate cancer progresses (117).  Unlike PSA, PSMA 
expression is upregulated under androgen-depleted conditions (118).  A 1.2 kb PSMA 
promoter has been identified with high promoter activity (119); however, significant non-
specific activity in PSMA-negative cells limits its clinical usefulness as a gene therapy 
promoter.  Recently, the PSMA enhancer (PSME) was discovered within the third intron 
of the PSMA gene, FOLH1 (120).  Lee et al. have demonstrated PSMA activity mediated 
by NFATc1 cooperatively binding at the AP-3 site within PSME (121). PSME has been 
used to transcriptionally target suicide (122) and oncolytic (123) gene therapies for 
prostate cancer under low androgen levels.         
 
Prostate-specific enhancing sequence.  To achieve the highest transcriptional 
activity with strong prostate-specificity, Lee et al. developed a novel chimeric promoter, 
called PSES, under the hypothesis that AREc and PSME could function synergistically in 
any androgen environment.  Through deletion and linker scan mutagenesis, the main 
prostate-specific enhancer activities of the PSA AREc and PSME were located in a 189 
bp region called AREc3 and a 331 bp region called PSME(del2), respectively.  PSES 
was developed by combining both AREc3 and PSME(del2) and placing AREc3 
upstream from PSME(del2).  AREc3 contains six GATA transcription factor binding sites 
and three AR binding sites, leading to high enhancer activity once surrounding silencer 
regions were deleted.  PSME(del2) contains eight AP-1 and three AP-3 binding sites 
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acting as positive regulators in the absence of androgen and a downstream deletion of 
an Alu transcription-silencing repeat.  PSES showed significantly stronger transcriptional 
activity than either AREc3 or PSME(del2) alone in the presence or absence of androgen.  
Furthermore, PSES demonstrated five-fold higher activity than universal promoter RSV 
and activity equal to CMV promoter.  In vitro studies revealed that PSES is active in 
several PSA- and PSMA-positive prostate cancer cell lines, but not in PSA- and PSMA-
negative prostate cells or non-prostate cell lines (124).  Due to its small size, high level 
of tissue-specificity, and strong promoter activity regardless of androgen status, PSES is 
an ideal promoter for use in prostate cancer gene therapy. 
 
Osteocalcin promoter.  Osteocalcin (OC) is a highly conserved bone gamma-
carboxyglutamic acid protein (BGP) that has been shown to be transcriptionally 
regulated by 1,25-dihydroxyvitamin D3 (125).  This noncollagenous bone protein 
constitutes 1-2% of the total protein in bone, and its expression is limited to differentiated 
osteoblasts and osteotropic tumors, especially primary and metastatic prostate cancer 
(126).  The osteoblastic nature of osseous prostate cancer metastases is well 
characterized (127), and the mechanism is believed to be via its osteomimetic 
properties, specifically its ability to express bone-related proteins such as OC (128).  The 
human OC promoter contains numerous regulatory elements including a vitamin D-
responsive element (VDRE), making it inducible by vitamin D3 administration (129, 130), 
a glucocorticoid-response element (GRE), an AP-1 binding site (131), and an AML-1 
binding site which has been shown to be responsible for 75% of OC expression (132).  
The OC promoter retained its tissue-specificity in a recombinant OC promoter-driven 
herpes simplex virus-thymidine kinase (HSV-TK)-expressing adenoviral vector.  Ko et al. 
developed a gene therapy for osteosarcoma in which co-administration of Ad-OC-TK 
and acyclovir (ACV) resulted in osteoblast-specific cell toxicity (133).  A similar strategy 
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was developed for the intralesional injection of Ad-OC-TK to osseous prostate cancer 
metastases followed by administration of valacyclovir (VAL).  In phase I clinical trials, 
this therapy induced apoptosis in every lesion treated, without serious adverse effects to 
the patients (134, 135). 
 
Human telomerase promoter.  Telomeres are tandem repeat structures found 
at the termini of chromosomes that maintain chromosomal integrity by preventing DNA 
rearrangements, degradation and end-to-end fusions.  In most normal somatic cells, the 
telomeric cap is shortened with each cycle of DNA replication and cell division.  When 
telomeres shorten to a critical length, cells progress toward irreversible arrest of growth 
and cellular senescence (136).  In contrast, tumor cells have evolved a means to prevent 
telomere shortening through the activation of the catalytic component of human 
telomerase reverse transcriptase (hTERT) (137).  The hTERT promoter region has been 
cloned and characterized, and contains a high GC content.  Unlike most promoters, it 
does not contain TATA or CAAT boxes (138).  Importantly, the hTERT promoter is active 
in most cancer cells including prostate cancer (139) and inactive in most normal cells, 
thereby providing a unique approach to specifically targeting cancer cells.  Promising 
results have been reported using the hTERT promoter to deliver TRAIL (140) and Bax 
(141), inducers of apoptosis, to prostate cancer cells.  Recently, the hTERT promoter 
was used to control adenoviral genes E1a and E1b to control the replication of an 
oncolytic Adenovirus in a tumor-specific manner.  This virus replicated efficiently in and 
killed a broad spectrum of cancer cells without harming normal human cells lacking 
telomerase activity (142).  Clinical use of this promoter may be limited, however, to local 
intralesional gene therapy, because systemic delivery of an hTERT virus could have 
toxic effects on normal proliferating cells and stem cells, in which telomerase is active. 
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Current Gene Therapy Approaches for Advanced Prostate Cancer 
The ideal therapy for hormone-refractory prostate cancer would be one that kills 
cancer cells, but spares normal cells.  This therapy would have limited toxicities, 
increase survival, and enhance the quality of life of men afflicted with prostate cancer.  
Due to its prior success in clinical studies, gene therapy promises to answer these 
challenges.  While locally advanced prostate cancer can cause much suffering, mortality 
is usually secondary to the inability to inhibit metastatic spread.  Lack of successful 
conventional therapies for locally advanced and metastatic prostate cancer makes this 
patient population an excellent candidate for gene therapy.  Of course, as with most 
therapies, the ability to treat men with low volume disease should enhance the success 
of the therapy. 
 Over the past decade, four categories of gene therapy approaches for prostate 
cancer have emerged: corrective gene therapy, oncolytic viral therapy, cytotoxic gene 
therapy and immunotherapy.  Each molecular therapy has a strong foundation of 
preclinical data allowing for the approval of several clinical studies.  Currently, 88 gene 
transfer protocols registered with the Office of Biotechnology Activities (OBA) are 
targeted against prostate cancer.  This accounts for 15% of all cancer gene therapy 
protocols listed to date (143).  Table 2 summarizes the approaches registered with the 
OBA and the Recombinant DNA Advisory Committee (RAC). 
 
Corrective Gene Therapy 
This approach repairs inherited or acquired genetic defects that give the cancer a 
survival advantage such as those affecting tumor suppressors or growth-promoting 
oncogenes.  These mutations affect the regulation of the cell growth cycle and are 
among the multiple mutations that occur in the pathogenesis and progression of prostate 
cancer.  Correction of a single genetic insult, however, may not be sufficient to change 
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Table 2.  Current approaches for prostate cancer gene therapy clinical trials.  This list 
includes all clinical trials listed on the Office of Biologic Activities (OBA) protocol list as of 
February 29, 2008 (143). 
Strategy Vector Transgene 
 
  
Corrective Adenovirus p16 
  p53 
 Retrovirus c-myc antisense 
   
Cytoreductive 
      (suicide) 
  
Adenovirus CD/HSV-TK 
  HSV-TK 
  NIS 
  TRAIL 
      (oncolytic) Adenovirus OC promoter 
  PSA promoter 
   
Immunotherapy AAV GM-CSF 
 Adenovirus IL-12 
  INF-β 
  MUC-1/CD40L 
  p501 
  PSA 
PSMA 
PTVP-1 
 Liposome hTERT/Ig heavy chain 
  IL-2 
  Prostatic acid phosphatase (PAP) 
  PSA 
  PSMA 
 Retrovirus α(1,3) galactosyltransferase 
  GM-CSF 
HPV-E6 
 RNA hTERT 
  PSA 
  Tumor RNA 
 Vaccinia 5T4 
MUC-1/IL-2 
  PSA 
  PSA/B7.1 
  PSA/B7.1/ICAM-1/LFA-3 
  PSA/B7.1/ICAM-1/LFA-3/GM-CSF 
   
 
 
24 
 
the cell phenotype.  Nevertheless, in vivo correction of single gene defects have shown 
success in several preclinical and clinical studies. 
 
p53.  Tumor suppressor p53 is referred to as the molecular gatekeeper, 
protecting the integrity of the genome (144).  When cellular DNA damage occurs, wild 
type p53 is activated and stimulates the expression of GADD45 (growth arrest and DNA 
damage-induced gene) and the cyclin-dependent kinase (CDK) inhibitor, p21.  p21 
inhibits the CDK-cyclin D complex required to phosphorylate Rb, thereby halting the cell 
at the G1/S checkpoint to allow for DNA repair.  If GADD45-mediated DNA repair is 
unsuccessful, p53 activates bax which mediates apoptosis (145).  p53 mutations occur 
in approximately one third of early prostate cancers (146), and this increases in patients 
with advanced and metastatic disease (147).  Replacement of wild-type p53 with 
recombinant adenoviral vectors (Ad-p53) resulted in growth inhibition and induction of 
apoptosis in prostate cancer both in vitro (148, 149) and in vivo (149, 150).  In addition, 
intratumoral administration of Ad-p53 has been shown to slow the progression of 
localized prostate cancer to metastatic disease (151).  Hernandez et al. described a 
natural variant of p53, p53(R172L), in which an arginine-to-leucine mutation at codon 
172 confered stronger protection against malignancy.  When introduced into a 
transgenic adenocarcinoma of the mouse prostate (TRAMP) model, higher levels of bax 
were detected in addition to a lower incidence and reduced rate of prostate cancer 
growth (152).  Perhaps the most powerful use of p53 replacement is in combination with 
conventional therapies.  Ad-p53 has been shown to sensitize prostate cancer cells in 
vitro and in vivo to DNA-damaging drugs such as cisplatin, doxorubicin, 5-fluorouracil (5-
FU), methotrexate and etoposide (153).  Similarly, correction of p53 mutations with 
adenoviral vectors sensitized radio-resistant prostate cancer cells to radiation in vitro 
(154, 155).  Cowen et al. described an additive effect when orthotopic LNCaP mouse 
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xenografts were treated with both Ad-p53 and radiation therapy (156).  Phase I/II clinical 
trials are ongoing to determine the safety of such therapies (157, 158). 
 
Murine double minute clone 2.  A key regulator of p53 is the oncoprotein 
murine double minute clone 2 (mdm2).  It binds to the native tetrameric form of p53 to 
inactivate its transcriptional function (159) or to promote the ubiquitination (160) and 
degradation (161) of p53.   Mdm2 primarily binds to p53 in the N-terminal transactivation 
domain, overlapping the p300 and TAF binding sites (162).  Overexpression of mdm2 in 
prostate cancer is associated with more aggressive tumors, increased cell proliferation, 
and larger tumor volumes (163).  Zhang et al. developed second-generation antisense 
oligonucleotides against mdm2 to target the degradation of mdm2 mRNA.  This led to 
decreased proliferation, increased apoptosis, and sensitization to paclitaxel in LNCaP, 
PC-3 and DU-145 cell lines in addition to chemosensitization and growth suppression in 
LNCAP and PC-3 xenografts (164).  As expected, antisense mdm2 sensitized prostate 
cancer cell lines and xenografts to radiation therapy (165, 166).  Interestingly, the 
delivery of antisense mdm2 to LNCaP cells restored the apoptotic response to androgen 
deprivation (167).  The addition of antisense mdm2 to existing p53 corrective gene 
therapy may enhance the antitumor effect and further sensitize prostate cancer to 
conventional therapies. 
 
Phosphatase and tensin homologue.  PTEN is a tumor suppressor with 
plasma membrane lipid phosphatase activity.  Its primary function is to remove the 3’ 
phosphate on phosphatidylinositol (3,4,5)-triphosphate (PIP3) in the phosphatidylinositol 
signaling cascade.  Upon growth factor stimulation, phosphoinositide 3-kinase (PI3K) 
phosphorylates phosphatidylinositol (3,4)-bisphosphate (PIP2), generating PIP3 which 
transmits growth and survival signals.  By regenerating PIP2, PTEN reverses the PI3K 
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signal (168).  Loss of PTEN occurs in 20% of prostate tumors and is associated with 
higher Gleason score and advanced stage cancer (31).  PTEN loss also leads to altered 
cell cycle regulation (169), increased cellular invasion (170), enhanced cell survival 
(171), and stimulation of angiogenesis (172).  Davies et al. demonstrated the inhibition of 
cell cycle progression in PC-3 cells infected with Ad-PTEN.  Intratumoral injection of Ad-
PTEN into orthotopic PC-3 tumors did not result in tumor growth inhibition; however, it 
suppressed metastasis formation (173).  In Bcl-2 overexpressing PC-3 and LNCaP 
prostate cancer cell lines, Ad-PTEN sensitized cells to radiation therapy and induced a 
G2/M cell cycle arrest (174).  Similarly, Ad-PTEN sensitized PC-3 and DU-145 cells to 
doxorubicin treatment (175).   
 
Oncolytic Viral Therapy 
Safety concerns of nonspecific viral replication in immune-compromised cancer 
patients limited the early clinical trials to the use of replication-deficient adenoviral 
vectors; however, previous studies have shown that the replication of adenovirus within 
a cell is sufficient to kill prostate cancer cells (176).  By placing adenoviral early genes 
under the control of prostate-specific promoters, viral replication can be limited to 
prostate cells.  This strategy allows the viral vector to propagate from a limited number of 
infected cells to the whole tumor mass, overcoming the problem of inadequate in vivo 
infectivity.  This local viral amplification limits the number of injections required. 
 
ONYX-015.  The first tumor-specific oncolytic adenovirus, named ONYX-015, 
was developed by Bischoff et al. to replicate specifically in p53-deficient cells, a mutation 
common to several cancers.  Tumor-specificity was achieved by deleting the adenoviral 
E1b-55K gene, whose gene product binds to and inactivates p53, enabling infected cells 
to enter S-phase and promote viral replication.  Theoretically, normal cells would not be 
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permissive to ONYX-015 replication.  Originally, this virus was reported to demonstrate 
mutant p53-dependent replication (177), effective tumor regression following 
intratumoral or systemic injection in several nude mouse xenograft models including 
colon, cervical and laryngeal carcinomas (178, 179), and augmentation of tumor killing 
with co-administration of chemotherapeutic agents such as cisplatin and 5-fluorouracil 
(178).  To date, ONYX-015 has been tested in sixteen phase I and II clinical trials for 
multiple malignancies including head and neck carcinoma, pancreatic cancer, ovarian 
cancer, colorectal cancer, hepatobiliary cancer, gastric cancer and gliomas.  In these 
trials, no dose-limiting toxicities were observed; however, only modest to no objective 
responses were achieved (180-186).  Although the virus has been shown clinically not to 
destroy normal tissues (187), several groups have reported that ONYX-015 replication is 
independent of p53 status (188-190).  Recently, O’Shea et al. reported that the tumor-
specific replication of ONYX-015 is due to differential late viral mRNA export in 
malignant cells rather than the cell’s p53 status (191).  Despite the conflicting reports, 
ONYX-015 appears to favor viral replication in malignant cells over normal cells.  The 
clinical utility of ONYX-015 for prostate cancer has not been tested, but prostate cancer 
gene therapy vectors with similar E1b-55K deletions have been developed (192). 
 
Calydon virus 706 and 787.  The first prostate-specific replication-competent 
adenovirus (PSRCA) was developed by Rodriguez et al.  Calydon virus (CV706) was 
engineered by placing the adenoviral E1a gene under the control of the minimal PSA 
promoter and enhancer sequences.  In vitro, E1a expression was limited to PSA-positive 
LNCaP cells.  Furthermore, in vivo analysis demonstrated the powerful antitumor 
efficacy of the virus against LNCaP mouse xenografts (193).  When combined with 
radiation therapy, a significant synergistic effect was demonstrated both in vitro and in 
vivo in LNCaP xenograft models (194).  CV706 was the first PSRCA tested in a human 
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gene therapy clinical trial.  The virus was found to be safe, as the maximum tolerable 
dose was not reached, and a drop in serum PSA greater than 50% was demonstrated in 
patients treated with the highest doses of CV706 (194).  Yu et al. developed CV787, a 
PSRCA with higher killing efficiency than CV706.  This virus retains the entire adenoviral 
E3 region, which enhances the virus’ oncolytic effect.  In addition, two promoters drive 
the expression adenoviral early genes.  E1a is under the control of the prostate-specific 
rat probasin promoter, and E1b is controlled by the human PSA promoter/enhancer.  
This virus replicated as efficiently as wild-type adenovirus and eliminated LNCaP 
xenograft tumors via tail vein injection (195).  Further in vivo analysis revealed a 
synergistic enhancement of CV787 with both radiation therapy (196) and 
chemotherapeutic agents such as paclitaxel or docetaxel (197).  Results from ongoing 
CV787 clinical studies are pending.  Although CV706 and CV787 promise success in 
combination with conventional therapies, the androgen-dependency of the promoter 
systems used may limit their success. 
 
Ad-OC-E1a and Ad-hOC-E1.  Matsubara et al. developed a PSRCA using the 
mouse OC promoter to restrict the expression of E1a to prostate epithelia and its 
supporting bone stroma in osseous metastases of prostate cancer.  This virus, named 
Ad-OC-E1a, appears to be more effective than a PSA-controlled virus at killing a broader 
spectrum of prostate cancer cells including LNCaP, C4-2, and ARCaP (PSA-positive) as 
well as PC-3 and DU-145 (PSA-negative).  Intratumoral injection of Ad-OC-E1a was 
effective at obliterating subcutaneous androgen-independent PC-3 athymic mouse 
xenograft models.  In addition, intraosseous C4-2 prostate cancer xenografts responded 
very well to the systemic administration of Ad-OC-E1a.  100% of the treated mice 
responded with a drop in serum PSA below detectable levels.  At the conclusion of the 
study, 40% of the treated mice were cured of prostate cancer, as no PSA rebound or 
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prostate cancer cells in the skeleton were detected (198).  To improve upon this virus, 
Hsieh et al. developed a second PSRCA, Ad-hOC-E1, containing a single bidirectional 
human OC promoter to control the expression of both E1a and E1b (199).  Previous 
studies have shown that controlling the expression of the early gene E1b in addition to 
E1a results in better viral replication control (195).  Under the control of this VDRE-
containing promoter, Ad-hOC-E1 replication was induced 10-fold higher than wild-type 
viral replication and cytotoxicity was enhanced by the administration of vitamin D (199).  
Although still controversial (200), some preclinical studies indicate that vitamin D has an 
anti-proliferative effect on androgen-independent prostate cancer (201, 202).  In 
preclinical studies, administration of vitamin D3 in nude mice with subcutaneous DU-145 
xenografts demonstrated a therapeutic effect; however, the systemic administration of 
Ad-hOC-E1 in combination with vitamin D showed marked repression of the tumors, 
indicating the potential for clinical use (199). 
 
Ad-E4PSESE1a.  As discussed above, the control of viral replication has been 
achieved by tightly controlling both E1a and E1b adenoviral genes under prostate-
specific promoters.  Recent studies have also demonstrated that tight control of viral 
replication can be achieved by placing E4 in addition to E1a under the control of two 
separate or duplicate tissue-specific promoters (203, 204).  Due to the difficulty of finding 
two active and tightly regulated promoters for the prostate and because promoter 
duplication might induce recombination, Li et al. developed a novel strategy to control 
E1a and E4 genes under a single promoter.  This is also the first report of the use of 
PSES to drive the replication of a PSRCA.  The virus, Ad-E4PSESE1a, also contains the 
gene encoding green fluorescent protein (GFP) driven by CMV promoter for the purpose 
of in vivo viral tracking.  In vitro, the replication and cell killing abilities of this virus were 
similar to that of wild-type adenovirus in PSA/PSMA-positive cells.  As expected, 
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replication of Ad-E4PSESE1a was severely impaired in PSA/PSMA-negative cells.  Ad-
E4PSESE1a effectively suppressed the growth of androgen-independent CWR22rv 
mouse xenograft tumors (205).  The oncolytic properties of this virus could be 
augmented by the replacement of CMV-GFP with a therapeutic gene under control of a 
prostate-specific promoter.   
 
Overcoming current limitations of oncolytic vectors.  Through the use of 
intravital imaging, Li et al. mapped the replication and spread of a PSRCA throughout 
prostate xenografts.  Three days after Ad-E4PSESE1a injection, a burst in GFP 
expression was observed, indicating rapid replication and viral spread, which decreased 
one week after injection.  At two weeks, tumor growth and cell killing reached 
equilibrium.  After this, tumor growth exceeded the killing rate.  A subsequent rebound in 
GFP expression was observed, indicating renewed viral amplification.  Although 
immunohistochemistry analysis revealed persistent viral infection for up to 28 days, the 
xenograft tumors did not completely respond to the viral therapy (205).  Other studies 
have also described limited viral spread and lack of tumor response despite the high 
oncolytic activity of a virus (206).  One explanation for this is that conditions within the 
established tumor may become unfavorable to support viral replication.  As tumor lysis 
occurs, the tumor environment becomes highly necrotic and hypoxic, unlike the well-
oxygenated tissues adenovirus usually infects.  The fact that virus particles accumulate 
around blood vessels within a tumor provides further supporting evidence (207).  Shen 
et al. found that levels of E1a protein but not mRNA are reduced in Ad-infected cells 
under hypoxic conditions (208).  The significance of this finding is great because 
transcription of adenoviral genes, and therefore adenoviral replication, is dependent on 
E1a.  Further work in this area is needed to improve the stability of E1a under hypoxic 
conditions. 
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 A second hypothesis to explain the poor tumor response to oncolytic therapy also 
involves the hypoxic environment created within the tumor.  Such a condition would 
induce angiogenesis, and the resulting neovasculature could then support new tumor 
growth.  Eventually, this growth may overcome viral replication. If this is a significant 
factor in lowering the efficacy of oncolytic viral therapy, then the use of an antiangiogenic 
factor as adjuvant therapy should enhance the tumor response to oncolytic therapy.  
Recently, Li et al. combined the PSRCA Ad-E4PSESE1a with a replication-defective 
adenovirus expressing the anti-angiogenic fusion product of endostatin and angiostatin, 
called EndoAngio.  It has been reported that replication-deficient vectors can co-amplify 
along with replication-competent vectors, resulting in enhanced transgene expression 
(209).  When co-administered in CWR22rv androgen-independent prostate xenografts in 
nude mice, 7 of 8 tumors completely regressed, while one demonstrated growth 
suppression for at least 14 weeks post-treatment (210).  Because the co-administration 
of multiple adenoviral vectors could result in reduced gene transduction efficiency, due 
to the need for both vectors to infect each tumor cell, Li et al. improved this therapy by 
inserting the EndoAngio expression cassette into a PSRCA.  The results were more 
dramatic, with 9 out 10 CWR22rv xenografts demonstrating complete regression and 
one tumor remaining dormant for at least 28 weeks (211).  
Another limitation to the use of early tissue-restricted replicative adenoviruses 
was the inability to deliver large or multiple therapeutic transgenes.  Critical vector 
backbone modifications have been made to allow for larger insert sizes.  The first 
modification is the chimeric Ad5/35 vector which retargets the virus by substituting the 
fiber from Ad5, which binds to CAR, with the shorter fiber from Ad35, which uses CD46 
as its cellular receptor.  The resulting chimeric genome is 756 bp shorter than wild-type 
Ad5.  In addition to this packaging advantage, Ad5/35 has greater infectivity for prostate 
cancer cells than Ad5, and neutralizing antibodies to Ad35 are not as prevalent as Ad5 
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neutralizing antibodies (81).  Modification of the adenoviral E4 region also results in 
genomic space conservation.  Open reading frames 1, 2 and 4 encode proteins with 
minimal or unknown function on viral replication and the lytic process (212), and the 
function of the gene products of open reading frames 3 and 6 overlap (213).  Deletion of 
open reading frames 1 to 4 does not significantly alter viral replication in tumor cells 
(213), and the deletion results in approximately 1.2 kb greater insert size.  The E3 region 
encodes several proteins that enable an infected cell to evade the host immune system 
and prevent apoptosis induction, functions that are not critical for viral replication (66).  In 
addition, it encodes ADP which is expressed late in infection and necessary for efficient 
cell lysis (72).  By removing the E3 region and reinserting the ADP coding sequence, 
approximately 2 kb of genomic space is conserved.  If all three vector backbone 
modifications are performed, approximately 4 kb additional space is allowed for insertion 
of therapeutic transgenes and transcriptional control elements. 
One final consideration is the circumvention of the host’s immune response.  
Transgene expression is limited by the adaptive cellular responses mounted against 
transduced cells.  One possible solution is to temporarily suppress the host’s immune 
system; however, shut-down of the entire immune system could be problematic during 
infection with replication-competent adenoviral vectors.  This has been attempted using 
cyclosporin A (214) and antibodies to deplete both CTLs and CD4 T-cells (215, 216).  
Activation of innate immunity also limits viral transduction efficiency and limits availability 
of active viral particles.  Previous studies have attempted to deplete macrophages with 
limited clinical utility (217).  Perhaps more appealing than systemic immunosuppression 
would be the local delivery of an immunomodulator.  This could best be achieved by 
direct delivery via the oncolytic vector.  Among the immune regulators, TGF-β is likely to 
the best candidates for incorporation into a PSRCA.  TGF-β is a mediator of immune 
suppression that allows tumors to escape immune surveillance (218), and its expression 
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in transduced tumor cells would decrease activation of macrophages, natural killer cells 
and CTLs.  Although local suppression of innate and adaptive immunity would be ideal 
to enhance transgene expression, it would inhibit any potential anti-tumor immune 
responses.  A third approach is to suppress the humoral anti-adenoviral immunity.  As 
stated previously, modifications to the capsid, including the fiber knob can decrease 
humoral neutralization of the vector.  Covalent modification of the viral capsid with inert 
compounds such as polyethylene glycol (PEG) has been described as a means to mask 
the neutralizing epitopes on adenoviral vectors (219).  Importantly, this modification is 
performed after viral production and purification, does not inhibit cell penetration and 
infectivity (219), and reduces both innate (220) and adaptive immune responses (221); 
however, its benefit would only be realized for one viral replication cycle. 
 
Cytotoxic Gene Therapy   
This approach to the molecular therapy of prostate cancer results in the killing of 
cancer cells by delivery and expression of pro-drug enzyme genes such as herpes 
simplex virus thymidine kinase (HSV-TK) or cytosine deaminase (CD) and apoptosis-
inducing genes such TRAIL or FasL.  To ensure the safety of such a therapy, the use of 
prostate-specific promoters is crucial to protect non-target tissues from the expression of 
such deadly gene products.  Furthermore, the use of PSRCA vectors to deliver the 
cytotoxic genes overcomes the need for multiple doses of the virus due to limited viral 
transduction and poor transgene expression. 
  
Herpes simplex virus-thymidine kinase.  In this approach HSV-TK is delivered 
to prostate cancer cells followed by systemic administration of any one of several anti-
herpetic agents such as acyclovir (ACV), ganciclovir (GCV) or valacyclovir (VAL).  These 
nucleoside analogues are phosphorylated specifically by HSV-TK, allowing incorporation 
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of the activated analogues into cellular DNA during DNA replication, resulting in chain 
termination and ultimately cell death.  The safety of this therapy resides in the fact that 
only the cells receiving HSV-TK are capable of converting the non-toxic pro-drug into an 
active metabolite.  Fortunately however, the toxic effect is not limited to the cells in which 
the pro-drug is activated.  Through a bystander effect mediated by intercellular gap 
junctions and phagocytosis of debris from dying cells, the activated drug is delivered to 
neighboring cells (222), resulting in an amplification of the cytotoxic effect throughout the 
entire tumor site.  
Previously, Eastham et al. demonstrated the sensitivity of human prostate cancer 
cells PC-3 and DU-145 to GCV cytotoxicity following the in vitro transduction of the cells 
with HSV-TK using a recombinant replication-deficient adenoviral vector (223).  Similar 
results were obtained in vivo in murine subcutaneous xenograft prostate cancer models 
following the intralesional injection of Ad-RSV-TK and Ad-CMV-TK (224, 225).  
Intratumoral injection of the vector is required if universal promoters such as RSV or 
CMV are used to drive the expression of HSV-TK.  Herman et al. developed the initial 
HSV-TK clinical trial in which a replication-deficient adenovirus carrying HSV-TK driven 
by RSV promoter was injected intralesionally, followed by administration of GCV in men 
with locally recurrent prostate cancer one or more years after definitive external beam 
radiotherapy.  This trial demonstrated the tumoricidal activity of this combination therapy, 
as evidenced by sustained decreases in serum PSA.  Unfortunately, several of the 
patients experienced self-limiting toxicities and one patient experienced moderate but 
reversible hepatic dysfunction and thrombocytopenia (99).  To circumvent such 
toxicities, Gotoh et al. developed a replication-deficient adenoviral vector which 
controlled HSV-TK expression by the PSA promoter (106). 
The first transcriptionally-targeted HSV-TK gene therapy to be translated into a 
clinical protocol was developed by Koeneman et al. to test the hypothesis that the OC 
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promoter could regulate HSV-TK expression specifically within prostate cancer cells and 
the supportive stroma of a metastasis (134).  Kubo et al. performed the phase I clinical 
trial in which two post-surgical local recurrences and nine metastatic lesions (five 
osseous and four lymph nodes) were injected with replication-defective Ad-OC-TK 
vector followed by the administration of oral VAL.  All patients tolerated this therapy with 
no severe adverse effects.  Of the eleven men, local cancer cell death was observed in 
seven patients; however, the treated lesions of all eleven men showed histological 
changes as a result of the treatment.  One patient demonstrated regression and 
stabilization of the treated lesion for up to 317 days post-treatment without additional 
treatments (135).  In follow-up Phase I/II testing of this virus, one of three men treated 
with intralesional injection of Ad-OC-TK demonstrated maintenance of a drastically 
reduced serum PSA for over 200 days post-therapy and complete radiographic 
regression of a treated lumbar metastasis by 180 days post-treatment (226).  To 
enhance transcriptional activity and transduction efficiency, Ahn et al. incorporated a 
PSES-HSV-TK expression cassette into a PSRCA called Ad-IU1 (227). 
 To improve the efficacy of HSV-TK gene therapy, Freytag et al. developed a 
novel three-legged approach to gene therapy for prostate cancer in which HSV-TK was 
fused with CD cDNA and delivered within an oncolytic virus, followed by treatment with 
external beam radiation therapy (192).  In this approach, CD, an enzyme found only in 
bacteria and certain yeast, converts the pro-drug 5-fluorocytosine (5-FC) to a highly toxic 
nucleoside analogue, 5-FU, conferring an additive effect to HSV-TK gene therapy.  This 
virus, Ad5-CD/TKrep, is based on the oncolytic ONYX-015 viral backbone.  In the initial 
phase I study, this virus showed moderate efficacy as demonstrated by decreased 
serum PSA values for several patients and complete tumor destruction in two of sixteen 
patients one year post-treatment (228).  In murine orthotopic C4-2 tumors, Ad5-
CD/TKrep was shown to be an effective adjuvant to radiation therapy (229).  This 
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efficacy was tested in a phase I study which combined Ad5-CD/TKrep prodrug therapy 
with radiation therapy.  All patients experienced a decrease in serum PSA, with a mean 
PSA half-life of 0.6 months, versus two months for patients receiving Ad5-CD/TKrep 
without radiation therapy or 2.4 months for patients receiving radiation therapy alone.  
Furthermore, up to nine months post-treatment, five out of ten patients maintained PSA 
levels ≤ 0.5 ng/ml (230).    
 
Immunotherapy 
 Prostate cancer, like most cancers, has developed mechanisms to evade the 
host immune system.  Such mechanisms include the down-regulation of class I major 
histocompatibility complex (MHC) molecules on the tumor cell surface (231) as well as 
the down-regulation of the co-stimulatory B7 molecules (232).  These means of evasion 
result in decreased presentation of tumor antigens to CD-4 T lymphocytes.  The goal of 
immunotherapy is to enhance the host immune response to prostate cancer cells.  
Current approaches involve ex vivo gene therapy of autologous or allogeneic tumor cells 
and subsequent vaccination with the irradiated cells now expressing cytokines such as 
interleukin 2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF), ex 
vivo gene transfer of prostate-specific cDNAs, such as PSA, PSMA and prostatic acid 
phosphatase (PAP), into autologous dendritic cells (DCs), and in vivo intratumoral gene 
transfer of cytokine genes. 
 
Prostate Cancer Vaccines.  The host immune system is capable of recognizing 
and eliminating malignant cells; however, the ability of tumor cells to evade immune 
surveillance and the inefficiency of the body’s antitumor response allows prostate cancer 
to persist and progress.  To develop a tumor vaccine, prostate cancer cells are 
harvested from the patient during radical prostatectomy, transfected with cytokines that 
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upregulate cell surface antigens such as B7 or MHC class I and II, expanded in culture, 
and irradiated to kill the cells.  After infusion of the autologous vaccine cells, the 
enhanced immunogenicity of the cells aids the immune system to mount a local or 
systemic immune response to the cancer (233, 234).  The first prostate vaccine clinical 
trial was developed by Simons et al.  In this study, eight men with metastatic prostate 
cancer were administered autologous, GM-CSF-transduced, irradiated cancer vaccines.  
Side effects were limited to pruritus, erythema and swelling at the site of vaccination.  
Both B and T cell responses were observed in seven of the eight patients, while T cell 
responses were observed in only two of the eight prior to vaccination (235).  A 
subsequent clinical trial demonstrated no therapeutic value of systemic administration of 
recombinant GM-CSF, thereby suggesting the importance of local secretion of GM-CSF 
by the cancer vaccines (236).  Clearly, a limitation of this approach is the harvesting and 
ex vivo manipulation of prostate cancer cells.  To overcome this, Simons et al. 
developed an allogeneic tumor vaccine, GVAX, from GM-CSF-transduced irradiated PC-
3 and LNCaP prostate cancer cell lines.  In a phase II clinical trial, the vaccines were 
well tolerated, and no dose-limiting toxicities were observed.  Two years post-treatment, 
the survival rate of patients receiving low booster doses was 41%, compared to 70% in 
patients who received higher booster doses (237).  A phase I/II clinical trial evaluated the 
safety of GVAX reengineered to secrete higher levels of GM-CSF (238).  Phase III 
clinical studies of this cancer vaccine are underway. 
 
Dendritic Cell Immunotherapy.  A second approach to prostate cancer 
vaccination involves the use of dendritic cells (DCs), the most potent antigen presenting 
cell (APC) of the immune system.  DCs produce a strong systemic T cell response by 
presenting tumor antigens on both MHC class I and II molecules (239).  In this 
vaccination strategy, autologous DCs are collected from the patient by leukopheresis, 
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expanded in culture, challenged with a prostate-specific antigen, such as PSA, PAP or 
PSMA by either peptide pulsing or transfection with antigen cDNA, and reintroduced into 
the patient.  Murphy et al. demonstrated the safety of HLA-A2-specific PSMA peptide-
pulsed DC immunotherapy in a phase I clinical trial in which an enhanced cellular 
immune response was observed in all HLA-A2-positive patients; however, only seven 
out of fifty-one patients experienced a decrease in serum PSA ≥ 50% (240, 241).  In a 
phase II clinical trial, GM-CSF was administered as a systemic adjuvant in patients 
receiving PSMA-pulsed autologous DC vaccines.  Nineteen out of sixty-two patients 
were identified as partial or complete responders.  Of the responders, 58% appeared to 
have durable responses (236, 242).      
 
In Vivo Immunotherapy.  A third approach to immunotherapy for prostate 
cancer is the delivery of cytokines to the local tumor environment.  IL-2 is a potent 
activator of CD4+ and CD8+ T cells as well as natural killer (NK) cells, and its effect on 
prostate cancer is due to its ability to expand T cell populations with antitumor activity.  
Tumors that respond to IL-2 therapy demonstrate an infiltration of lymphocytes.  In 
mouse PC-3 orthotopic tumor models, tumor growth was suppressed by 94% following 
systemic injection of IL-2 (243).  Belldegrun et al. developed a gene therapy protocol in 
which twenty-four men with locally advanced prostate cancer were injected 
intraprostatically with a DNA-liposome complex encoding the IL-2 gene.  This therapy 
was well tolerated.  Immunohistochemical analysis of the tumor site demonstrated T cell 
infiltration, and serum PSA responses were observed in sixteen of the  men on day one 
and fourteen of the twenty-four on day eight (244).  Trudel et al. developed a phase I 
clinical trial to evaluate the safety of intraprostatic injection of adenoviral vectors 
encoding the IL-2 gene.  Twelve men were injected with Ad-IL-2 four weeks prior to 
prostatectomy.  No dose-limiting toxicities were observed.  On pathological evaluation, 
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all patients experienced a local inflammatory response with an infiltrate of CD3+CD8+ 
cells.  At low viral doses, five out of five patients experienced a mean decrease in PSA 
of 33%, while patients receiving the highest viral doses experienced transient elevations 
in PSA levels before returning to baseline (245).  IL-12 is also under investigation as a 
potent immunotherapy for prostate cancer.  In addition to activation of NK cells and 
CTLs, IL-12 has direct cytotoxic effects on tumor cells and anti-angiogenic properties 
(246, 247). 
 
Thesis Overview 
Dose-limiting toxicities and treatment resistance with conventional therapies for 
advanced prostate cancer warrant the development of novel therapeutic strategies.  The 
studies described in this thesis characterize a novel molecular therapy for advanced 
prostate cancer and examine its efficacy in combination with conventional therapy.  The 
first aim of the thesis is to determine whether the addition of the cytotoxic transgene 
TRAIL will enhance the in vitro and in vivo anti-tumor activity of a replication-competent 
adenovirus against androgen-independent prostate cancer.  The second aim is to 
determine whether the neoadjuvant treatment of advanced prostate cancer with a 
PSCRA expressing TRAIL will result in the radio-sensitization of tumor cells, thereby 
enhancing the therapeutic effect of EBRT.  The third aim is to delineate the mechanism 
responsible for the enhancement of the therapeutic efficacy of EBRT by a PSRCA 
expressing TRAIL.  I expect that these studies will provide insight into new treatment 
modalities for high risk prostate cancer and lead to translation to a clinical trial.     
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Materials and Methods 
 
Cell Culture 
The packaging cell line HER911E4 stably expresses the adenoviral E4 gene 
under control of the inducible tetR promoter (248) and was derived from the human 
embryonic retinoblast (HER911) cell line which was transformed with a plasmid 
containing the adenoviral genome (bp 79-5789) (249).  HER911E4 cells were cultured in 
DMEM supplemented with 10% FBS (Atlanta Biologicals, Lawrenceville, GA), 1% 
penicillin-streptomycin (Gibco, Grand Island, NY), 0.1 mg/ml hygromycin B (Calbiochem, 
San Diego, CA) and 2 µg/ml doxycycline (Sigma, St. Louis, MO).  To induce adenoviral 
E4 gene expression, HER911E4 cells were cultured in medium without doxycycline for 
24 hours prior to infection.  CWR22rv is an androgen-independent, PSA/PSMA-positive 
prostate cancer cell line derived by the propagation of the androgen-dependent parental 
xenograft, CWR22, in nude mice (250).  LNCaP is an androgen-dependent, PSA/PSMA-
positive prostate cancer cell line established from a lymph node of a patient with 
metastatic disease (251).  C4-2, an androgen-independent, PSA/PSMA-positive prostate 
cancer line, was derived by co-injection of LNCaP and bone stromal cells into nude mice 
(252).  PC-3 is an androgen-independent, PSA/PSMA-negative prostate cancer cell line 
that was originally derived from the bone marrow aspirates of a patient with bone 
metastases (253).  DU-145, an androgen-independent prostate cancer cell, is 
PSA/PSMA-negative and was derived from a brain lesion from a patient with confirmed 
metastatic disease (254).  Prostate cancer cell lines used in these studies (Table 3) were 
cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin and streptomycin.  
Adult human dermal fibroblasts (HDFa) were cultured in Medium 106 supplemented with 
2% FBS, 1 µg/ml hydrocortisone, 10 ng/ml human epidermal growth factor, 3 ng/ml basic 
fibroblast growth factor and 10 µg/ml heparin (Cascade Biologics, Portland, OR).  LoVo 
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is a colorectal adenocarcinoma cell line derived from a supraclavicular lymph node of a 
patient with metastatic Dukes’ type C, grade IV disease (255).  T24 was established 
from a transitional cell carcinoma of the urinary bladder (256).  LoVo and T24 cell lines 
were cultured in RPMI 1640 media supplemented with 10% FBS and 1% penicillin and 
streptomycin.  All cells were maintained in a humidified incubator at 37oC and 5% CO2. 
 
Table 3.  Characterization of prostate cancer cell lines used in these studies.  PSES is 
transcriptionally active in PSA/PSMA-positive cells.  Common mutations in prostate 
cancer cell lines include androgen receptor (AR) and tumor suppressor p53. 
Cell Line PSA/PSMA Androgen Mutations Origin 
 
    
CWR22rv + Independent AR, p53 Primary tumor 
LNCaP + Dependent AR Lymph node met. 
C4-2 + Independent AR LNCaP derivative 
PC-3 - Independent p53 Lumbar met. 
DU-145 - Independent p53 Brain met. 
 
    
 
 
 
Production of Adenoviral Vectors 
  Ad-IU2 was developed by modifying Ad-E4PSESE1a, the previously described 
PSRCA with a CMV promoter-driven enhanced green fluorescent protein (EGFP) marker 
(205).  To construct Ad-IU2, human full-length TRAIL cDNA from pORF-hTRAIL 
(InvivoGen, San Diego, CA) was cloned downstream of PSES into pAd1020SfidA (OD 
260, Boise, ID), the adenoviral cloning vector containing the left ITR and packaging 
signal, to make pAd1020SfidA-PSES-TRAIL, which was further digested with SfiI to 
release the left ITR and PSES-TRAIL expression cassette.  This fragment was cloned 
into pAd288E1b-E4PSESE1a (205), the modified adenoviral genome vector, and the 
ligation product was transformed into TOP10 E. coli competent cells (Invitrogen, 
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Carlsbad, CA).  The adenoviral genome was released by digestion with PacI and 
transfected into HER911E4 cells with Lipofectamine 2000 (Invitrogen) at 80% confluency 
in a 6-well plate.  After 7 to 10 days, once cytopathic effect of the virus was evident by 
light microscopy, the viral supernatant was harvested by 3 rounds of freezing (mixture of 
95% ethanol and dry ice) and thawing (37oC water bath).  To further amplify Ad-IU2, 
HER911E4 cells were infected with the viral supernatants, in succession from a P60 
dish, to a T75 flask, to a triple flask, and finally to 10 triple flasks.  The final viral 
supernatant was applied to a CsCl gradient (1.5 g/ml, 1.35 g/ml and 1.25 g/ml) and 
centrifuged at 75,000 x g and 10oC for 1 hour.  The adenoviral band, found between the 
1.25 g/ml and 1.35 g/ml gradients, was applied to 1.35 g/ml CsCl and centrifuged 
overnight at 75,000 x g and 10oC.  The double gradient-purified adenoviral stock was 
dialyzed for 24 hours against a dialysis buffer of 1 µM MgCl2, 10 µM Tris-HCl (pH 7.5) 
and 10% glycerol, changing the buffer every 8 hours.  Dialyzed virus was aliquoted and 
stored at -70oC.  Experiments were repeated using a second batch of adenovirus to 
verify results. 
Replication-competent control viruses used in this study include Ad-E4PSESE1a 
and Ad-IU1.  Ad-IU1 was constructed in a similar fashion as Ad-IU2; however, a PSES-
HSV-TK expression cassette replaces the PSES-TRAIL expression cassette (227).  
Without administration of a nucleoside analog prodrug, the only cytotoxicity provided by 
Ad-IU1 is due to replication.  As a replication-defective control, Ad-∆TATA-E1a, in which 
the E1a TATA box was deleted from the Ad-E4PSESE1a viral backbone, was used.  To 
achieve equal bioactivity of Ad-IU2 and control viruses, a titer assay was performed.  1 x 
104 HER911E4 cells were plated overnight in 96-well plates and infected with serial 
dilutions of Ad-IU2, Ad-IU1, Ad-E4PSESE1a or Ad-∆TATA-E1a, so that 10 wells in every 
row received the same dose, ranging from 10-3 to 10-10.  Media were changed 24 hours 
after infection, and cells were observed daily under light microscopy for cytopathic effect.  
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7 days after infection, lethal dose (LD50) was determined to be the dose at which 50% of 
cells or greater were killed (at least 5 wells per row).  Viral titers were calculated as LD50 
units (LDU) per µl.  Conversions from viral particles (vp) to LDU were as follows:  Ad-
IU2, 1 x 10-5 LDU/vp; Ad-IU1, 6 x 10-6 LDU/vp; Ad-E4PSESE1a, 7.8 x 10-5 LDU/vp; and 
Ad-∆TATA-E1a, 1.5 x 10-5 LDU/vp. 
 
Western Blot Analysis 
 For TRAIL expression, 1 x 106 CWR22rv cells were cultured overnight in 6-well 
plates and infected with 0.01 LDU/cell Ad-IU2 or Ad-∆TATA-E1a.  As a positive control, 
CWR22rv cells were transfected with pORF-hTRAIL using Lipofectamine 2000.  Media 
were changed 24 or 3 hours after infection or transfection, respectively.  For adenoviral 
E1a expression, 1 x 106 C4-2, CWR22rv, DU-145 and PC-3 cells were cultured 
overnight in 6-well plates and treated with Ad-IU1, Ad-IU2, Ad5-Wt and PBS at 100 
vp/cell for C4-2 and CWR22rv and 1000 vp/cell for DU-145 and PC3 cells.  Media were 
changed 24 hours after infection.  48 hours after infection, cells were washed with cold 
PBS and harvested with radioimmunoprecipitation assay (RIPA) buffer containing 1 ml 
modified RIPA buffer, 20 µl 57 mmol/L phenylmethylsulfonyl fluoride and 2.5 µl 
phosphatase inhibitor cocktail (Sigma-Aldrich, St. Louis, MO).  Cell lysates were kept on 
ice for 1 hour, centrifuged to pellet debris, and supernatants kept at -70oC.  To determine 
whether cleaved TRAIL was present in Ad-IU2 conditioned media, 1 x 106 CWR22rv 
cells were infected with 0.01 LDU/cell, as above.  48 hours after infection, the medium 
was harvested, centrifuged at 800 x g for 10 minutes, and the cell lysate was prepared 
as above.  As positive controls, various dilutions from 100 to 25 ng/ml recombinant 
human TRAIL (rhTRAIL) (BioSource, Camarillo, CA) were loaded.  Protein concentration 
was analyzed by Bradford assay (Bio-Rad, Hercules, CA), and 20 µg of protein (with 0.3 
M DTT) were separated by 10 or 12% SDS-PAGE and transferred to a nitrocellulose 
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membrane.  Membranes were blocked overnight at 4oC in 5% fat-free milk and TBST 
and incubated with primary antibodies against human TRAIL (Santa Cruz Biotechnology, 
Santa Cruz, CA), β-actin (Sigma) or Ad5 E1a (BD Biosciences, Franklin Lakes, NJ).  
Blots were incubated with appropriate HRP-conjugated secondary antibodies, and 
specific binding was detected by ECL (Pierce, Rockford, IL). 
 
Measurement of TRAIL Surface Expression 
 1 x 105 CWR22rv cells were plated overnight in 24-well plates and infected with 
0.01 LDU/cell Ad-IU2 or Ad-IU1 or treated with PBS.  Fresh media were replaced 24 
hours after infection.  48 hours post-infection, cells were harvested and resuspended in 
100 µl ice cold staining buffer (PBS containing 10% FBS and 1% sodium azide) in 
fluorescence-activated cell sorting (FACS) tubes.  Cells were stained with PE-
conjugated anti-human TRAIL antibody (Abcam, Cambridge, MA) for 1 hour at 4oC, 
protected from light.  Cells were washed twice with ice cold PBS and resuspended in 
500 µl staining buffer.  Analysis was performed on a FacScan flow cytometer (BD 
Biosciences) and data analyzed using WinMDI 2.9 software.   
 
Viral Replication Assay 
 1 x 106 CWR22rv, C4-2, LNCaP, PC-3 and DU-145 prostate cancer cell lines 
were seeded in 6-well plates overnight and infected with standardized doses of virus 
based on each cell line’s infectivity (205).  Media were changed 24 hours after infection, 
and cells were observed daily by light microscopy for cytopathic effect.  Viral 
supernatants were harvested 3 days after infection by subjecting the cells and media to 
three freeze-thaw cycles and centrifuging to remove the cell debris pellet.  HER911E4 
cells were plated in 96-well plates and infected with serial dilutions of viral supernatant 
ranging from 1 to 10-11, so that every well in each column received the same dose.  Cells 
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were examined for cytopathic effect on day 7, and LD50 was recorded as the dose 
causing cytopathic effect in at least four of eight wells in one column. 
 
Measurement of Apoptosis Induction 
 CWR22rv, C4-2, LNCaP, PC-3 and DU-145 prostate cancer cells were seeded in 
24-well plates overnight and infected with 0.01 LDU/cell Ad-IU2 or Ad-IU1 or treated with 
PBS.  24 hours after infection, media and cells were harvested, washed with PBS and 
resuspended in 100 µl binding buffer.  LNCaP cells were also infected with 0.01 LDU/cell 
Ad-IU2 or Ad-IU1 or treated with PBS, and 48 hours after treatment, media and cells 
were harvested, washed with PBS and resuspended in 100 µl binding buffer.  Cells were 
stained with 2.5 µl each of Annexin V-FITC and propidium iodide (PI) (BD Biosciences, 
Pharmingen) for 15 minutes at room temperature and analyzed by FACS analysis as 
above.  Cells that were single-positive for Annexin V-FITC or double-positive for Annexin 
V-FITC and PI were considered positive for apoptosis. 
 
In Vitro Cell Killing Assay 
 CWR22rv, C4-2, LNCaP and HDFa cells were seeded in 24-well plates overnight 
and treated with various doses of Ad-IU2, Ad-E4PSESE1a, Ad-∆TATA-E1a or PBS.  
Media were replaced with fresh medium 24 hours after infection, and cells were 
maintained in culture, changing media every other day, until a cytopathic effect was 
observed under light microscopy.  Once a cytopathic effect was evident, cells were fixed 
with 1% paraformaldehyde, washed twice with cold PBS, stained with 0.5% crystal violet 
solution for 10 minutes and washed with cold tap water.  To quantitate the remaining 
attached cells, stained cells were permeabilized with 1% SDS and analyzed for optical 
density at 570 nm on a Spectra Max Plus spectrophotometer (Molecular Devices, 
Sunnyvale, CA).  Relative cell number was determined as the ratio of the A570 value for 
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Ad-IU2-, Ad-E4PSESE1a- or Ad-∆TATA-E1a-treated cells to the A570 value for untreated 
(PBS) cells at each viral dose and was used to evaluate cell survival. 
 
Evaluation of Bystander Effect 
 CWR22rv cells were plated in a 12-well plate overnight and infected with 0.01 
LDU/cell Ad-IU2 or Ad-IU1 or treated with PBS.  24 hours post-infection, cells were 
washed three times with cold PBS to remove residual virus, and fresh medium was 
replaced.  PC-3 cells stably expressing a fusion of humanized Renilla luciferase (hrl) and 
monomeric red fluorescent protein (mrfp) reporter genes were co-cultured with the 
CWR22rv cells at a ratio of 3 CWR22rv cells to 1 PC-3 cell.  The plasmid conferring 
expression, pcDNA3.1-CMV-hrl-mRFP, was constructed from pcDNA3.1-CMV-hrl-mrfp-
ttk (a gift from Dr. Sanjiv Gambhir, Stanford University, CA) by deleting truncated 
thymidine kinase (ttk) from the vector.  24 hours after co-culture, media and cells were 
harvested, washed with PBS and resuspended in 100 µl binding buffer.  Cells were 
stained with 2.5 µl Annexin V-FITC for 15 minutes at room temperature and analyzed by 
FACS analysis as above.  Percent apoptotic PC-3 cells was determined as the fraction 
of Annexin V-FITC-positive cells in the mRFP-positive population. 
 To determine whether direct cell-to-cell contact was required to mediate a 
bystander effect, CWR22rv cells were seeded overnight in 6-well plates and infected 
with 0.01 LDU/cell Ad-IU2, Ad-IU1 or Ad-E4PSESE1a.  48 hours after infection, media 
were harvested, centrifuged at 800g for 10 minutes to remove dead cells and debris, and 
heat-inactivated at 56oC for 30 minutes.  CWR22rv or PC-3 cells were seeded in 24-well 
plates overnight and treated with the heat-inactivated medium for 24 hours, at a ratio of 
1:1.  Media and cells were harvested and analyzed for apoptosis by FACS analysis as 
described above.  To determine whether adenovirus was inactivated by heat-treatment, 
CWR22rv cells were seeded onto 24-well plates overnight and treated with conditioned 
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medium from Ad-E4PSESE1a-infected CWR22rv cells, as above, before or after heat-
inactivation at 56oC for 30 minutes.  24 hours after treatment, cells were washed with 
cold PBS, harvested, fixed with 2% paraformaldehyde, resuspended in PBS, and 
analyzed for GFP expression by FACS analysis. 
 
In Vivo Evaluation of Ad-IU2 Anti-Tumor Effect 
 CWR22rv xenografts were established by injecting 2 x 106 CWR22rv cells 
subcutaneously (SQ) into the flanks of 6 week-old male athymic nude mice.  One week 
after injection, mice were anesthetized and bilateral orchiectomies were performed to 
ablate the production of androgens.  Once tumors were established (33.5 to 65.5 mm3), 
mice were injected intratumorally with 2 x 104 LDU Ad-IU2, Ad-IU1 (PSRCA control) or 
PBS (vehicle control).  Tumor sizes were monitored weekly, and tumor volumes were 
calculated as (L2 x W) / (π/6).  Tumor data was presented as fold-increase in tumor size 
relative to initial size at time of treatment.  Mice were sacrificed at 6 weeks, and tumors 
were harvested, fixed in formalin and embedded in paraffin.  All animal procedures were 
approved by the Indiana University School of Medicine Institutional Animal Care and Use 
Committee (IACUC).  Tumor sections were deparaffinized with xylene, hydrated in 
ethanol and distilled water, and stained with Hematoxylin and Eosin (H&E).  Tumor 
sections were evaluated for in situ apoptosis using a fluorometric terminal dUTP nick-
end labeling (TUNEL) assay (Promega, Madison, WI).  Nuclei were counterstained with 
DAPI and tumor sections visualized by confocal microscopy on a Bio-Rad MRC1024 
laser scanning dual-photon confocal microscope (Bio-Rad). 
 
Clonogenic Assay 
 1 x 106 CWR22rv or C4-2 cells were plated overnight in T25 flasks and treated 
with 0.003 LDU/cell Ad-IU2, Ad-E4PSESE1a, 75 ng/ml rhTRAIL or PBS.  24 hours after 
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infection, media were replaced with fresh media, and each treatment group was 
irradiated using a Gammacell 40 Cs-137 irradiator (MDS Nordion, Ottawa, ON, Canada) 
for a dose of 0, 1, 2, 3 or 4 Gy.  24 hours after irradiation, cells were washed with cold 
PBS, harvested, counted and reseeded at low densities into 5 P100 dishes for each 
treatment group.  Cell seeding was adjusted for the relative plating efficiencies of each 
experimental group.  Cells were maintained in culture for ~3 weeks (CWR22rv) and ~2 
weeks (C4-2), changing the media once per week.  Colony formation was monitored by 
light microscopy, and at the end of the incubation period, colonies were washed with 
cold PBS, stained with 0.5% crystal violet solution for 10 minutes and washed with cold 
tap water.  Colonies of at least 50 cells were counted, and plating efficiencies were 
calculated as the number of colonies formed / the number of cells plated.  Survival for 
each experimental group was calculated as the plating efficiency for the irradiated cells / 
the plating efficiency of non-irradiated cells within each treatment group.  Survival data 
was analyzed on a logarithmic scale using the linear-quadratic model [ ln(SF/SFo) = -αD 
+ βD2 ] to determine the shape of the curve.  The mean lethal dose (D0) was determined 
as the RT dose at which 37% of cells survive, and was compared to that of PBS for each 
treatment group to calculate the dose reduction factor (DRF).   
 
Infectivity Assay 
 To achieve equal infectivity in non-prostatic bladder and colorectal cell lines, GFP 
expression was compared for these cells to that of prostate cancer cells following 
infection with Ad-GFP, a replication-deficient adenovirus expressing GFP under control 
of the CMV promoter.  7.5 x 104 CWR22rv, LoVo and T24 cells were plated overnight in 
24-well plates and infected with Ad-GFP at doses ranging from 0 to 1000 vp/cell for 
CWR22rv, 0 to 5,000 vp/cell for LoVo and 0 to 10,000 for T24 cells.  24 hours after 
infection, cells were washed with cold PBS, harvested, fixed with 2% paraformaldehyde, 
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resuspended in PBS, and analyzed for GFP expression by FACS analysis.  GFP 
expression of LoVo and T24 cell lines was compared to that of CWR22rv cells to 
determine relative infectivity, which was used in subsequent experiments.   
 
MTT Assay for In Vitro Cell Survival 
 1 x 104 LoVo and 7.5 x 103 T24 cells were cultured overnight in 96-well plates 
and infected with 0.2 LDU/cell (LoVo) or 4 LDU/cell (T24) Ad-IU2, Ad-E4PSESE1a or 
PBS.  24 hours after infection, media were changed and the cells were irradiated using a 
Nordion Gammacell 40 for a dose of 0, 1, 2, 3 or 4 Gy.  Cells were maintained in culture, 
changing the media every other day.  96 hours after irradiation for LoVo cells or 48 hours 
after irradiation for T24 cells, cell survival was assessed by MTT assay.  25 µl of 5 mg/ml 
MTT solution (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added 
to each well of cells containing 100 µl of medium and incubated at 37oC for 3 hours.  
Following the incubation period, the media were removed, and the converted dye was 
solubilized with 75 µl acidic isopropanol (0.04 N HCl in absolute 2-propanol).  
Absorbance of the reduced dye was analyzed by photospectroscopy at a wavelength of 
570 nm.  Cell viability at each radiation dose was determined as the percentage of the 
A570 value for each viral treatment group compared to the A570 value for untreated (PBS), 
Ad-IU2- or Ad-E4PSESE1a-treated cells at 0 Gy. 
 
Measurement of Apoptosis Induction Following Irradiation of Cells 
 7.5 x 104 CWR22rv and C4-2 cells were cultured overnight in 24-well plates and 
infected with 0.003 LDU/cell Ad-IU2, Ad-E4PSESE1a or PBS.  24 hours after infection, 
media were replaced with fresh media, and the cells were irradiated using a Nordion 
Gammacell 40 for 0 or 3 Gy.  24 hours after irradiation, media and cells were harvested, 
washed with PBS and resuspended in 100 µl binding buffer.  Cells were stained with 2.5 
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µl each of Annexin V-FITC and propidium iodide (PI) (BD Biosciences, Pharmingen) for 
15 minutes at room temperature and analyzed by FACS analysis as above.  Cells that 
were single-positive for Annexin V-FITC or double-positive for Annexin V-FITC and PI 
were considered as positive for apoptosis. 
 
Cell Cycle Analysis 
 To determine the effect of Ad-IU2 infection on the cell cycle of PSA/PSMA 
prostate cancer cells, 1.5 x 105 CWR22rv and C4-2 cells were plated in 12-well plates 
overnight and treated with 0.003 LDU/cell Ad-IU2, Ad-E4PSESE1a, 100 ng/ml rhTRAIL 
or PBS.  24 hours after treatment, the cells were washed with cold PBS, harvested and 
fixed with 2% paraformaldehyde.  To determine the effect of Ad-IU2 infection on the cell 
cycle of irradiated prostate cancer cells, CWR22rv and C4-2 cells were treated as 
above.  24 hours after treatment, cells were irradiated with a dose of 0 or 3 Gy RT.  8, 16 
and 24 hours after irradiation, cells were washed with cold PBS, harvested and fixed 
with 2% paraformaldehyde.  All cells were then permeabilized with 0.6 % NP-40 
detergent, treated with 1 mg/ml RNaseA and stained with 0.1 mg/ml PI for 30 minutes.  
DNA content was analyzed by FACS analysis on a Beckton Dickinson Facscan flow 
cytometer.  Cell cycle data was plotted as a histogram from FL2-area on WinMDI 2.9, 
and cell cycle calculations were performed by the standard algorithms within the 
Windows software, Cylchred.  The percentage of cells in G1, S and G2/M following 
combined treatment was compared for all treatment groups. 
 
Statistical Analysis 
 Statistical significance was determined using two-way ANOVA with Bonferroni’s 
post-test or unpaired t test, as indicated, using GraphPad Prism version 5.01 for 
Windows (GraphPad Software, San Diego, CA).  Statistical significance was defined as 
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a P value < 0.05, or better.  Experiments were plated in triplicate, unless otherwise 
noted, and performed as at least three independent experiments. 
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Development of Ad-IU2 for Androgen-Independent Prostate Cancer 
 
Background 
Current therapies for men presenting with localized prostate cancer include 
radical prostatectomy, external beam radiation therapy and brachytherapy; however, 
25% of these men will experience local failure within ten years of treatment (50, 258).  
ADT is used for locally advanced and high risk prostate cancer, resulting in a slower rate 
of cancer growth and dissemination to distant sites; however, nearly all advanced 
prostate cancers eventually fail hormone therapy.  Results from phase III clinical studies 
have recently suggested a role for docetaxel in the treatment of androgen-independent 
prostate cancer, demonstrating a two month survival advantage in addition to palliation 
(259, 260).  Unfortunately, dose-limiting toxicities associated with such therapies limit the 
amount of the drug that can be delivered to the tumor, allowing the cancer to survive and 
fail therapy.  Due to its ability to selectively target prostate cancer cells through the use 
of tissue-specific promoters and its widely demonstrated clinical safety profile, molecular 
therapy for androgen-independent prostate cancer is an attractive adjuvant to 
conventional therapies. 
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), also known as 
Apo-2 ligand, is a member of the tumor necrosis factor (TNF) family.  Originally 
discovered because of its similarity to Fas-ligand, TRAIL is a 32 kDa type II 
transmembrane protein, whose C-terminal extracellular domain (amino acids 114-281) is 
homologous to other members of the TNF family (261, 262).  After binding of 
homotrimeric TRAIL to the death domain-containing receptors DR4 (263) and DR5 
(264), the apoptotic signal is transduced via the adapter molecule, Fas-associated death 
domain (FADD), which recruits the initiator caspases to the death-inducing signaling 
complex (DISC) (265) (Figure 4).  TRAIL has been shown to preferentially kill tumor cells
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Figure 4.  Induction of 
apoptosis by TRAIL via the 
extrinsic and intrinsic 
pathways.  Trimerized 
TRAIL induces 
trimerization of the TRAIL 
receptors (DR4 or DR5).  
This in turn causes 
clustering of the death 
domains (DD) and 
association with the Fas-
associated death domain 
(FADD), which serves as  
an  adaptor   molecule   for 
the death effector domain (DED) of the initiator caspases.  Upon formation of the death-
inducing signaling complex (DISC), procaspase 8 is recruited to the membrane and 
autocatalytically cleaved to its active state, caspase 8.  In the extrinsic pathway, the 
caspase cascade continues with activation of caspase 3 by caspase 8.  The apoptosis 
signal is amplified through a loop in the intrinsic pathway.  Activated caspase 8 truncates 
Bid to tBid, which destabilizes the mitochondrial membrane, releasing cytochrome C 
from the cytosol.  Cytochrome c binds to apoptotic protease activating factor 1 (Apaf1) 
which results in the cleavage and activation of caspase 9.  This in turn further activates 
caspase 3 leading to enhanced apoptotic protease activation. 
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over normal cells, which reflects its role as a key tumor immunosurveillance molecule in 
the body (266).  This marked specificity for cancer cells gives TRAIL a distinct 
advantage over other cancer therapies. 
TRAIL expression has been detected in several normal human tissues, 
suggesting that TRAIL is not toxic to those cells in vivo (263).  These cells are shielded 
from TRAIL by the surface expression of antagonistic decoy receptors.  Three non-
apoptotic signaling receptors exist for TRAIL, and these include DcR1 which lacks an 
intracellular death domain (264), DcR2 which contains a truncated death domain that 
activates anti-apoptotic NFκB signaling (267), and osteoprotegrin, a secreted receptor 
for TRAIL which also inhibits osteoclastogenesis (268).  Several prostate cancer cell 
lines including ALVA-31, DU-145 and PC-3 are extremely sensitive to TRAIL and 
undergo apoptosis when exposed; however, other cell lines such as LNCaP are highly 
resistant (269).  This resistance has been shown to be reversed by infection with 
adenovirus (270), treatment with chemotherapeutic agents such as paclitaxel, 
vincristine, etoposide, doxorubicin or camptothecin (271), or treatment of the cells with 
radiation therapy (272). 
Recent preclinical and clinical studies of molecular therapy approaches with 
TRAIL have involved a soluble form of the protein that is secreted out of producer cells 
and into the surrounding tumor matrix.  This strategy proved advantageous over the 
repeated intravenous administration of recombinant TRAIL protein, as the 
pharmacologic half-life of the protein in serum is only 32 minutes (273).  Although 
repeated administration of soluble TRAIL was not toxic to normal tissues in mice (274) 
and non-human primates (273), recent data suggest that cultured human hepatocytes 
may be sensitive to soluble forms of TRAIL (275, 276).  To enhance the safety and 
clinical feasibility of this gene therapy strategy for high risk prostate cancer, I developed 
a PSRCA, called Ad-IU2, encoding full-length membrane-bound TRAIL under the 
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transcriptional control of PSES.  Furthermore, to limit the replication of Ad-IU2 to 
prostate cancer cells, adenoviral E1a, E1b and E4 genes were placed under control of 
PSES.  As PSES is active only in PSA/PSMA-positive cells, adenoviral replication and 
TRAIL expression should be limited to PSA/PSMA-positive cells.  To date, this is the first 
prostate-specific promoter-driven TRAIL molecular therapeutic strategy for advanced 
prostate cancer.  In this portion of my thesis, I test the hypothesis that the addition of the 
cytotoxic transgene TRAIL will enhance the in vitro and in vivo anti-tumor activity of a 
replication-competent adenovirus against androgen-independent prostate cancer. 
 
In Vitro and In Vivo Characterization of Ad-IU2 
Ad-IU2 Delivered Surface-Bound TRAIL and Replicated Effectively in PSA/PSMA-
Positive Cells 
The structure of Ad-IU2 (Figure 5) is based on the PSRCA, Ad-E4PSESE1a, in 
which the E1 promoter was deleted and E1a moved to the right ITR E4 region under 
control of the bidirectional PSES enhancer sequence (205).  Full-length, membrane-
bound TRAIL cDNA was inserted at the left ITR in the E1a region upstream from  
 
 
 
Figure 5.  Genomic structure of Ad-IU2.  TRAIL cDNA was cloned into the left ITR under 
control of the bidirectional PSES enhancer.  To avoid interference with the adenoviral 
packaging sequence (ψ), E1a was placed at the right ITR under the transcriptional 
control of PSES along with E4.  Replication competent adenoviral control vector, Ad-IU1 
was constructed by replacing the PSES-TRAIL cassette with a PSES-HSV-TK 
expression cassette (*). 
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adenoviral E1b, both under the control of PSES.  As depicted in Figure 6, full-length 
TRAIL protein expression was confirmed by western blot in Ad-IU2-infected PSA/PSMA-
positive CWR22rv prostate cancer cells.  Immunoblot of Ad-IU2-infected cells revealed a 
32 kD band comparable in size to that of full-length TRAIL expressed in pORF-hTRAIL-
transfected cells.  Infection with Ad-∆TATA-E1a confirmed the lack of endogenous 
TRAIL expression or the upregulation of TRAIL by adenoviral infection in CWR22rv cells.   
 
 
Figure 6.  Expression of TRAIL in 
PSA/PSMA-positive CWR22rv 
cells was confirmed by western 
blot.  CWR22rv cells were 
infected with 0.01 LDU/cell Ad-IU2 
or Ad-∆TATA-E1a (negative 
vector control).  As a positive 
control,    cells   were   transfected    
with pORF-hTRAIL.  Forty-eight hours after infection or transfection, cells lysates were 
harvested and 20 µg of sample were separated by 10% SDS-PAGE.  The blot was 
probed with anti-human TRAIL antibody.  Full length monomer TRAIL was detected in 
the lysates of Ad-IU2-infected and pORF-hTRAIL-transfected CWR22rv cells at 
approximately 32 kDa.  The double band detected in Ad-IU2-infected lysates 
demonstrates a commonly observed phenomenon in our laboratory, likely due to 
alternative ATG sites in adenoviral-expressed transgenes.  No endogenous TRAIL 
expression was detected following infection with Ad-∆TATA-E1a. 
 
To confirm that TRAIL was expressed on the cellular membrane of infected cells, FACS 
analysis for cell-surface expression of TRAIL was performed.  Infection of CWR22rv 
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prostate cancer cells with Ad-IU2 resulted in a significant enhancement of TRAIL surface 
expression (28.6% vs. 2.7%, p <0.001), compared to infection with the non-TRAIL 
expressing vector, Ad-IU1 (Figure 7). 
 
 
Figure 7.  Cell surface expression of 
TRAIL was confirmed in CWR22rv 
prostate cancer cells following infection 
with Ad-IU2.  CWR22rv cells were infected 
with 0.01 LDU/cell Ad-IU2 or Ad-IU1.  
Forty-eight hours after infection, cells were 
harvested and stained with PE-conjugated 
anti-human  TRAIL  antibody  for  one hour 
and analyzed for cell surface expression by FACS.  Membrane-bound TRAIL was 
detected in Ad-IU2-infected CWR22rv cells. 
 
Previous studies have demonstrated that adenoviral vectors expressing 
apoptosis-inducing transgenes and death ligands replicate poorly due to decreased 
adenoviral gene expression and producer cell toxicity.  This results in decreased 
replication efficiencies, low production yields and poor transduction efficiencies (277).  
Expression of TRAIL protein in cells may be inversely proportional to the ability of the 
virus to replicate in those cells; therefore, I performed a replication assay in prostate 
cancer cell lines to determine whether Ad-IU2 replication efficiency was inhibited by 
TRAIL expression.  Ad-IU2 replicated as efficiently as the PSRCA, Ad-E4PSESE1a, in 
PSA/PSMA-positive cells; however, Ad-IU2 failed to propagate in PSA/PSMA-negative 
cells, resulting in viral output yields comparable to that of the replication-deficient virus, 
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Ad-∆TATA-E1a (Table 4).  These results demonstrate that Ad-IU2 replication was not 
hindered by the expression of TRAIL in PSA/PSMA-positive prostate cancer cells.  
Because control of viral replication was achieved through prostate-specific 
transcriptional regulation of adenoviral early genes, including E1a, I tested whether E1a 
protein expression was limited to PSA/PSMA-positive cells.  As demonstrated in Figure 
8, E1a protein was expressed in all cell lines following infection with Ad-wt.  On the other 
hand, after infection with Ad-IU2, E1a protein expression was restricted to PSA/PSMA-
positive C4-2 and CWR22rv cells.  These data are consistent with the results from the 
propagation assay, suggesting that the selectivity of Ad-IU2 replication for PSA/PSMA- 
 
 
Table 4.  Ad-IU2 replicated efficiently in and restricted to PSA/PSMA-positive prostate 
cancer cells.  1 x 106 PSA/PSMA-positive (CWR22rv, C4-2 and LNCaP) and 
PSA/PSMA-negative (PC-3 and DU-145) cells were infected with the indicated input 
dose of either Ad-∆TATA-E1a, Ad-E4PSESE1a or Ad-IU2.  Viral supernatants were 
harvested 72 hours post-infection and applied to HER911E4 producer cells at serial 
dilutions ranging from 1 to 10-11.  Cytopathic effect was examined by light microscopy, 
and LD50 was calculated as the greatest viral dilution factor producing a cytopathic effect 
in at least 4 of 8 wells.  *Replication-deficient negative control.  **Replication-competent 
negative control. 
Cell Line Input Dose (LDU) 
Output Viral Dose (LD50) 
∆TATA* Ad-E4PSESE1a** Ad-IU2 
 
    
CWR22rv 1 x 104 3.4 x 102 3.7 x 106 3.7 x 106 
C4-2 1 x 104 7 x 101 4 x 105 4 x 105 
LNCaP 1 x 104 7 x 101 7 x 105 3.7 x 106 
PC-3 1 x 105 7 x 101 4 x 101 4 x 101 
DU-145 1 x 105 7 x 101 7 x 101 7 x 101 
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positive prostate cancer cells was due to limited expression of adenoviral early genes in 
PSA/PSMA-negative cells. 
 
 
Figure 8.  PSES-driven expression of adenoviral E1a was limited to PSA/PSMA-positive 
cells.  PSA/PSMA-positive C4-2 and CWR22rv cells were infected with 100 vp/cell and 
PSA/PSMA-negative DU-145 and PC-3 cells were infected with 1000 vp/cell Ad-IU1 
(PSRCA control), Ad-IU2 or Ad-Wt.  Forty-eight hours after infection or transfection, cells 
lysates were harvested and 20 µg of sample were separated by 10% SDS-PAGE.  The 
blot was probed with anti-Ad5 E1a antibody.  Adenoviral E1a proteins were detected by 
western blot from 36 kD to 50 kD.  E1a expression, which controls adenoviral replication, 
was limited to PSA/PSMA-positive prostate cancer cells. 
 
Ad-IU2 Effectively Induced Apoptosis and Reversed Resistance in PSA/PSMA-
Positive Prostate Cancer Cells 
 Apoptosis-inducing agents such as TRAIL have shown promising clinical 
potential against solid tumors (83, 270, 278); therefore, I tested the ability of Ad-IU2 to 
induce apoptosis in prostate cancer cell lines.  PSA/PSMA-positive prostate cancer cells, 
CWR22rv, C4-2 and LNCaP, as well as PSA/PSMA-negative cell lines, PC-3 and DU-
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145 were treated with PBS, Ad-IU2 or Ad-IU1 for 24 hours and analyzed for apoptosis by 
FACS analysis.  As depicted in Figure 9, apoptosis induction within 24 hours of Ad-IU2  
 
 
Figure 9.  Apoptosis 
induction by Ad-IU2.  
CWR22rv, C4-2, LNCaP, 
PC-3 and DU-145 cells were 
plated overnight in a 24-well 
plate and treated with PBS or 
0.01 LDU/cell Ad-IU1 or Ad-
IU2.  Twenty-four hours after 
Infection, media and cells were harvested, stained with Annexin V-FITC and PI and 
analyzed by FACS.  Ad-IU2 induced 5-fold greater apoptosis at 24 hours than the 
PSRCA control, Ad-IU1, specifically in PSA/PSMA-positive prostate cancer cells.  
PSA/PSMA-positive LNCaP cells were resistant to apoptosis induction at 24 hours.  *** = 
p<0.001 difference between Ad-IU2 and Ad-IU1. 
 
infection in CWR22rv and C4-2 cells was nearly 5-fold higher than baseline or Ad-IU1-
induced levels.  As expected, no apoptosis above baseline was detected in PSA/PSMA-
negative PC-3 and DU-145 prostate cancer cell lines.  Likewise, no apoptosis was 
detected in the PSA/PSMA-positive LNCaP cell line, which has been shown to be highly 
resistant to TRAIL-mediated apoptosis due to high AKT activity (269).  This TRAIL 
resistance was overcome however, by prolonged infection with Ad-IU2.  LNCaP cells 
infected with Ad-IU2 for 48 hours demonstrated greater than 5-fold induction of 
apoptosis above that of control virus infection (Figure 10).  This is consistent with 
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previous reports demonstrating that TRAIL resistance can be overcome by co-
expression of TRAIL and adenoviral E1a (279).    
 
 
Figure 10.  TRAIL resistance was reversed in 
LNCaP cells following prolonged viral infection.  
LNCaP cells were treated with PBS, 0.01 LDU/cell 
Ad-IU1 or Ad-IU2 for 48 hours.  Infection of 
TRAIL-resistant PSA/PSMA-positive LNCaP cells 
with Ad-IU2 for 48 hours reversed resistance to 
TRAIL-mediated apoptosis.  *** = p<0.001 
difference between Ad-IU2 and Ad-IU1. 
 
 
Ad-IU2 Effectively Killed Prostate Cancer Cells, While It Spared Normal Cells 
To assure that apoptosis induction and viral replication within cells was sufficient 
to kill prostate cancer cells, an in vitro killing assay was performed on CWR22rv, C4-2, 
LNCaP and adult human dermal fibroblast (HDFa) cells.  Following treatment with PBS 
or serial dilutions of Ad-IU2, Ad-E4PSESE1a or Ad-∆TATA-E1a (replication-defective 
adenoviral control), cytopathic effect of the virus was monitored by light microscopy and 
viral killing was determined by staining attached cells with crystal violet.  The oncolytic 
effect was observed earliest in C4-2 and LNCaP cells, resulting in assay end-points of 3 
days post-infection for C4-2 and LNCaP and 4 days post-infection for CWR22rv.  This 
difference in time course between prostate cancer cell lines is consistent with delayed 
replication and transgene expression due to slightly reduced PSES transcriptional 
activity in CWR22rv cells (124).  Ad-IU2 exhibited greater killing efficiency in 
PSA/PSMA-positive prostate cancer cells at doses markedly lower than the PSRCA, Ad- 
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Figure 11.  Ad-IU2 induced marked in vitro cell killing of PSA/PSMA-positive prostate 
cancer cells.  Cells were plated in 24-well plates and treated with various doses of Ad-
IU2, Ad-E4PSESE1a (replication-competent control), Ad-∆TATA-E1a (replication-
deficient control) or PBS.  Crystal violet survival curves for CWR22rv (A), C4-2 (B), 
LNCaP (C) and human dermal fibroblasts (D).  Ad-IU2 induced marked cell killing above 
that of Ad-E4PSESE1a at earlier time points specifically in PSA/PSMA-positive prostate 
cancer cells.  Viability was assayed once cytopathic effect was detected by light 
microscopy at 4 days (CWR22rv), 3 days (C4-2 and LNCaP) and 7 days post-infection 
(HDFa, cytopathic effect was not detected).  % cell death was calculated as the ratio of 
A570 for viral-treated cells to that of PBS-treated cells.  * = p<0.05, *** = p<0.001 
difference between Ad-IU2 and Ad-E4PSESE1a. 
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E4PSESE1a.  As depicted in Figure 11A-C, the dose of Ad-IU2 required to kill at least 
50% of CWR22rv, C4-2 and LNCaP cells was 5-, 6- and 8-fold lower than that of Ad-
E4PSESE1a, respectively.  To demonstrate specificity for PSA/PSMA-positive cells, this 
experiment was repeated using normal human fibroblasts.  Despite treatment of cells for 
a longer period of time, Ad-IU2 produced no cytotoxicity in HDFa cells (Figure 11D).  
These data suggest that expressing TRAIL in a PSRCA enhanced its anti-tumor 
cytotoxicity, while maintaining its PSA/PSMA-specificity.   
 
Ad-IU2 Demonstrated a Bystander Effect in PSA/PSMA-Negative Prostate Cancer 
Cells 
Due to limited viral transduction efficiency in vivo and the heterogeneity of human 
prostate tumors with regards to PSA/PSMA-expression, the ability to target and destroy 
prostate cancer cells in which a PSRCA cannot replicate and lyse the cell is critical to 
prevent the development of foci of untreated cells within a tumor.  The killing power of 
Ad-IU2 might be enhanced through cell-to-cell contact of neighboring cells with infected 
prostate cancer cells or cell contact with the apoptotic bodies from dying cells.  To 
determine whether Ad-IU2 imparted a bystander killing effect on neighboring 
PSA/PSMA-negative prostate cancer cells, I co-cultured Ad-IU1- or Ad-IU2-infected 
CWR22rv cells with mRFP-stably transfected PC-3 cells and detected the level of 
apoptosis induction in the mRFP-labeled PC-3 cells.  As depicted in Figure 12, PC-3 
cells, which failed to undergo apoptosis following direct infection with Ad-IU2 (Figure 9), 
exhibited a 4-fold induction of apoptosis above the level induced by Ad-IU1 co-culture 
when co-cultured with Ad-IU2-infected CWR22rv cells.   
To determine whether direct cell-to-cell contact was necessary to produce a 
bystander killing effect, I tested the ability of conditioned media from Ad-IU2-infected 
cells  to  elicit a  similar  response.   Conditioned  media  collected  from  CWR22rv  cells  
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Figure 12.  Ad-IU2 demonstrated a 
bystander effect in PSA/PSMA-negative 
cells in co-culture with infected 
PSA/PSMA-positive cells.  CWR22rv 
cells were infected with 0.01 LDU/cell 
Ad-IU1 or Ad-IU2.  Twenty-four hours 
post-infection,  cells  were  washed  three 
times with PBS and mRFP-labeled PSA/PSMA-negative PC-3 cells were co-plated at a 
ratio of 3 CWR22rv cells to 1 PC-3 cell.  After 24 hours in co-culture, media and cells 
were harvested, and the percent apoptotic mRFP-labeled PC-3 cells was analyzed by 
FACS analysis.  A significant level of apoptosis was induced in PC-3 cells co-cultured 
with Ad-IU2-infected cells. 
 
infected with Ad-IU2 or control virus were heat-treated to inactivate any adenoviral 
particles present.  When treated with conditioned media, both CWR22rv and PC-3 cells 
achieved a similar level of apoptosis induction (Figure 13).  To assure that this effect 
was not directly mediated by adenoviral infection and that adenovirus was inactivated 
effectively by heat treatment, CWR22rv cells were treated with conditioned media from 
Ad-E4PSESE1a-infected CWR22rv cells.  Heat inactivation of the conditioned media 
resulted in a 40-fold reduction in GFP-positivity compared to conditioned media without 
heat inactivation (Figure 14), demonstrating effective inactivation of adenovirus by heat 
treatment of the conditioned media.  These results suggest that unidentified soluble 
factors can mediate the Ad-IU2 bystander effect.  This in turn would enhance distribution 
of the cytotoxic effects throughout the entire tumor, as direct cell-to-cell contact is not 
required.  To determine whether soluble TRAIL was cleaved from the cell membranes of 
infected  cells   and   contributed  to  the  bystander   killing  of  prostate   cancer  cells,  I  
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Figure 13.  Heat-inactivated 
conditioned media from Ad-
IU2-infected CWR22rv cells 
induced significant levels of 
apoptosis in PSA/PSMA-
negative prostate cancer 
cells.   CWR22rv  cells  were 
infected with 0.01 LDU/cell Ad-IU1 or Ad-IU2.  Forty-eight hours after infection, media 
were harvested and heat-inactivated at 56oC for 30 minutes.  Conditioned media were 
applied to CWR22rv or PC-3 cells for 24 hours.  Marked induction of apoptosis was 
achieved in PSA/PSMA-positive CWR22rv and PSA/PSMA-negative PC3 cells following 
treatment with Ad-IU2-infected conditioned media.  *** = p<0.001. 
 
 
Figure 14.  Heat treatment of conditioned media was sufficient to inactivate adenovirus.  
Media from CWR22rv cells infected with 0.01 LDU/cell Ad-E4PSESE1a for 48 hours was 
harvested and heat-inactivated at 56oC for 30 minutes.  Conditioned media was applied 
to CWR22rv cells for 24 hours before or after heat-inactivation.  Heat inactivation of 
conditioned media from Ad-E4PSESE1a-infected cells resulted in a drastic reduction in 
GFP-positive CWR22rv cells, demonstrating significant inactivation of adenovirus. 
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performed western blot analysis on conditioned media from Ad-IU2-infected CWR22rv 
cells for TRAIL protein.  As shown in Figure 15, cell lysate from Ad-IU2-infected 
CWR22rv cells expressed full-length, 32 kD TRAIL protein; however, no band was 
detected in the conditioned media from these cells.  As a control, various dilutions of 
rhTRAIL were immunoblotted from 100 to 25 ng/ml, and the intensity of the 18 kD bands 
decreased with respect to protein concentration.  These results confirm that soluble 
TRAIL was not secreted or cleaved from Ad-IU2 infected cells at concentrations suitable 
to induce cytotoxicity in prostate cancer cells.           
 
 
Ad-IU2 Inhibited the Growth of SQ Androgen-Independent CWR22rv Xenografts 
Previously, we investigated the oncolytic potential of Ad-E4PSESE1a, a PSRCA, 
which significantly inhibited the growth of CWR22rv xenografts as compared to control 
virus; however, the response only lasted two weeks, after which the tumor growth 
 
Figure 15.  TRAIL was not cleaved 
from the surface of Ad-IU2-infected 
CWR22rv cells and present in 
conditioned medium at 
physiologically relevant 
concentrations.  CWR22rv cells were 
infected with 0.01 LDU/cell Ad-IU2 
for    48    hours.     Cell   lysate   and  
conditioned medium (CM) were harvested.  Cell lysate, CM and various concentrations 
of rhTRAIL were separated by 12% SDS-PAGE and immunoblotted with anti-human 
TRAIL antibody.  Soluble TRAIL was not detected in the CM from Ad-IU2-infected cells. 
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exceeded the rate of oncolysis.  Rapid intratumoral viral replication and spread peaked 
at 3 days and was diminished by 1 week after injection (205).  For this reason, I 
determined whether TRAIL could augment the in vivo antitumor effects of a PSRCA.  
Androgen-independent CWR22rv human prostate cancer xenografts were established 
SQ in the flanks of castrated athymic male mice and injected with Ad-IU2, Ad-IU1 
(replication-competent control) and PBS (vehicle control).  As shown in Figure 16, Ad-
IU2 significantly suppressed the growth of CWR22rv tumor xenografts as compared to 
Ad-IU1 (3.1- vs. 17.1-fold growth of tumor, respectively).  4 weeks after treatment, Ad-
IU1-treated tumors began to fail therapy, resulting in a rebound of tumor growth.  On the 
other hand, Ad-IU2 continued to inhibit tumor growth through the 6-week end-point of the  
 
 
 
Figure 16.  Ad-IU2 suppressed 
the growth of androgen-
independent human prostate 
tumors in athymic mice.  SQ 
androgen-independent CWR22rv 
xenografts were established in 
castrated male athymic mice and 
treated with   intratumoral    
injections  of 2 x 104  LDU  Ad-IU1 
(n=6), Ad-IU2 (n=9) or PBS (n=5).  Tumor volumes were calculated as (L2 x W) / (π/6).  
Four weeks after treatment, Ad-IU1-treated tumors began to fail therapy, resulting in 
rebound of tumor growth.  PBS-treated mice were sacrificed at 5 weeks due to tumor 
burden.  Ad-IU2 significantly suppressed the growth of CWR22rv tumors as compared to 
Ad-IU1 (3.1- vs. 17.1-fold growth, respectively).  *** = p<0.001 (Ad-IU2 vs. Ad-IU1). 
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study.  Mock-treated mice were sacrificed at 5 weeks due to overwhelming tumor 
burden.  Of the nine tumors treated with Ad-IU2, six responded favorably with partial 
regression in four of six or complete regression in two of six tumors.  Of the three tumors 
that failed to respond, two were significantly suppressed compared to Ad-IU1-treated 
tumors at 6-weeks (Figure 17).  Given the fact that CWR22rv xenografts are clonogenic, 
the variation in treatment outcome may be attributable to incomplete infiltration of the 
tumor or leakage at the time of injection.  Histological examination of PBS-treated  
 
 
Figure 17.  Individual fold tumor growth 
at the 6-week study endpoint.  Of 9 Ad-
IU2-treated tumors, 6 responded 
favorably with partial regression in 4 of 6 
or complete regression in 2 of 6 tumors.  
Of  the  3   tumors  that  failed,  two  were 
significantly suppressed compared to Ad-IU1-treated tumors at 6 weeks.     
 
tumors revealed healthy cells arranged in normal tumor architecture with significant 
tumor vasculature in the margins of the growing tumor (Figure 18A).  Ad-IU1-treated 
tumors were characterized by scattered necrotic patches surrounded by healthy tumor 
cells, indicative of incomplete oncolysis due to limited viral replication and propagation 
throughout the entire tumor mass (Figure 18B).  Although patches of healthy tumor cells 
remained within the Ad-IU2-treated tumors, necrotic centers of viral replication and 
oncolysis were more diffuse throughout the entire tumor.  Furthermore, cells immediately 
surrounding the necrotic centers appeared unhealthy with condensed nuclei, indicating 
spread of the cytotoxic and apoptotic effect beyond the necrotic centers (Figure 18C).  
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To determine whether apoptosis contributed significantly to the tumor killing process, in 
situ TUNEL assays were performed on the tumor sections.  No apoptotic nuclei were 
detected in the control tumors (Figure 19A,B).  On the other hand, Ad-IU2-treated 
tumors displayed marked apoptosis in the margins surrounding necrotic centers of 
oncolysis (Figure 19C).  These data suggest that TRAIL potentiated the in vivo killing 
power of a PSRCA through apoptosis induction in cells beyond the margin of viral 
replication.    
 
 
 
nuclei) (H&E, 200X).  Treatment effect of Ad-IU2 was diffuse throughout a greater extent 
of the tumor, unlike the focal appearance of Ad-IU1, suggesting a TRAIL-mediated 
bystander effect. 
Figure 18.  Histological appearance of 
CWR22rv tumors 6 weeks after treatment.  
PBS (A), Ad-IU1 (B) (large arrows, 
necrotic centers of oncolysis; small 
arrows, foci of healthy tumor cells) or Ad-
IU2 (C) (large arrows,       necrotic centers 
of oncolysis; small arrows, condensed        
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No significant apoptosis was detected in tumors treated with PBS (A) or Ad-IU1 (B) and 
marked apoptosis was detected in tumors treated with Ad-IU2 (C). 
Figure 19.  In situ detection of apoptosis 
in harvested CWR22rv xenografts.  Tumor 
xenografts from athymic nude mice were 
harvested at 6 weeks (Ad-IU1 and Ad-
IU2) or 5 weeks (PBS).  Tumors were 
stained for TUNEL analysis, 
counterstained with DAPI and examined 
under dual photon confocal microscopy.         
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Radio-Sensitization of Androgen-Independent Prostate Cancer with Ad-IU2 
 
Background 
Recent studies supporting the use of EBRT as standard of care for high risk 
prostate cancer have also demonstrated that monotherapy is insufficient for the 
treatment of locally advanced disease, leading to higher rates of biochemical failure and 
PCSM (39, 280-282).  Furthermore, clinical studies indicate that adequate locoregional 
elimination of prostate cancer is necessary to decrease the risk of metastases from a 
nidus of continuously shedding cancer cells (50).  Recently, this has been achieved by 
improved targeting and dose escalation of EBRT through the use of 3D-CRT and IMRT 
(283, 284).  However, the persistence of radio-resistant prostate cancer cells and dose-
limiting toxicities to surrounding normal tissues in the pelvis, such as the rectum and 
bladder, prevent complete tumor eradication, leading to failure of the therapy and a 
potentially fatal disseminated disease.  For these reasons, the development of novel 
therapies to enhance the efficacy of conventional treatments is critically needed. 
Recently, the combination of EBRT and chemotherapy has been evaluated 
clinically to achieve improved locoregional control of a tumor following radiotherapy 
(285).  Although the greatest clinical efficacy has been achieved for head and neck 
(286), non-small cell lung (287), and cervical (288) cancer, chemoradiotherapy with 
docetaxel is currently being tested in early clinical trials for prostate cancer (289, 290).  
Radiation sensitizers, such as chemotherapy, modulate the response of cancer cells to 
EBRT leading to improved local tumor control and through dose-reduction, protection of 
normal tissue from the acute toxicity of radiation.  The ideal radiosensitizer would have 
adequate spread throughout the entire tumor, sensitize tumor cells selectively and cause 
minimal toxicity to normal tissue. 
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Over the past fifteen years, gene therapy has been widely studied as an 
alternative approach to the treatment of prostate cancer; however, current limitations of 
viral replication and transduction efficiency reduce its clinical feasibility as a 
monotherapy.  Likewise, the efficacy of EBRT for prostate cancer is limited by toxicity to 
the surrounding organs.  In the first half of my thesis, I evaluated the preclinical efficacy 
of Ad-IU2 as a single modality against androgen-independent prostate cancer.  In 
addition to being a powerful tumor-specific cytotoxic molecule, TRAIL has proven to be a 
potent radio-sensitizing agent.  I hypothesized that the neoadjuvant treatment of high 
risk prostate cancer with a PSRCA expressing TRAIL would result in the radio-
sensitization of tumor cells, thereby enhancing the therapeutic effect of EBRT.  The 
goals of this multi-modal approach combining viral lysis, apoptosis-inducing gene 
therapy, and radiation therapy are to achieve complete local tumor control, reduce 
radiation dose and associated treatment morbidities, and improve the clinical outcome 
for patients with high risk locally advanced prostate cancer. 
 Recent investigations have demonstrated the potentiation of the antitumor 
activity of EBRT by combining it with TRAIL.  Initially, the link between TRAIL and RT 
was made in non-Hodgkin’s patients undergoing EBRT, where TRAIL expression was 
upregulated in blood cells distant from the irradiated tissue.  This was thought to provide 
some therapeutic benefit and contribute partially to the abscopal effect of RT (291, 292).  
To further support the role of rhTRAIL in radiation-induced apoptosis, DR5-knockout 
mice exhibited reduced amounts of apoptosis in tissues exposed to ionizing radiation 
(293).  Pretreatment of cancer cells with soluble TRAIL or an adenoviral vector 
expressing TRAIL resulted in sensitization to EBRT.  In DU-145 prostate cancer cells, a 
synergistic effect on apoptosis was observed with combinatorial therapy and was found 
to be Bax-dependent, implicating a role for the mitochondrial or intrinsic apoptosis-
amplification loop (294).  El Hassan et al. also described the role of the intrinsic 
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mitochondrial pathway in the response to combined treatment.  In non-small cell lung 
cancer cell lines, synergy was accompanied by caspase-8 and Bid cleavage, which was 
reversible by Bcl-2 overexpression (295).  On the other hand, the mechanism of synergy 
in Jurkat cells did not appear to be related to death receptor upregulation or 
mitochondrial apoptosis, as cytochrome c was not released from the mitochondrial 
membrane and Bcl-2 overexpression as well as p53 mutation did not inhibit apoptosis 
(296). This multimodal approach has been studied preclinically for three types of cancer.  
An RGD-retargeted adenovirus, Ad/TRAIL-F/RGD, expressing full-length TRAIL under 
control of an hTERT/GAL4VP16/GT promoter system, has been investigated for use in 
esophageal adenocarcinoma, where combination with EBRT resulted in enhanced 
apoptosis induction and decreased clonogenic survival.  This radio-sensitization 
appeared to be synergistic and specific to cancer cells.  Furthermore, combined therapy 
inhibited tumor growth in vivo and prolonged nude mouse survival from 16.7 and 21.5 
days (RT and Ad/TRAIL-F/RGD alone, respectively) to 31.6 days (combined) in the 
esophageal adenocarcinoma model (297).  Similarly, Ad/TRAIL-F/RGD improved nude 
mouse survival from 16.5 and 23.7 days (RT and Ad/TRAIL-F/RGD alone, respectively) 
to 43.7 days (combined) in a non-small cell lung cancer model (298).  Kaliberov et al. 
developed a replication-deficient adenovirus, AdFlt-TRAIL, which expressed full-length 
TRAIL under control of the VEGF receptor promoter, FLT-1.  AdFlt-TRAIL was studied 
for the treatment of prostate cancer in DU-145 cells where cell death in combination with 
RT was merely additive.  In an athymic mouse DU-145 xenograft model, there was no 
significant difference between tumors treated with AdFlt-TRAIL alone or in combination 
with RT (299).  The previous study was limited by the use of a replication-deficient virus 
and the weak activity of Flt-1 promoter in DU-145 cells.  In the current study, I improved 
upon this approach through the use of a replication-competent adenovirus in which 
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replication and TRAIL expression are driven by a prostate-specific promoter with strong 
activity in PSA/PSMA-positive prostate cancer cells. 
 
Evaluation of the Combination of Ad-IU2 and Radiation Therapy for the Treatment 
of Androgen-Independent Prostate Cancer 
Ad-IU2 Reduced the Clonogenic Survival of Irradiated Prostate Cancer Cells More 
Effectively Than rhTRAIL Alone   
 To test the combined effect of TRAIL gene therapy with Ad-IU2 and radiotherapy, 
I first determined the optimal dose of virus required to produce the greatest 
radiosensitization of prostate cancer cells.  A radiosensitizing agent should decrease the 
clonogenic survival of cancer cells following irradiation when administered in sub-optimal 
concentrations for use as a single agent.  For this reason, in accordance with data from 
the in vitro cytotoxicity assay (Figure 11), the dose range of 0.0015 to 0.0045 LDU/cell 
was selected.  CWR22rv cells were pretreated with the above concentrations of Ad-IU2 
24 hours prior to irradiation and then allowed to rest for 24 hours prior to plating for 
clonogenicity.    3 weeks after plating, colonies were counted and survival data fitted to 
the linear-quadratic regression model, normalizing for viral cytotoxicity with each RT 
dose.  Radiosensitization of CWR22rv cells following infection with Ad-IU2 was 
evidenced by a reduction in the shoulder of the clonogenic survival curve (Figure 20).  
The Ad-IU2 dose of 0.0015 LDU/cell resulted in the least reduction of clonogenic 
survival, while an Ad-IU2 dose of 0.003 LDU/cell produced the greatest 
radiosensitization.  Interestingly, this effect was not strictly dose-dependent, as a higher 
dose of 0.0045 LDU/cell of Ad-IU2 resulted in less reduction of survival fraction.  As a 
result, the viral dose 0.003 LDU/cell was chosen for use in subsequent combinatorial 
experiments. 
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Figure 20.  Determination of optimal 
viral dose for clonogenic assay.  1 x 
106 CWR22rv cells were infected with 
0, 0.0015, 0.003 or 0.0045 LDU/cell 
Ad-IU2 for 24 hours and irradiated 
with 0, 1, 2 or 3 Gy.  24 hours after 
irradiation, cells were plated at low 
densities in p100 dishes.  3 weeks 
after seeding, plates were stained 
with crystal violet, and colonies of 50 
cells  or  greater  were  counted.   The 
dose response survival curve was fitted to the linear-quadratic regression model [ ln 
(SF/SF0) = -(αD + βD2) ].  0.003 LDU/cell Ad-IU2 was chosen as the optimal dose for 
future experiments. 
 
The treatment of CWR22rv cells with ionizing radiation resulted in a dose-
dependent decrease in clonogenicity, exhibiting a broad shoulder in the radiation 
survival curve (Figure 21).  Pretreatment of CWR22rv cells with 0.003 LDU/cell Ad-
E4PSESE1a, PSRCA vector control, resulted in a minimal left-ward shift in the survival 
curve and no reduction of the shoulder, indicating no radio-sensitization by a PSRCA 
alone.  On the other hand, pretreatment of the PSA/PSMA-positive cells with 0.003 
LDU/cell Ad-IU2 resulted in a dramatic reduction of clonogenic survival, indicating radio-
sensitization.  Pretreatment of cells with rhTRAIL (75 ng/ml) resulted in a decrease in 
clonogenic survival of irradiated CWR22rv cells and a reduction in the shoulder of the 
radiation survival curve; however, radio-sensitization by rhTRAIL alone was not as 
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dramatic as that achieved by Ad-IU2, despite similar concentrations of TRAIL protein in 
both treatment groups (Figure 15).  These data suggest that the expression of full-length 
TRAIL by a replication-competent vector is a more potent radio-sensitizer than the 
administration of rhTRAIL. 
 
 
Figure 21.  Combination of 
Ad-IU2 and RT resulted in 
a decrease in the 
clonogenicity of CWR22rv 
cells.  1 x 106 CWR22rv 
cells were plated overnight 
in a T24 flask and treated 
with 0.003 LDU/cell Ad-IU2 
or Ad-E4, rhTRAIL (75 
ng/ml) or PBS.  24 hours 
post-treatment, cells were 
irradiated at a dose of 0, 1, 
2,  3  or 4 Gy and  plated at 
low densities in p100 dishes 24 hours after irradiation.  3 weeks after seeding, plates 
were stained with crystal violet, and colonies of 50 cells or greater were counted.  The 
dose-response survival curve was fitted to the linear-quadratic regression model [ ln 
(SF/SF0) = -(αD + βD2) ].  Radio-sensitization was evidenced by a reduction in the 
shoulder of the curves for cells treated with rhTRAIL and Ad-IU2 and was greatest for 
cells infected with Ad-IU2. 
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Compared to PBS or Ad-E4PSESE1a, Ad-IU2 drastically reduced the clonogenic 
survival of CWR22rv cells.  EBRT at a dose of 2 Gy resulted in a survival fraction of 
49.2% following monotherapy or 41.5% in combination with Ad-E4PSESE1a; however, 
in cells pretreated with Ad-IU2, irradiation with 2 Gy resulted in a survival fraction of 
5.24%, compared to 21.8% for cells pretreated with rhTRAIL.  The mean lethal dose of 
ionizing radiation was reduced from 2.52 Gy for mock-treated cells to 0.512 Gy for 
CWR22rv cells pretreated with Ad-IU2.  This radio-sensitization corresponded to dose 
reduction factors (DRF) of 4.91 for 0.003 LDU/cell Ad-IU2 and 2.06 for 75 ng/ml rhTRAIL 
(Table 5). 
 
Table 5.  Ad-IU2 sensitized CWR22rv cells to EBRT.  The linear-quadratic regression 
analysis for CWR22rv cells demonstrated radio-sensitization as evidenced by an 
increase in the lethal, irreparable events (α), a reduction in sublethal damage (β) 
component, and a reduction in the D0 (RT dose at which 37% of cells for colonies) from 
2.52 Gy with RT alone to 0.0524 Gy in combination with 0.003 LDU/cell Ad-IU2, resulting 
in a dose reduction factor (DRF) of 4.91 for Ad-IU2.  Radio-sensitization was specific to 
Ad-IU2, as infection with 0.003 LDU/cell Ad-E4PSESE1a failed to enhance the radiation 
effect.  Greater radio-sensitization was achieved with Ad-IU2 than with 75 ng/ml rhTRAIL 
which had a DRF of 2.06.  R2, regression coefficient; SF2, surviving fraction at 2 Gy. 
 PBS Ad-IU2 Ad-E4 rhTRAIL 
     
R2 0.990 0.997 0.993 0.998 
α 0.198 2.10 0.240 0.894 
β 0.0786 -0.314 0.100 -0.0666 
α/β 2.51 -6.69 2.39 -13.4 
 
    
SF2 0.492 0.0524 0.415 0.218 
D0 2.52 Gy 0.512 Gy 2.18 Gy 1.22 Gy 
DRF 
 4.91 1.16 2.06 
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Compared to CWR22rv cells, C4-2 cells were more radio-sensitive, as indicated 
by a steeper slope to the radiation dose-response curve and a narrower shoulder to the 
curve (Figure 22).  Likewise, the mean lethal dose for C4-2 cells was 2.35 Gy, compared  
 
 
Figure 22.  Combination of 
Ad-IU2 and RT resulted in a 
decrease in the 
clonogenicity of C4-2 cells.  
1 x 106 C4-2 cells were 
plated overnight in a T24 
flask and treated with 0.003 
LDU/cell Ad-IU2 or Ad-E4, 
rhTRAIL (75 ng/ml) or PBS.  
24 hours post-treatment, 
cells were irradiated at a 
dose of 0, 1, 2, 3 or 4 Gy 
and plated  at low  densities      
in p100 dishes 24 hours after irradiation.  2 weeks after seeding, plates were stained 
with crystal violet, and colonies of 50 cells or greater were counted.  The dose-response 
survival curve was fitted to the linear-quadratic regression model.  Radio-sensitization 
was evidenced by a reduction in the shoulder of the curves for cells treated with rhTRAIL 
and Ad-IU2 and was greatest for cells infected with Ad-IU2. 
 
to 2.52 Gy for CWR22rv cells (Table 6).  The treatment effect was less dramatic in C4-2 
cells than in CWR22rv cells;  however, pretreatment of C4-2 cells with both rhTRAIL and  
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Table 6.  Ad-IU2 sensitized C4-2 cells to EBRT.  The linear-quadratic regression model [ 
ln (SF/SF0) = -( αD + βD2) ] for C4-2 cells demonstrated radio-sensitization as evidenced 
by an increase in the α component, a reduction in the β component, and a reduction in 
the D0 (RT dose at which 37% of cells for colonies) from 2.35 Gy with RT alone to 0.168 
Gy in combination with 0.003 LDU/cell Ad-IU2, This resulted in a dose reduction factor 
(DRF) of 2.35 for Ad-IU2.  Radio-sensitization was specific to Ad-IU2, as infection with 
0.003 LDU/cell Ad-E4PSESE1a failed to enhance the radiation effect.  Greater radio-
sensitization was achieved with Ad-IU2 than with 75 ng/ml rhTRAIL which had a DRF of 
1.66.  R2, regression coefficient; SF2, surviving fraction at 2 Gy. 
 PBS Ad-IU2 Ad-E4 rhTRAIL 
     
R2 0.985 0.994 0.997 0.990 
α 0.0476 1.16 0.275 0.756 
β 0.160 -0.132 0.0852 -0.0389 
α/β 0.298 -8.76 3.22 -19.4 
 
    
SF2 0.480 0.168 0.411 0.257 
D0 2.35 Gy 0.966 Gy 2.17 Gy 1.42 Gy 
DRF 
 2.43 1.08 1.66 
     
 
 
 
Ad-IU2 markedly decreased the colony formation of irradiated cells and reduced the 
shoulder of the curve.  In C4-2 cells, 2 Gy of radiation alone decreased clonogenic 
survival by 52%, whereas the addition of 75 ng/ml rhTRAIL or 0.003 LDU/cell Ad-IU2 
reduced survival by 74.3 and 83.2%, respectively.  The resulting DRFs were 2.43 for Ad-
IU2 and 1.66 for rhTRAIL.  These results suggest that TRAIL gene therapy with Ad-IU2 
is a more potent radiation-sensitizing agent than rhTRAIL in PSA/PSMA-positive 
androgen-independent prostate cancer cell lines and that reduction of EBRT dose can 
be achieved by pretreatment with Ad-IU2. 
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Radio-Sensitization by Ad-IU2 was Specific to PSA/PSMA-Positive Prostate 
Cancer Cells 
 Due to the proximity of the prostate to the rectum and the bladder, I tested 
whether Ad-IU2 would sensitize cells from the surrounding normal tissues.  For this 
reason, the colorectal adenocarcinoma cell line, LoVo, and bladder transitional cell 
carcinoma cell line, T24, were selected.  Infectivity assays were performed to achieve 
equal infectivity of Ad5 in these cell lines as in prostate cancer cell lines.  LoVo and T24 
cells were infected with Ad5-GFP and analyzed by FACS analysis for GFP expression.  
As depicted in Figure 23, 500 vp/cell Ad5-GFP caused a shift in GFP expression of 
14.68% in LoVo cells and 10,000 vp/cell caused a shift of 11.47% in T24 cells.  To  
 
 
Figure 23.  Adenoviral infectivity assay for LoVo and T24 cells.      LoVo and T24 cells 
were infected with varying doses of Ad5-GFP, a replication-defective adenovirus 
expressing GFP under control of the CMV promoter.  For LoVo cells, a range of 0 to 
5,000 vp/cell was used, and for T24 cells, a range of 0 to 10,000 vp/cell was used.  
Twenty-four hours after infection, GFP expression was analyzed by FACS analysis. 
 
achieve equal infectivity, LoVo required 57-fold more adenoviral vector than CWR22rv 
cells, while T24 cells required 1400-times the adenoviral dose (Table 7). 
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Table 7.  Relative infectivity of LoVo and T24 cells for Ad5.  CWR22rv, LoVo and T24 
cells were infected with varying doses of Ad5-GFP for 24 hours and analyzed for GFP-
positivity (% FL1-H) by FACS analysis.  Values for LoVo and T24 cells were compared 
to CWR22rv values to determine relative infectivities, which were used in subsequent 
experiments to standardize viral doses. 
 
Ad5-GFP 
(vp/cell) % FL1-H CWR22rv Rel. Infectivity 
     
LoVo 500 14.68 8.70 vp/cell 57 X 
T24 10,000 11.47 6.85 vp/cell 1,460 X 
     
 
 
 
To determine whether combinatorial treatment sensitized colorectal or bladder 
cancer cell lines to radiotherapy, LoVo and T24 cells were pretreated with cell line-
specific equivalent doses of Ad-IU2 or Ad-E4PSESE1a for 24 hours and then irradiated.  
Because distinct colony formation was difficult to achieve in LoVo and T24 cells, cell 
viability was assessed by MTT assay, rather than clonogenic assay.  As depicted in 
Figure 24, treatment of LoVo and T24 cells with EBRT resulted in a dose-dependent 
decrease in cell viability.  LoVo cells demonstrated a higher basal level of radio-
sensitivity than T24 cells.  Pretreatment of both PSA/PSMA-negative cell lines with Ad-
IU2 did not enhance cell killing.  This was expected, as TRAIL was under transcriptional 
control of PSES; however, the effect of rhTRAIL on LoVo and T24 cells was not 
evaluated due to its lack of tissue-specificity. 
 
Combinatorial Therapy Failed to Augment Induction of Apoptosis 
 Previous studies have demonstrated that the enhanced cell killing and radio-
sensitization that occurred from the combination of TRAIL and EBRT was caused by 
enhanced  apoptosis  induction;  however,  most  studies  used  high  doses  of radiation  
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Figure 24.  Ad-IU2 failed to sensitize PSA/PSMA-negative colorectal and bladder cancer 
cell lines to EBRT.  LoVo and T24 cells were plated in 96-well plates and infected with 
Ad-IU2 or Ad-E4PSESE1a in doses adjusted for relative infectivity of each cell line.  
Twenty-four hours after infection, cells were irradiated with 0, 1, 2, 3 or 4 Gy.  Cells were 
analyzed for survival by MTT assay at 96 hours post-irradiation for LoVo cells or 48 
hours post-irradiation for T24 cells.  Ad-IU2 failed to enhance the sensitivity of 
PSA/PSMA-negative cell lines to EBRT. 
 
 
ranging from 5 to 40 Gy (294, 295, 299).  To determine whether the enhanced cell killing 
of androgen-independent prostate cancer cell lines was due to increased apoptosis with 
the lower RT doses and suboptimal viral doses used in this study, I analyzed Annexin V 
and PI staining of cells treated with Ad-IU2 and EBRT.  As seen in Figure 25, in both 
CWR22rv and C4-2 cells, infection with 0.003 LDU/cell Ad-IU2 resulted in a slight 
induction of apoptosis above that of the PSRCA control.  Treatment of CWR22rv and 
C4-2 cells with 3 Gy RT resulted in nearly 2-fold induction of apoptosis above that of 
mock PBS-treated cells; however, no increase in apoptosis induction was observed in 
the combined treatment group.  These data suggest that at the minimal doses of virus 
and   EBRT  required   to  reduce   clonogenic  survival   in  CWR22rv   and  C4-2   cells,  
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augmentation of apoptosis induction did not contribute to the mechanism of radio-
sensitization.       
 
 
 
Figure 25.  Combination of Ad-IU2 plus EBRT did not enhance apoptosis induction at 
doses sufficient to decrease clonogenicity of PSA/PSMA-positive prostate cancer cells.  
CWR22rv and C4-2 cells were treated with 0.003 LDU/cell Ad-IU2, Ad-E4PSESE1a or 
PBS and irradiated 24 hours after infection for a dose of 0 or 3 Gy.  Twenty-four hours 
after irradiation, cells were harvested and analyzed for apoptosis by Annexin V-FITC and 
PI staining.  At a low dose of 0.003 LDU/cell, Ad-IU2 significantly induced apoptosis 
compared to PSRCA control alone; however, this level was lower than that induced by 
0.01 LDU/cell (Figure 9), as expected.  In addition, EBRT at a dose of 3 Gy was 
sufficient to induce significant levels of apoptosis compared to untreated cells; however, 
in combination, 0.003 LDU/cell Ad-IU2 failed to augment RT-induced apoptosis 
induction.   * = p<0.05, ** = p<0.01, *** = p<0.001. 
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Pretreatment of Androgen-Independent Prostate Cancer Cells with Ad-IU2 or 
rhTRAIL Resulted in G1 Phase Accumulation and Diminished Radiation-Induced G2 
Phase Arrest 
 To elucidate the mechanism for radio-sensitization of prostate cancer cells by 
Ad-IU2, I performed cell cycle analysis on the cells following pretreatment with Ad-IU2 or 
rhTRAIL and also following combination treatment.  As depicted in Figure 26, infection of  
 
 
Figure 26.  Treatment of CWR22rv and C4-2 cells with Ad-IU2 or rhTRAIL resulted in 
accumulation of cells in G1 phase.  Androgen-independent prostate cancer cell lines 
CWR22rv (A) and C4-2 (B) were treated with PBS, 100 ng/ml rhTRAIL, 0.003 LDU/cell 
Ad-IU2 or Ad-E4PSESE1a for 24 hours.  Cells were washed, harvested, permeabilized 
and treated with RNaseA.  DNA content was stained with PI and analyzed by FACS 
analysis.  % cells in each phase of the cell cycle is listed for each histogram.  Following 
treatment with Ad-IU2 or rhTRAIL, both prostate cancer cell lines arrested in G1 phase. 
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cells with Ad-E4PSESE1a resulted in no significant change in DNA content, compared to 
PBS-treated cells.  On the other hand, infection of cells with 0.003 LDU/cell Ad-IU2 or 
treatment with 100 ng/ml rhTRAIL produced approximately a 20% increase in the G1 
population.  This was a significant finding, as previous studies have demonstrated that 
cells arrested in the G1 or G2 phases of the cell cycle are most sensitive to ionizing 
radiation (300).  This was consistent with the observation that C4-2 cells, which were 
more sensitive to ionizing radiation, had a greater percentage of cells in G1 phase before 
treatment with Ad-IU2 or rhTRAIL. 
 To determine whether pretreatment of prostate cancer cells with Ad-IU2 or 
rhTRAIL affected the cell cycle of irradiated cells, DNA content of CWR22rv and C4-2 
cells, pretreated for 24 hours, was analyzed 8, 16 and 24 hours after irradiation.  As 
seen in Table 8, 3 Gy RT induced a G2 phase arrest which lasted up to 16 hours in 
CWR22rv cells and 24 hours for C4-2 cells.  A similar G2 phase arrest was observed in 
cells pretreated with 0.003 LDU/cell Ad-E4PSESE1a.  The radiation-induced G2 arrest 
was dramatically inhibited in cells pretreated for 24 hours with Ad-IU2 or rhTRAIL.  This 
effect lasted up to 8 hours in CWR22rv cells or 16 hours in C4-2 cells after irradiation.  In 
addition, accumulation of cells in G1 phase was observed in both irradiated and 
unirradiated for up to 8 or 16 hours after RT in CWR22rv or C4-2 cells, respectively.  
Representative DNA content histograms for CWR22rv and C4-2 cells 8 hours after 
combinatorial treatment are displayed in Figure 27.  Diminishment of the RT-induced G2 
arrest was most dramatic in C4-2 cells, with an approximately 55% reduction for C4-2 
and 40% for CWR22rv cells.  These data suggest that combinatorial therapy with Ad-IU2 
or rhTRAIL plus EBRT caused significant cell cycle redistribution, which may contribute 
to the mechanism of radio-sensitization of prostate cancer cells. 
  
Table 8.  Combination of Ad-IU2 or rhTRAIL and EBRT resulted in perturbation of RT-induced G2 arrest.  CWR22rv and C4-2 cells 
were pretreated with 0.003 LDU/cell Ad-IU2, Ad-E4PSESE1a or 100 ng/ml rhTRAIL for 24 hrs, irradiated and analyzed. 
 8 hours after RT 16 hours after RT 24 hours after RT 
CWR22rv G1 (%) S (%) G2 (%) G1 (%) S (%) G2 (%) G1 (%) S (%) G2 (%) 
          
0 Gy PBS 46.7 40.2 13.1 50.4 35.6 14.0 50.9 32.6 16.5 
0 Gy Ad-IU2 54.0 32.7 13.3 56.8 29.3 13.9 57.9 23.7 18.4 
0 Gy Ad-E4 45.9 37.7 16.4 54.8 32.5 12.7 54.0 32.8 13.2 
0 Gy rhTRAIL 55.8 29.9 14.3 53.5 34.4 12.1 56.5 25.0 18.5 
 
         
3 Gy PBS 29.4 42.5 28.1 51.2 25.0 23.8 52.9 27.0 20.1 
3 Gy Ad-IU2 47.4 35.4 17.2 50.4 21.8 27.8 50.7 23.5 25.8 
3 Gy Ad-E4 31.1 39.5 29.4 48.6 22.6 28.8 52.9 26.9 20.2 
3 Gy rhTRAIL 52.2 30.1 17.7 45.7 28.4 25.9 64.0 10.5 25.5 
          
 
 
 8 hours after RT 16 hours after RT 24 hours after RT 
C4-2 G1 (%) S (%) G2 (%) G1 (%) S (%) G2 (%) G1 (%) S (%) G2 (%) 
          
0 Gy PBS 64.5 28.7 6.8 72.2 23.9 3.9 71.0 20.9 8.1 
0 Gy Ad-IU2 79.7 13.7 6.6 86.6 10.3 3.1 80.0 8.3 11.7 
0 Gy Ad-E4 62.8 26.5 10.7 72.1 22.9 5.0 70.2 16.7 13.1 
0 Gy rhTRAIL 74.5 17.4 8.1 86.5 9.8 3.7 75.4 9.2 15.4 
 
         
3 Gy PBS 66.2 17.6 16.2 68.0 15.7 16.3 60.9 19.6 19.5 
3 Gy Ad-IU2 75.9 18.3 5.8 78.3 15.4 6.3 70.7 11.3 18.0 
3 Gy Ad-E4 64.9 19.1 16.0 71.3 13.3 15.4 66.9 9.8 23.3 
3 Gy rhTRAIL 70.2 21.3 8.5 76.2 15.8 8.0 73.5 12.6 13.9 
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Figure 27.  Combination of Ad-IU2 or rhTRAIL and EBRT resulted in perturbation of RT-
induced G2 phase arrest.  CWR22rv (A) and C4-2 (B) cells were treated with PBS, Ad-
IU2, Ad-E4PSESE1a or rhTRAIL for 24 hours, followed by treatment with 3 Gy RT.  8 
hours after irradiation, cells were harvested and stained for DNA content with PI.  
Percent of cells in each phase of the cell cycle is listed for each histogram.  The 
radiation-induced G2 arrest was dramatically diminished in cells pretreated with Ad-IU2 
or rhTRAIL.   
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Discussion 
 
The safety and efficacy of gene therapy for prostate cancer has been 
demonstrated through various preclinical and clinical trials.  In recent years, interest in 
this field has expanded and will continue to do so.  Preliminary results from clinical trials 
indicate that gene therapy alone may not cure prostate cancer; however, in combination 
with conventional therapies, gene therapy promises to fill the therapeutic void left by 
chemotherapy and androgen ablation therapy for advanced disease.  It is conceivable 
that such multi-modal therapies will result in fewer undesirable side effects and 
improvement in the quality of life for the patient.  Due to its convenient administration 
through ultrasound-guided transrectal injection, it is also conceivable that gene therapy, 
applied in an outpatient setting, may one day augment radical prostatectomy and 
radiation therapy to treat early stage disease.  Factors impeding the widespread use of 
gene therapy for prostate cancer include slow clinical translation of laboratory research, 
lack of funding for expensive clinical trials, and misconceptions and fear of gene therapy 
by the general public.  As the number of successful gene therapy trials increase, these 
factors will diminish.  
Significant progress in basic medical science research has lead to an 
understanding of the molecular events underlying the development and progression of 
prostate cancer.  Such preclinical studies have translated into strategies for the 
molecular therapy of hormone-refractory prostate cancer.  Advances in molecular and 
cellular biology have lead to the discovery of novel therapeutic genes and improvement 
of vector systems for the delivery of those genes.  Prostate-specific targeting of 
molecular therapies is now possible due to the identification and characterization of 
prostate-specific sequences.  Our laboratory has focused much of its efforts on the 
development of chimeric tissue-specific promoters such as PSES and the application of 
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well-characterized promoters such as OC in the development of molecular therapy for 
androgen-independent primary and metastatic prostate cancer. 
 Early gene therapy clinical trials for cancer involved replication-deficient 
adenoviral vectors due to safety concerns of nonspecific viral replication in 
immunocompromised patients; however, these studies were limited by poor viral 
transduction efficiencies.  To overcome this, replication-competent oncolytic adenoviral 
vectors were developed to kill cancer cells directly and further propagate the vector.  The 
first tumor-specific oncolytic adenovirus developed was ONYX-015, in which E1b-55kd 
was deleted to restrict replication to p53-deficient cancer cells (177); however, later 
studies have demonstrated replication independent of p53 status (189).  ONYX-015 has 
been widely tested in clinical trials and has demonstrated inefficient cell lysis and viral 
replication, resulting in poor clinical outcomes (180, 301).  In a second approach, the 
adenoviral immediate early E1a gene was placed under control of tissue-specific 
promoters (193, 198, 302).  To achieve greater control of viral replication, both E1a and 
E1b genes were placed under control of multiple or single bidirectional promoters (195, 
199).  We developed a prostate-specific oncolytic adenovirus, called Ad-E4PSESE1a, in 
which adenoviral E1a and E4 genes were controlled by the bidirectional PSES enhancer 
(205).  Previous studies have demonstrated that TRAIL-mediated apoptosis potentiated 
oncolysis and spread of a replication-competent adenovirus throughout a tumor (303).  
Therefore, to enhance the oncolytic and therapeutic potential of this PSRCA, I 
incorporated TRAIL cDNA under the transcriptional control of PSES, making Ad-IU2 the 
first prostate-specific TRAIL vector. 
 Currently, four strategies have been developed to deliver TRAIL via conditionally-
replicating adenoviral vectors.  Ad5/35.IR-E1a/TRAIL is an adenovirus containing an 
inverted E1a sequence that replicated exclusively in tumor cells via complementation 
with unknown cellular factors (304).  Through an adenoviral replication-dependent 
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homologous recombination event, the bicistronic 3’ to 5’ TRAIL-IRES-E1a cassette is 
flipped to the correct orientation and expressed under control of the universal RSV 
promoter (83).  In a second tumor-specific approach, a CMV-TRAIL expression cassette 
was incorporated into the E1b-55kd-deleted adenovirus, ONYX015.  To improve the 
anti-tumor efficacy of this virus, ZD55-hTRAIL, against colorectal carcinoma, it was 
administered in combination with 5-FU (305).  Ad/TRAIL-E1 contains two duplicated 
synthetic promoters in close proximity comprised of the full hTERT promoter and 
minimal sequences from the CMV promoter to control the expression of both E1a and 
TRAIL as separate transcripts (306).  The final approach achieved tissue-specific 
replication and TRAIL expression for hepatocellular carcinoma using the α-fetoprotein 
promoter to control the expression of a bicistronic E1a-TRAIL cassette (307).  My 
strategy is unique to the previously described replication-competent TRAIL vectors in 
that tight tissue-specific regulation of adenoviral replication was achieved by controlling 
three early adenoviral genes, E1a, E1b and E4.  Furthermore, in my study TRAIL was 
co-expressed with adenoviral E1a in PSA/PSMA-positive cells without the use of 
bicistronic elements, which can result in decreased gene expression of transgenes 
downstream of the internal ribosomal entry sequence (IRES), or universal promoters, 
which may induce adenoviral replication outside of the target tissue.  The use of a 
prostate-specific promoter such as PSES to control viral replication and transgene 
expression enhanced the safety of this vector, while enabling its use for both locally 
advanced and metastatic prostate cancer. 
 We hypothesized that arming a prostate-specific oncolytic adenoviral vector with 
TRAIL would enhance the anti-tumor efficacy of a replication-competent adenovirus.  In 
this approach, prostate cancer cells would undergo apoptosis by the tumor-specific 
apoptosis inducer, TRAIL.  Furthermore, the replication of the adenoviral vector would 
kill prostate cancer cells directly by oncolysis and result in amplification of both 
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adenoviral vector and viral transduction efficiency.  Finally, through a TRAIL-mediated 
bystander effect, cytotoxicity of this molecular therapy would spread throughout the 
tumor, killing nontransduced cells. 
 In this study, I developed and characterized Ad-IU2, a novel PSRCA, in which 
adenoviral replication and the expression of TRAIL were controlled by the prostate-
specific PSES promoter.  I demonstrated that the adenoviral early gene product, E1a, 
which controls adenoviral replication, was restricted to PSA/PSMA-positive prostate 
cancer cells (Figure 8).  Likewise, replication of Ad-IU2 was diminished in PSA/PSMA-
negative cells (Table 4).  While TRAIL was expressed in PSA/PSMA-positive prostate 
cancer cells (Figures 6 and 7), this did not hinder viral replication.  This was consistent 
with my ability to produce high titers of Ad-IU2 (1.02 x 1012 vp/ml).  Other groups have 
had difficulty producing adenoviral vectors expressing TRAIL or similar death ligands 
due to toxicity to producer cells such as HEK293 or HER911.  Previous attempts have 
used caspase inhibitors to allow adenoviral replication without the premature death of 
producer cells (277).  In my approach, the unintended death of HER911E4 producer 
cells is prevented by tissue-specific regulation of TRAIL expression. 
Ad-IU2 effectively induced apoptosis in TRAIL-sensitive, PSA/PSMA-positive 
CWR22rv and C4-2 cells (Figure 9).  Interestingly, TRAIL resistance in the PSA/PSMA-
positive prostate cancer cell line LNCaP was reversed by prolonged Ad-IU2 infection 
(Figure 10).  Ad-IU2 exhibited marked in vitro killing activity against both androgen-
dependent and androgen-independent PSA/PSMA-positive prostate cancer cells, 
compared to the PSRCA, Ad-E4PSESE1a, suggesting that the addition of TRAIL to a 
PSRCA augmented the killing power of a replication-competent adenovirus (Figure 11A-
C).  The ability to maintain strong PSES activity regardless of androgen status will allow 
Ad-IU2 to be used for either early or advanced prostate tumors.  TRAIL is a valuable 
anti-tumor molecular therapeutic agent because of its preference for inducing apoptosis 
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in cancer cells.  Retaining this ability, Ad-IU2 failed to kill PSA/PSMA-negative normal 
human dermal fibroblasts (Figure 11D). 
 Due to the heterogeneity of cells within a single tumor of the prostate, with 
respect to PSA, PSMA, AR and CAR expression, as well as the reduced in vivo 
transduction efficiency of adenoviral vectors, the ability of Ad-IU2 gene therapy to induce 
a bystander killing effect is critical to its success as a therapeutic agent.  In co-culture 
with Ad-IU2-infected PSA/PSMA-positive CWR22rv cells, apoptosis was detected in 
PSA/PSMA-negative PC-3 cells, implicating a potential role for cell-to-cell contact with 
Ad-IU2-infected cells expressing surface-bound TRAIL (Figure 12).  Similarly, apoptosis 
was detected in both CWR22rv and PC-3 cells treated with conditioned medium from 
Ad-IU2-infected cells which had been heat-inactivated to deplete viable Ad-IU2 virus 
particles from the medium (Figure 13).  However, western blot analysis of the 
conditioned medium revealed that soluble TRAIL was not cleaved from the cell 
membranes of Ad-IU2-infected cells (Figure 15), suggesting that other soluble factors, 
such as TRAIL-containing apoptotic bodies or even non-TRAIL proteins, were 
responsible for the bystander killing effect. 
Ad-IU2 significantly suppressed the in vivo growth of androgen-independent 
CWR22rv xenografts in nude athymic mice compared to a PSRCA control (3.1 vs. 17.1-
fold growth of tumor).  At the 6-week endpoint of the study, 6 tumors responded 
favorably with partial regression in 4 of 6 or complete regression in 2 of 6 tumors.  Of the 
3 tumors that failed treatment, two were still significantly suppressed compared to 
PSRCA-treated tumors (Figures 16 and 17).  The histological appearance of Ad-IU2-
treated tumors was drastically different than PSRCA-treated tumors.  In the Ad-IU2 
treatment group, the treatment effect appeared to extend beyond the necrotic viral 
centers of replication, whereas in the PSRCA control group, the treatment effect was 
limited to the margin of cells surrounding viral centers of replication (Figure 18), 
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demonstrating enhanced therapeutic effect and viral spread throughout a greater tumor 
volume.  The use of the highly tissue-specific PSES promoter will not only for allow intra-
tumoral injection of the vector for locally advanced or recurrent tumors, but also systemic 
administration of the virus to target distant metastases; however, the greatest limitation 
of this approach to be overcome is the dilution effect of the virus in the bloodstream.  Of 
the prostate-specific promoters available, PSES retains the highest tissue-specificity and 
activity in environments depleted of androgens, giving this PSRCA greater clinical utility 
in patients undergoing simultaneous ADT.  Although gene therapy with Ad-IU2 shows 
favorable preclinical promise as a therapeutic agent for advanced androgen-independent 
prostate cancer, its use as a monotherapy may not be feasible.  Ad-IU2 viral therapy 
would benefit greatly from combination with conventional therapies such as radiation 
therapy. 
Recently, it has been demonstrated that an enhanced anti-tumor effect can be 
achieved when rhTRAIL therapy is combined with EBRT.  I hypothesized that the 
neoadjuvant treatment of high risk prostate cancer with a PSRCA expressing TRAIL 
would result in the radio-sensitization of tumor cells, thereby enhancing the therapeutic 
effect of EBRT.  This approach is ideal over the use of rhTRAIL to sensitize tumors to 
radiotherapy because replication-competent vectors can achieve enhanced distribution 
throughout the entire tumor.  Furthermore, through the use of a tissue-specific promoter 
such as PSES, radio-sensitization can be limited to prostate cancer cells, minimizing 
toxicity to normal tissues. 
EBRT is viewed as the standard of care for high risk locally advanced prostate 
cancer; however, clinical outcomes are merely intermediate to moderate, despite 
combination with ADT.  In order to achieve a long-term cure, the local disease must be 
controlled; however, the persistence of radio-resistant cancer cells and RT dose-limiting 
toxicities prevent the complete elimination of all tumor cells.  For this reason, a treatment 
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modality that enhances the therapeutic efficacy of EBRT within the local tumor 
environment and effectively reduces the required dose of radiation administered is quite 
appealing. 
In this study, the pretreatment of androgen-independent CWR22rv and C4-2 
prostate cancer cells with 0.003 LDU/cell resulted in significant radio-sensitization as 
evidenced by a reduction in the shoulder of the radiation survival curves, an increase in 
lethal DNA damage (α), and a decrease in sublethal events (β).  Untreated C4-2 cells 
were found to be more radio-sensitive than CWR22rv cells, with a mean lethal dose of 
2.35 Gy, compared to 2.52 Gy.  Ad-IU2 had the greatest radio-sensitizing effect on 
CWR22rv cells (DRF = 4.91), compared to C4-2 (DRF = 2.43).  In both cell lines, Ad-IU2 
was a significantly better radiation-sensitizing agent than 75 ng/ml rhTRAIL (Figures 21 
and 22).  Radio-sensitization by Ad-IU2 did not occur in PSA/PSMA-negative LoVo and 
T24 cells (Figure 24).  Because these cell lines differ genetically from normal cells, they 
may not behave similarly.  Therefore, a limitation of this study is that the radio-
sensitization of primary urothelial, colorectal and bladder smooth muscle cells was not 
tested; however, the difficulty of performing clonogenic assays on primary cells 
precludes this method.  These data suggest that Ad-IU2 is a potent radio-sensitizer in 
PSA/PSMA-positive androgen-independent prostate cancer cells that will result in 
enhancement of the RT effect and radiation dose-reduction.  Through the tight control of 
TRAIL expression by the PSES promoter, toxicity to surrounding normal tissues should 
also be reduced.  Although the in vitro Ad-IU2 data show promise as a radio-sensitizing 
agent for clinical use, no radio-sensitizing data in similar cell lines exist for comparison.  
Radiation-sensitizers for prostate cancer have not been widely evaluated in the 
laboratory.  Currently, the use of docetaxel in combination with EBRT is being 
investigated clinically.  The combinatorial therapy was tolerated well, and the maximum 
tolerable dose has not yet been met (290).            
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 Several mechanisms could explain or contribute to the enhancement of the 
therapeutic effect when molecular therapy with TRAIL is combined with EBRT.  First, 
ionizing radiation may upregulate the expression of DR4 or DR5, the cell surface 
receptors for TRAIL.  Such an increase in TRAIL receptor may enhance TRAIL tumor 
killing by reversing resistance to TRAIL.  Secondly, concurrent treatment with RT may 
enhance expression of TRAIL throughout the tumor, as it has been shown that ionizing 
radiation improves the transduction efficiency and transgene integration of adenoviral 
vectors (308, 309).  In addition, TRAIL may kill residual radio-resistant prostate cancer 
cells that remain after treatment with EBRT.  Next, it is known that TRAIL and RT act 
upon distinct pathways to trigger apoptosis, TRAIL through an extrinsic caspase-
mediated pathway and ionizing radiation through an intrinsic mitochondrial-dependent 
pathway.  Therefore, the combination of TRAIL receptor stimulation and radiation should 
activate both pathways, resulting in an amplification of apoptosis.  Previous studies have 
demonstrated this effect in cells treated with TRAIL molecular therapy and EBRT; 
however, this effect was only seen at very high doses of EBRT (294, 295, 299).  In the 
present study, at the minimal doses of Ad-IU2 and EBRT required to reduce the 
clonogenic survival of CWR22rv and C4-2 cells, enhancement of apoptosis induction 
with combinatorial therapy was not observed (Figure 25).  This suggests that a different 
mechanism exists for radio-sensitization in prostate cancer cells treated with Ad-IU2.   
Cell cycle analysis of prostate cancer cells infected with Ad-IU2 or pretreated 
with rhTRAIL for 24 hours revealed a 20% increase in the G1 population for both 
CWR22rv and C4-2 cells (Figure 26).  This may contribute to the mechanism of radio-
sensitization, as cells arrested in G1 or G2 phases are most sensitive to RT.  Following 
combination with EBRT, this effect was still observed for 8 hours after irradiation in 
CWR22rv cells or 24 hours in C4-2 cells.  This cell cycle redistribution also resulted in a 
reduction of the radio-resistant S phase.  The most striking cell cycle effect was 
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observed following combinatorial therapy where pretreatment of prostate cancer cells 
with Ad-IU2 or rhTRAIL resulted in an decrease in the RT-induced G2 arrest.  At 8 hours 
after irradiation, a 40% reduction in the G2 arrest was observed in CWR22rv cells and a 
55% reduction was observed in C4-2 cells (Figure 27).  This effect lasted up to 8 hours 
for CWR22rv cells and up to 16 hours for C4-2 cells (Table 8).  The mitotic checkpoint is 
in place to prevent cells with significant chromosomal damage from exiting mitosis.  
Perturbation of the RT-induced G2 arrest is significant because it can lead to genomic 
instability and mitotic catastrophe, playing a significant role in the radio-sensitization of 
cells and contributing to the death of irradiated prostate cancer cells. 
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Future Directions 
 
 Within the last several years, studies in the field of cancer gene therapy have 
attempted to improve gene delivery vectors by creating viruses with the ability to 
package a greater number of transgenes, hide from the host’s immune system, deliver 
transgenes with greater transduction efficiency, and target tumor cells selectively.  Since 
the cloning and initial production of Ad-IU2, many of these improvements have been well 
characterized.  As with most agents currently under investigation in clinical trials, an 
improved version of the therapeutic modality is usually available in the laboratory, but 
less thoroughly studied.  By manipulation of the adenoviral genome, such improvements 
can be made to Ad-IU2 as well.  These vector improvements might enhance the 
therapeutic efficacy of Ad-IU2 as a single agent or in combination with EBRT.   
Perhaps the most beneficial vector modification would be the deletion of the E3 
adenoviral region.  This early adenoviral gene encodes several gene products that 
prevent or diminish apoptosis induction in the host cell and are not critical for viral 
replication (67).  If the E3 region is deleted, the adenoviral late coding sequence ADP, 
which is found within the E3 region, should be reinserted to enhance cell lysis and 
release of viral progeny (72).  In the current study, although Ad-IU2 induced apoptosis 
significantly above that of a PSRCA, levels of apoptosis achieved were no greater than 
25% at 24 hours after infection (Figure 9).  These low levels of apoptosis induction may 
be the result of adenoviral anti-apoptotic proteins.  The resulting deletion of the E3 
region and reinsertion of the ADP coding sequence would also provide an additional 2 
kb of packaging space.  A second modification would be to substitute the Ad5 fiber knob 
from Ad-IU2 with the fiber knob from Ad35.  This improvement would result in greater 
infectivity in prostate cancer cells, decreased viral tropism for hepatic cells, and 
reduction in innate immunity against the vector, because neutralizing antibodies against 
98 
 
Ad35 are less common in patients than against Ad5 (81).  In addition, this modification 
would result in a gain of 756 bp of genome space for more therapeutic inserts.  With the 
approximately 2.8 kb of gained insert space, an additional transgene could be inserted 
such as the anti-angiogenic factor, EndoAngio (211).  One final consideration for a 
vector modification would be to replace one PSES sequence for another prostate-
specific promoter such as OC.  Because Ad-IU2 contains two copies of PSES, one near 
each ITR, although rare, there exists the risk that a homologous recombination event 
might occur between the sequences in an infected cell, resulting in excision from the 
genome and loss of the therapeutic vector. 
   One further question remains to be answered regarding the evaluation of the 
Ad-IU2 bystander effect.  Is the bystander effect that is observed in conditioned medium 
from Ad-IU2-infected cells due to apoptotic bodies containing TRAIL on the membrane 
surface or other soluble factors released from infected cells?  To begin to answer this, 
the conditioned medium from Ad-IU2-infected cells could be applied to LNCaP cells, 
which are highly resistant to TRAIL.  The induction of apoptosis in LNCaP cells could 
indicate that soluble factors, other than apoptotic bodies, are responsible for the 
bystander effect.  However, perhaps a better experimental method would be to use anti-
TRAIL receptor blocking antibodies in TRAIL-sensitive cells treated with conditioned 
medium.  A reduction or complete blockade of apoptosis would suggest that TRAIL-
containing apoptotic bodies played a role in or were entirely responsible for the 
bystander effect.  If apoptosis induction was not affected by TRAIL-blocking antibodies, 
this would suggest a role for other soluble factors released from Ad-IU2-infected cells. 
Another area of investigation is the study of the molecular events responsible for 
the cell cycle changes that occurred in prostate cancer cells treated with combinatorial 
therapy.  Treatment of prostate cancer cells with Ad-IU2 or rhTRAIL for 24 hours 
resulted in arrest of cells in G1 phase, a stage in the cell cycle in which cells are more 
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radio-sensitive.  Following combinatorial therapy, cells pretreated with Ad-IU2 or 
rhTRAIL demonstrated a diminished RT-induced G2 arrest.  It was recently discovered 
that FADD was required for the combined effect of TRAIL and RT (310).  Nuclear 
localization (311) and phosphorylation of FADD at serine 194 by casein kinase Iα (CKIα) 
(312) has also been shown to be essential for cell cycle regulation.  It is known that 
FADD is dephosphorylated in G1 phase; however, its role in regulating progression 
through the G1/S checkpoint is unclear (313).  Further investigation is warranted to 
determine whether FADD is responsible for the accumulation of cells in G1 phase 
following Ad-IU2 or rhTRAIL treatment.  In prostate cancer cells, it was discovered that 
Ser 194-phosphorylated nuclear FADD contributed to G2 arrest of cells (314).  It is 
possible that activation of the DISC and sequestration of FADD to the cell membrane 
would result in a decrease in the amount of FADD available in the nucleus, leading to an 
abrogation of the RT-induced G2 arrest.  To better understand the role of FADD in cell 
cycle regulation, the nuclear sublocalization and phosphorylation of FADD should be 
studied in prostate cancer cells following combinatorial therapy.  Finally, a second 
possible mechanism for the perturbation of G2 arrest may be caspase-dependent 
degradation of mitotic checkpoint proteins.  Kim et al. recently described a similar G2 
arrest abrogation when rhTRAIL was combined with the microtubule-targeting drugs 
nocodazole or paclitaxel.  The combination of drugs resulted in the degradation of the 
mitotic checkpoint proteins BubR1 and Bub1 by activated caspases (315).  A screen of 
several G1/S and G2/M checkpoint proteins following the combinatorial treatment of 
prostate cancer cells with Ad-IU2 and EBRT may be useful to determine whether 
caspase-mediated cleavage of check point proteins was responsible for the radio-
sensitization of prostate cancer cells by Ad-IU2 and rhTRAIL.  However, one should also 
consider that arrest of cells in G1 alone may be responsible for the decrease in the G2 
population, due to fewer cycling cells.  Synchronization experiments may be necessary 
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to further understand the role of cell cycle in the radio-sensitization of prostate cancer 
cells.  A working hypothesis model for the sensitization of prostate cancer cells to 
radiation therapy by Ad-IU2 is represented in Figure 28. 
 
 
 
Figure 28.  Hypothetical mechanism of radio-sensitization by Ad-IU2.  Exposure of 
prostate cancer cells to TRAIL by Ad-IU2 infection or rhTRAIL administration resulted in 
G1 phase arrest.  One possible mechanism for this is the sequestration of FADD to the 
cell membrane, preventing its phosphorylation at serine residue 194.  In an untreated 
prostate cancer cell, exposure to ionizing radiation activates the G2/M checkpoint, 
induces FADD phosphorylation and causes G2 arrest, allowing sufficient time to repair 
double strand breaks (DSB) in chromosomes.  In prostate cancer cells pretreated with 
Ad-IU2 or rhTRAIL, the RT-induced G2 arrest was diminished.  Two possible 
mechanisms may explain this cell cycle alteration.  First, activation of the caspase 
cascade by TRAIL may induce degradation of G2/M checkpoint proteins, allowing cells to 
progress without chromosomal repair.  The second method involves the reduction of 
phosphorylated FADD due to sequestration of the DISC at the cell membrane, resulting 
in progression through the G2/M checkpoint and a mitotic catastrophe. 
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The final area of investigation remaining in this study is to test the in vivo efficacy 
of combinatorial therapy against androgen-independent CWR22rv tumor xenografts in 
nude mice.  This is necessary to confirm the in vitro radio-sensitizing properties of Ad-
IU2 and will require dosimetry experiments on SQ CWR22rv tumors to determine the 
proper in vivo RT dose.  Once this has been achieved, a combinatorial treatment 
regimen must be designed and evaluated to achieve EBRT dose reduction.  This animal 
experiment will serve as the proof-of-principle for clinical evaluation of the therapy.  To 
assess the safety of this multi-modal therapy, a toxicology study should be performed in 
mice evaluating the safety of the vector alone and in combination with EBRT, looking for 
toxicity to major organ systems including cardiovascular, hematologic, central nervous, 
pulmonary, renal and hepatobiliary.  The results obtained from the in vitro study showed 
great promise for translation to a clinical trial.  After successful completion of the 
toxicology study, IND status should be obtained and a clinical protocol developed and 
filed with the RAC for the combinatorial treatment of locally advanced disease or spinal 
metastatic lesions through intratumoral injection of Ad-IU2 and co-administration of 
EBRT. 
102 
 
References 
 
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008 
Mar-Apr;58(2):71-96. 
2. Isaacs JT. Molecular markers for prostate cancer metastasis. Developing 
diagnostic methods for predicting the aggressiveness of prostate cancer. Am J Pathol 
1997 May;150(5):1511-21. 
3. Dijkman GA, Debruyne FM. Epidemiology of prostate cancer. Eur Urol 
1996;30(3):281-95. 
4. Meikle AW, Smith JA, Jr. Epidemiology of prostate cancer. Urol Clin North Am 
1990 Nov;17(4):709-18. 
5. Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence 
rates as related to obesity and race in men with prostate cancer undergoing radical 
prostatectomy. J Clin Oncol 2004 Feb 1;22(3):439-45. 
6. Freedland SJ, Aronson WJ, Kane CJ, et al. Impact of obesity on biochemical 
control after radical prostatectomy for clinically localized prostate cancer: a report by the 
Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 
2004 Feb 1;22(3):446-53. 
7. Platz EA, Leitzmann MF, Michaud DS, Willett WC, Giovannucci E. Interrelation of 
energy intake, body size, and physical activity with prostate cancer in a large prospective 
cohort study. Cancer Res 2003 Dec 1;63(23):8542-8. 
8. Bosetti C, Micelotta S, Dal Maso L, et al. Food groups and risk of prostate cancer 
in Italy. Int J Cancer 2004 Jun 20;110(3):424-8. 
9. Colli JL, Colli A. International comparisons of prostate cancer mortality rates with 
dietary practices and sunlight levels. Urol Oncol 2006 May-Jun;24(3):184-94. 
10. Talamini R, Franceschi S, La Vecchia C, Serraino D, Barra S, Negri E. Diet and 
prostatic cancer: a case-control study in northern Italy. Nutr Cancer 1992;18(3):277-86. 
11. West DW, Slattery ML, Robison LM, French TK, Mahoney AW. Adult dietary 
intake and prostate cancer risk in Utah: a case-control study with special emphasis on 
aggressive tumors. Cancer Causes Control 1991 Mar;2(2):85-94. 
12. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable 
factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, 
and Finland. N Engl J Med 2000 Jul 13;343(2):78-85. 
13. Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate 
cancer on chromosome 1 suggested by a genome-wide search. Science 1996 Nov 
22;274(5291):1371-4. 
14. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG 
trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation 
function. Nucleic Acids Res 1994 Aug 11;22(15):3181-6. 
15. Kazemi-Esfarjani P, Trifiro MA, Pinsky L. Evidence for a repressive function of 
the long polyglutamine tract in the human androgen receptor: possible pathogenetic 
relevance for the (CAG)n-expanded neuronopathies. Hum Mol Genet 1995 Apr;4(4):523-
7. 
16. Nam RK, Toi A, Vesprini D, et al. V89L polymorphism of type-2, 5-alpha 
reductase enzyme gene predicts prostate cancer presence and progression. Urology 
2001 Jan;57(1):199-204. 
  
103 
 
17. Herman CM, Kattan MW, Ohori M, Scardino PT, Wheeler TM. Primary Gleason 
pattern as a predictor of disease progression in gleason score 7 prostate cancer: a 
multivariate analysis of 823 men treated with radical prostatectomy. Am J Surg Pathol 
2001 May;25(5):657-60. 
18. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and 
the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004 Jul 
8;351(2):125-35. 
19. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end 
point for prostate cancer-specific mortality after radical prostatectomy or radiation 
therapy. J Natl Cancer Inst 2003 Sep 17;95(18):1376-83. 
20. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after 
radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for 
clinically localized prostate cancer. JAMA 1998 Sep 16;280(11):969-74. 
21. Thompson KE, Hernandez J, Canby-Hagino ED, Troyer D, Thompson IM. 
Prognostic features in men who died of prostate cancer. J Urol 2005 Aug;174(2):553-6; 
discussion 6. 
22. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal 
anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000 Jan-
Feb;7(1):169-70. 
23. Nelson WG, De Marzo AM, Deweese TL, et al. Preneoplastic prostate lesions: an 
opportunity for prostate cancer prevention. Ann N Y Acad Sci 2001 Dec;952:135-44. 
24. Lin X, Tascilar M, Lee WH, et al. GSTP1 CpG island hypermethylation is 
responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J 
Pathol 2001 Nov;159(5):1815-26. 
25. Brooks JD, Weinstein M, Lin X, et al. CG island methylation changes near the 
GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 
1998 Jun;7(6):531-6. 
26. Bieberich CJ, Fujita K, He WW, Jay G. Prostate-specific and androgen-
dependent expression of a novel homeobox gene. J Biol Chem 1996 Dec 
13;271(50):31779-82. 
27. Chen H, Nandi AK, Li X, Bieberich CJ. NKX-3.1 interacts with prostate-derived 
Ets factor and regulates the activity of the PSA promoter. Cancer Res 2002 Jan 
15;62(2):338-40. 
28. Bowen C, Bubendorf L, Voeller HJ, et al. Loss of NKX3.1 expression in human 
prostate cancers correlates with tumor progression. Cancer Res 2000 Nov 
1;60(21):6111-5. 
29. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS 
transcription factor genes in prostate cancer. Science 2005 Oct 28;310(5748):644-8. 
30. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate 
cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007 
Jun;31(6):882-8. 
31. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of 
PTEN expression in paraffin-embedded primary prostate cancer correlates with high 
Gleason score and advanced stage. Cancer Res 1999 Sep 1;59(17):4291-6. 
32. Suzuki H, Freije D, Nusskern DR, et al. Interfocal heterogeneity of PTEN/MMAC1 
gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998 Jan 
15;58(2):204-9. 
33. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: 
a possible molecular mechanism for androgen deprivation therapy failure in prostate 
cancer. Cancer Res 1997 Jan 15;57(2):314-9. 
104 
 
34. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-
independent prostate cancer through modulation of androgen receptor signaling by the 
HER-2/neu tyrosine kinase. Nat Med 1999 Mar;5(3):280-5. 
35. Culig Z, Hobisch A, Cronauer MV, et al. Mutant androgen receptor detected in an 
advanced-stage prostatic carcinoma is activated by adrenal androgens and 
progesterone. Mol Endocrinol 1993 Dec;7(12):1541-50. 
36. Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW. Functional analysis of 44 
mutant androgen receptors from human prostate cancer. Cancer Res 2002 Mar 
1;62(5):1496-502. 
37. Carver BS, Bianco FJ, Jr., Scardino PT, Eastham JA. Long-term outcome 
following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 
2006 Aug;176(2):564-8. 
38. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy 
for clinically advanced (cT3) prostate cancer since the advent of prostate-specific 
antigen testing: 15-year outcome. BJU Int 2005 Apr;95(6):751-6. 
39. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical 
prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005 Aug 13-
19;366(9485):572-8. 
40. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of 
estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the 
prostate. CA Cancer J Clin 1972 Jul-Aug;22(4):232-40. 
41. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide 
with and without flutamide in prostatic carcinoma. N Engl J Med 1989 Aug 
17;321(7):419-24. 
42. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with 
or without flutamide for metastatic prostate cancer. N Engl J Med 1998 Oct 
8;339(15):1036-42. 
43. Coleman CN. International Conference on Translational Research and Preclinical 
Strategies in Radio-Oncology (ICTR)--conference summary. Int J Radiat Oncol Biol Phys 
2001 Feb 1;49(2):301-9. 
44. Osborn JL, Getzenberg RH, Trump DL. Spinal cord compression in prostate 
cancer. J Neurooncol 1995;23(2):135-47. 
45. Hanks GE, Hanlon AL, Epstein B, Horwitz EM. Dose response in prostate cancer 
with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys 2002 Oct 1;54(2):427-35. 
46. Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Schultheiss TE. Survival 
advantage for prostate cancer patients treated with high-dose three-dimensional 
conformal radiotherapy. Cancer J Sci Am 1999 May-Jun;5(3):152-8. 
47. O'Connor KM, Fitzpatrick JM. Side-effects of treatments for locally advanced 
prostate cancer. BJU Int 2006 Jan;97(1):22-8. 
48. Roach M, 3rd. Reducing the toxicity associated with the use of radiotherapy in 
men with localized prostate cancer. Urol Clin North Am 2004 May;31(2):353-66. 
49. Fuks Z, Leibel SA, Wallner KE, et al. The effect of local control on metastatic 
dissemination in carcinoma of the prostate: long-term results in patients treated with 125I 
implantation. Int J Radiat Oncol Biol Phys 1991 Aug;21(3):537-47. 
50. Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized 
prostate cancer: local persistence of disease results in a late wave of metastases. J Clin 
Oncol 2002 Aug 1;20(15):3199-205. 
51. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms 
dominate elimination of adenoviral vectors following in vivo administration. Hum Gene 
Ther 1997 Jan 1;8(1):37-44. 
105 
 
52. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses 
to adenovirus and adeno-associated virus in humans. Gene Ther 1999 Sep;6(9):1574-
83. 
53. Schiedner G, Morral N, Parks RJ, et al. Genomic DNA transfer with a high-
capacity adenovirus vector results in improved in vivo gene expression and decreased 
toxicity. Nat Genet 1998 Feb;18(2):180-3. 
54. Hearing P, Samulski RJ, Wishart WL, Shenk T. Identification of a repeated 
sequence element required for efficient encapsidation of the adenovirus type 5 
chromosome. Journal of virology 1987 Aug;61(8):2555-8. 
55. Nevins JR. Mechanism of activation of early viral transcription by the adenovirus 
E1A gene product. Cell 1981 Oct;26(2 Pt 2):213-20. 
56. Rich DP, Couture LA, Cardoza LM, et al. Development and analysis of 
recombinant adenoviruses for gene therapy of cystic fibrosis. Hum Gene Ther 1993 
Aug;4(4):461-76. 
57. Bagchi S, Raychaudhuri P, Nevins JR. Adenovirus E1A proteins can dissociate 
heteromeric complexes involving the E2F transcription factor: a novel mechanism for 
E1A trans-activation. Cell 1990 Aug 24;62(4):659-69. 
58. Mal A, Poon RY, Howe PH, Toyoshima H, Hunter T, Harter ML. Inactivation of 
p27Kip1 by the viral E1A oncoprotein in TGFbeta-treated cells. Nature 1996 Mar 
21;380(6571):262-5. 
59. Somasundaram K, El-Deiry WS. Inhibition of p53-mediated transactivation and 
cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene 1997 Mar 
6;14(9):1047-57. 
60. Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E. The 
adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and 
Bcl-2 proteins. Proc Natl Acad Sci U S A 1992 Aug 15;89(16):7742-6. 
61. Halbert DN, Cutt JR, Shenk T. Adenovirus early region 4 encodes functions 
required for efficient DNA replication, late gene expression, and host cell shutoff. Journal 
of virology 1985;56(1):250-7. 
62. Pilder S, Moore M, Logan J, Shenk T. The adenovirus E1B-55K transforming 
polypeptide modulates transport or cytoplasmic stabilization of viral and host cell 
mRNAs. Molecular and cellular biology 1986 Feb;6(2):470-6. 
63. Nevels M, Rubenwolf S, Spruss T, Wolf H, Dobner T. The adenovirus E4orf6 
protein can promote E1A/E1B-induced focus formation by interfering with p53 tumor 
suppressor function. Proc Natl Acad Sci U S A 1997 Feb 18;94(4):1206-11. 
64. Field J, Gronostajski RM, Hurwitz J. Properties of the adenovirus DNA 
polymerase. J Biol Chem 1984 Aug 10;259(15):9487-95. 
65. Challberg MD, Desiderio SV, Kelly TJ, Jr. Adenovirus DNA replication in vitro: 
characterization of a protein covalently linked to nascent DNA strands. Proc Natl Acad 
Sci U S A 1980 Sep;77(9):5105-9. 
66. Burgert HG, Maryanski JL, Kvist S. "E3/19K" protein of adenovirus type 2 inhibits 
lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility 
class I antigens. Proc Natl Acad Sci U S A 1987;84(5):1356-60. 
67. Elsing A, Burgert HG. The adenovirus E3/10.4K-14.5K proteins down-modulate 
the apoptosis receptor Fas/Apo-1 by inducing its internalization. Proc Natl Acad Sci U S 
A 1998 Aug 18;95(17):10072-7. 
68. Mathews MB, Shenk T. Adenovirus virus-associated RNA and translation control. 
Journal of virology 1991 Nov;65(11):5657-62. 
69. Leibowitz J, Horwitz MS. Synthesis and assembly of adenovirus polypeptides. III. 
Reversible inhibition of hexon assembly in adenovirus type 5 temperature-sensitive 
mutants. Virology 1975 Jul;66(1):10-24. 
106 
 
70. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor 
for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997 Feb 
28;275(5304):1320-3. 
71. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 
and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 
1993 Apr 23;73(2):309-19. 
72. Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WS. The 
adenovirus death protein (E3-11.6K) is required at very late stages of infection for 
efficient cell lysis and release of adenovirus from infected cells. Journal of virology 1996 
Apr;70(4):2296-306. 
73. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, Wold WS. Tumor-
specific, replication-competent adenovirus vectors overexpressing the adenovirus death 
protein. Journal of virology 2000;74(13):6147-55. 
74. Rauen KA, Sudilovsky D, Le JL, et al. Expression of the coxsackie adenovirus 
receptor in normal prostate and in primary and metastatic prostate carcinoma: potential 
relevance to gene therapy. Cancer Res 2002 Jul 1;62(13):3812-8. 
75. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT. Targeted 
gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 1996 
Nov;14(11):1574-8. 
76. Wickham TJ, Segal DM, Roelvink PW, et al. Targeted adenovirus gene transfer 
to endothelial and smooth muscle cells by using bispecific antibodies. Journal of virology 
1996 Oct;70(10):6831-8. 
77. Kraaij R, van Rijswijk AL, Oomen MH, Haisma HJ, Bangma CH. Prostate specific 
membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of 
prostate cancer in vitro. Prostate 2005 Feb 15;62(3):253-9. 
78. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I. Adenovirus targeted to 
heparan-containing receptors increases its gene delivery efficiency to multiple cell types. 
Nat Biotechnol 1996 Nov;14(11):1570-3. 
79. Krasnykh V, Dmitriev I, Mikheeva G, Miller CR, Belousova N, Curiel DT. 
Characterization of an adenovirus vector containing a heterologous peptide epitope in 
the HI loop of the fiber knob. Journal of virology 1998 Mar;72(3):1844-52. 
80. Lupold SE, Rodriguez R. Disulfide-constrained peptides that bind to the 
extracellular portion of the prostate-specific membrane antigen. Molecular cancer 
therapeutics 2004 May;3(5):597-603. 
81. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A. 
Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. 
Journal of virology 2000 Mar;74(6):2567-83. 
82. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B 
adenoviruses. Nat Med 2003 Nov;9(11):1408-12. 
83. Sova P, Ren XW, Ni S, et al. A tumor-targeted and conditionally replicating 
oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol 
Ther 2004 Apr;9(4):496-509. 
84. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular 
immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl 
Acad Sci U S A 1994 May 10;91(10):4407-11. 
85. Schiedner G, Hertel S, Johnston M, Biermann V, Dries V, Kochanek S. Variables 
affecting in vivo performance of high-capacity adenovirus vectors. Journal of virology 
2002 Feb;76(4):1600-9. 
86. Sandig V, Youil R, Bett AJ, et al. Optimization of the helper-dependent 
adenovirus system for production and potency in vivo. Proc Natl Acad Sci U S A 2000 
Feb 1;97(3):1002-7. 
107 
 
87. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-
dependent adenovirus vector system: removal of helper virus by Cre-mediated excision 
of the viral packaging signal. PNAS USA 1996;93:13565-70. 
88. Fallaux FJ, Bout A, van der Velde I, et al. New helper cells and matched early 
region 1-deleted adenovirus vectors prevent generation of replication-competent 
adenoviruses. Hum Gene Ther 1998 Sep 1;9(13):1909-17. 
89. Kotin RM, Siniscalco M, Samulski RJ, et al. Site-specific integration by adeno-
associated virus. Proc Natl Acad Sci U S A 1990 Mar;87(6):2211-5. 
90. Linden RM, Ward P, Giraud C, Winocour E, Berns KI. Site-specific integration by 
adeno-associated virus. Proc Natl Acad Sci U S A 1996 Oct 15;93(21):11288-94. 
91. Kearns WG, Afione SA, Fulmer SB, et al. Recombinant adeno-associated virus 
(AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized 
epithelial cell line. Gene Ther 1996 Sep;3(9):748-55. 
92. Rolling F, Samulski RJ. AAV as a viral vector for human gene therapy. 
Generation of recombinant virus. Mol Biotechnol 1995 Feb;3(1):9-15. 
93. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce adeno-
associated virus type 2 vectors. Hum Gene Ther 2002 Nov 1;13(16):1935-43. 
94. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a 
rate-limiting step for efficient transduction by recombinant adeno-associated virus 
vectors. Journal of virology 1996 May;70(5):3227-34. 
95. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant 
adeno-associated virus (scAAV) vectors promote efficient transduction independently of 
DNA synthesis. Gene Ther 2001 Aug;8(16):1248-54. 
96. Warrington KH, Jr., Gorbatyuk OS, Harrison JK, Opie SR, Zolotukhin S, 
Muzyczka N. Adeno-associated virus type 2 VP2 capsid protein is nonessential and can 
tolerate large peptide insertions at its N terminus. Journal of virology 2004 
Jun;78(12):6595-609. 
97. Recchia A, Perani L, Sartori D, Olgiati C, Mavilio F. Site-specific integration of 
functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol Ther 
2004 Oct;10(4):660-70. 
98. Brand K, Arnold W, Bartels T, et al. Liver-associated toxicity of the HSV-tk/GCV 
approach and adenoviral vectors. Cancer Gene Therapy 1997;4:9-16. 
99. Herman JR, Adler HL, Aguilar-Cordova E, et al. In situ gene therapy for 
adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 1999 May 
1;10(7):1239-49. 
100. Stamey TA, Yang N, Hay AR, McNeal JE, Feiha FS, Redwine E. Prostate-
Specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 
1987;317:909-16. 
101. Riegman PH, Vlietstra RJ, van der Korput J, Romijn JC, Trapman J. 
Characterization of the prostate-specific antigen gene: a novel human kallikrein-like 
gene. Biochemical & Biophysical Research Communications 1989;159(1):95-102. 
102. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, 
Trapman J. An androgen response element in a far upstream enhancer region is 
essential for high, androgen-regulated activity of the prostate- specific antigen promoter. 
Mol Endocrinol 1997;11(2):148-61. 
103. Pang S, Dannull J, Kaboo R, et al. Identification of a positive regulatory element 
responsible for tissue-specific expression of prostate-specific antigen. Cancer Res 1997 
Feb 1;57(3):495-9. 
104. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson 
DR. Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol 
Chem 1996;271(12):7043-51. 
108 
 
105. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman J. The 
promoter of the prostate-specific antigen gene contains a functional androgen 
responsive element. Molecular Endocrinology 1991;5(12):1921-30. 
106. Gotoh A, Ko SC, Shirakawa T, et al. Development of prostate-specific antigen 
promoter-based gene therapy for androgen-independent human prostate cancer. J Urol 
1998 Jul;160(1):220-9. 
107. Lu Y, Carraher J, Zhang Y, et al. Delivery of adenoviral vectors to the prostate for 
gene therapy. Cancer Gene Ther 1999 Jan-Feb;6(1):64-72. 
108. Yeung F, Li X, Ellett J, Trapman J, Kao C, Chung LW. Regions of prostate-
specific antigen (PSA) promoter confer androgen- independent expression of PSA in 
prostate cancer cells. J Biol Chem 2000;275(52):40846-55. 
109. Wu L, Matherly J, Smallwood A, et al. Chimeric PSA enhancers exhibit 
augmented activity in prostate cancer gene therapy vectors. Gene Ther 2001 
Sep;8(18):1416-26. 
110. Latham JP, Searle PF, Mautner V, James ND. Prostate-specific antigen 
promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a 
tissue-specific adenovirus vector. Cancer Res 2000 Jan 15;60(2):334-41. 
111. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new 
antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. 
Anticancer Res 1987;7(5B):927-35. 
112. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a 
novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 
1996;2(9):1445-51. 
113. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a 
hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc 
Natl Acad Sci U S A 1996;93(2):749-53. 
114. Pangalos MN, Neefs JM, Somers M, et al. Isolation and expression of novel 
human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase 
and dipeptidyl peptidase IV activity. J Biol Chem 1999;274(13):8470-83. 
115. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific 
membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 
1997 Jan;3(1):81-5. 
116. Xiao Z, Adam BL, Cazares LH, et al. Quantitation of serum prostate-specific 
membrane antigen by a novel protein biochip immunoassay discriminates benign from 
malignant prostate disease. Cancer Res 2001;61(16):6029-33. 
117. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane 
antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. 
Urology 1998;52(4):637-40. 
118. Wright GL, Grob BM, Haley C, et al. Upregulation of Prostate-specific membrane 
antigen after androgen-deprivation therapy. Urology 1996;48(2):326-34. 
119. O'Keefe DS, Su SL, Bacich DJ, et al. Mapping, genomic organization and 
promoter analysis of the human prostate-specific membrane antigen gene. Biochim 
Biophys Acta 1998;1443(1-2):113-27. 
120. Watt F, Martorana A, Brookes DE, et al. A tissue-specific enhancer of the 
prostate-specific membrane antigen gene, FOLH1. Genomics 2001;73(3):243-54. 
121. Lee SJ, Lee K, Yang X, et al. NFATc1 with AP-3 site binding specificity mediates 
gene expression of prostate-specific-membrane-antigen. J Mol Biol 2003 Jul 
18;330(4):749-60. 
  
109 
 
122. Uchida A, O'Keefe DS, Bacich DJ, Molloy PL, Heston WD. In vivo suicide gene 
therapy model using a newly discovered prostate- specific membrane antigen 
promoter/enhancer: a potential alternative approach to androgen deprivation therapy. 
Urology 2001;58(2 Suppl 1):132-9. 
123. Lee SJ, Zhang Y, Lee SD, et al. Targeting prostate cancer with conditionally 
replicative adenovirus using PSMA enhancer. Mol Ther 2004 Dec;10(6):1051-8. 
124. Lee SJ, Kim HS, Yu R, et al. Novel prostate-specific promoter derived from PSA 
and PSMA enhancers. Mol Ther 2002;6(3):415-21. 
125. Pan LC, Price PA. The effect of transcriptional inhibitors on the bone gamma-
carboxyglutamic acid protein response to 1,25-dihydroxyvitamin D3 in osteosarcoma 
cells. J Biol Chem 1984 May 10;259(9):5844-7. 
126. Jung C, Ou YC, Yeung F, Frierson HF, Jr., Kao C. Osteocalcin is incompletely 
spliced in non-osseous tissues. Gene 2001;271(2):143-50. 
127. Wu TT, Sikes RA, Cui Q, et al. Establishing human prostate cancer cell 
xenografts in bone: induction of osteoblastic reaction by PSA-producing tumors in 
athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. 
International Journal of Cancer 1998;In press. 
128. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer 
cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth 
in the bone environment. Prostate 1999 Jun 1;39(4):246-61. 
129. Bortell R, Owen TA, Bidwell JP, et al. Vitamin D-responsive protein-DNA 
interactions at multiple promoter regulatory elements that contribute to the level of rat 
osteocalcin gene expression. Proc Natl Acad Sci U S A 1992 Jul 1;89(13):6119-23. 
130. Lian JB, Stein GS, Stein JL, van Wijnen AJ. Regulated expression of the bone-
specific osteocalcin gene by vitamins and hormones. Vitam Horm 1999;55:443-509. 
131. Banerjee C, Stein JL, Van Wijnen AJ, Frenkel B, Lian JB, Stein GS. 
Transforming growth factor-beta 1 responsiveness of the rat osteocalcin gene is 
mediated by an activator protein-1 binding site. Endocrinology 1996 May;137(5):1991-
2000. 
132. Banerjee C, Hiebert SW, Stein JL, Lian JB, Stein GS. An AML-1 consensus 
sequence binds an osteoblast-specific complex and transcriptionally activates the 
osteocalcin gene. Proc Natl Acad Sci U S A 1996 May 14;93(10):4968-73. 
133. Ko SC, Cheon J, Kao C, et al. Osteocalcin promoter-based toxic gene therapy for 
the treatment of osteosarcoma in experimental models. Cancer Res 1996 Oct 
15;56(20):4614-9. 
134. Koeneman KS, Kao C, Ko SC, et al. Osteocalcin-directed gene therapy for 
prostate-cancer bone metastasis. World J Urol 2000;18(2):102-10. 
135. Kubo H, Gardner TA, Wada Y, et al. Phase I dose escalation clinical trial of 
adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine 
kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 
2003 Feb 10;14(3):227-41. 
136. Chiu CP, Harley CB. Replicative senescence and cell immortality: the role of 
telomeres and telomerase. Proc Soc Exp Biol Med 1997 Feb;214(2):99-106. 
137. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human 
telomerase activity with immortal cells and cancer. Science 1994 Dec 
23;266(5193):2011-5. 
138. Horikawa I, Cable PL, Afshari C, Barrett JC. Cloning and characterization of the 
promoter region of human telomerase reverse transcriptase gene. Cancer Res 1999 Feb 
15;59(4):826-30. 
110 
 
139. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS. 
Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 
1996 Jan 1;56(1):218-22. 
140. Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C. Phosphorylation-dependent 
ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. 
Embo J 2002 Aug 1;21(15):4037-48. 
141. Gu J, Andreeff M, Roth JA, Fang B. hTERT promoter induces tumor-specific Bax 
gene expression and cell killing in syngenic mouse tumor model and prevents systemic 
toxicity. Gene Ther 2002 Jan;9(1):30-7. 
142. Kawashima T, Kagawa S, Kobayashi N, et al. Telomerase-specific replication-
selective virotherapy for human cancer. Clin Cancer Res 2004 Jan 1;10(1 Pt 1):285-92. 
143. Office of Biotechnology Activities' Recombinant DNA and Gene Transfer Web 
Page, www4.od.nih.gov/oba/rdna.htm (Accession date: February 29, 2008). 
144. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997 Feb 
7;88(3):323-31. 
145. Sherr CJ. Cancer cell cycles. Science 1996 Dec 6;274(5293):1672-7. 
146. Downing SR, Russell PJ, Jackson P. Alterations of p53 are common in early 
stage prostate cancer. Can J Urol 2003 Aug;10(4):1924-33. 
147. Eastham JA, Stapleton AM, Gousse AE, et al. Association of p53 mutations with 
metastatic prostate cancer. Clin Cancer Res 1995 Oct;1(10):1111-8. 
148. Yang C, Cirielli C, Capogrossi MC, Passaniti A. Adenovirus-mediated Wild-Type 
p53 Expression Induces Apoptosis and Suppresses Tumorigenesis of Prostatic Tumor 
Cells. Cancer research 1995;55:4210-3. 
149. Eastham JA, Hall SJ, Sehgal I, et al. In vivo gene therapy with p53 or p21 
adenovirus for prostate cancer. Cancer Res 1995 Nov 15;55(22):5151-5. 
150. Ko SC, Gotoh A, Thalmann GN, et al. Molecular therapy with recombinant p53 
adenovirus in an androgen-independent, metastatic human prostate cancer model. Hum 
Gene Ther 1996 Sep 10;7(14):1683-91. 
151. Eastham JA, Grafton W, Martin CM, Williams BJ. Suppression of primary tumor 
growth and the progression to metastasis with p53 adenovirus in human prostate 
cancer. J Urol 2000 Sep;164(3 Pt 1):814-9. 
152. Hernandez I, Maddison LA, Wei Y, et al. Prostate-specific expression of 
p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer 
progression and prolong survival. Mol Cancer Res 2003 Dec;1(14):1036-47. 
153. Gurnani M, Lipari P, Dell J, Shi B, Nielsen LL. Adenovirus-mediated p53 gene 
therapy has greater efficacy when combined with chemotherapy against human head 
and neck, ovarian, prostate, and breast cancer. Cancer Chemother Pharmacol 
1999;44(2):143-51. 
154. Colletier PJ, Ashoori F, Cowen D, et al. Adenoviral-mediated p53 transgene 
expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to 
radiation. Int J Radiat Oncol Biol Phys 2000 Dec 1;48(5):1507-12. 
155. Sasaki R, Shirakawa T, Zhang ZJ, et al. Additional gene therapy with Ad5CMV-
p53 enhanced the efficacy of radiotherapy in human prostate cancer cells. Int J Radiat 
Oncol Biol Phys 2001 Dec 1;51(5):1336-45. 
156. Cowen D, Salem N, Ashoori F, et al. Prostate cancer radiosensitization in vivo 
with adenovirus-mediated p53 gene therapy. Clin Cancer Res 2000 Nov;6(11):4402-8. 
157. Pantuck AJ, Zisman A, Belldegrun AS. Gene therapy for prostate cancer at the 
University of California, Los Angeles: preliminary results and future directions. World J 
Urol 2000 Apr;18(2):143-7. 
158. Sweeney P, Pisters LL. Ad5CMVp53 gene therapy for locally advanced prostate 
cancer--where do we stand? World J Urol 2000 Apr;18(2):121-4. 
111 
 
159. Maki CG. Oligomerization is required for p53 to be efficiently ubiquitinated by 
MDM2. J Biol Chem 1999 Jun 4;274(23):16531-5. 
160. Fuchs SY, Adler V, Buschmann T, Wu X, Ronai Z. Mdm2 association with p53 
targets its ubiquitination. Oncogene 1998 Nov 12;17(19):2543-7. 
161. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of 
p53. Nature 1997 May 15;387(6630):296-9. 
162. Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein 
bound to the p53 tumor suppressor transactivation domain. Science 1996 Nov 
8;274(5289):948-53. 
163. Leite KR, Franco MF, Srougi M, et al. Abnormal expression of MDM2 in prostate 
carcinoma. Mod Pathol 2001 May;14(5):428-36. 
164. Zhang Z, Li M, Wang H, Agrawal S, Zhang R. Antisense therapy targeting MDM2 
oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene 
expression, and chemotherapy. Proc Natl Acad Sci U S A 2003 Sep 30;100(20):11636-
41. 
165. Wang H, Oliver P, Zhang Z, Agrawal S, Zhang R. Chemosensitization and 
radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro 
and in vivo activities and mechanisms. Ann N Y Acad Sci 2003 Dec;1002:217-35. 
166. Zhang Z, Wang H, Prasad G, et al. Radiosensitization by antisense anti-MDM2 
mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin 
Cancer Res 2004 Feb 15;10(4):1263-73. 
167. Mu Z, Hachem P, Agrawal S, Pollack A. Antisense MDM2 oligonucleotides 
restore the apoptotic response of prostate cancer cells to androgen deprivation. Prostate 
2004 Aug 1;60(3):187-96. 
168. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates 
the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998 
May 29;273(22):13375-8. 
169. Burgering BM, Kops GJ. Cell cycle and death control: long live Forkheads. 
Trends Biochem Sci 2002 Jul;27(7):352-60. 
170. Kotelevets L, van Hengel J, Bruyneel E, Mareel M, van Roy F, Chastre E. The 
lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and 
reverting invasiveness. J Cell Biol 2001 Dec 24;155(7):1129-35. 
171. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-
dependent cell survival by the tumor suppressor PTEN. Cell 1998 Oct 2;95(1):29-39. 
172. Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-
mediated gene expression. Genes Dev 2000 Feb 15;14(4):391-6. 
173. Davies MA, Kim SJ, Parikh NU, Dong Z, Bucana CD, Gallick GE. Adenoviral-
mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human 
prostate cancer cells. Clin Cancer Res 2002 Jun;8(6):1904-14. 
174. Rosser CJ, Tanaka M, Pisters LL, et al. Adenoviral-mediated PTEN transgene 
expression sensitizes Bcl-2-expressing prostate cancer cells to radiation. Cancer Gene 
Ther 2004 Apr;11(4):273-9. 
175. Tanaka M, Rosser CJ, Grossman HB. PTEN gene therapy induces growth 
inhibition and increases efficacy of chemotherapy in prostate cancer. Cancer Detect 
Prev 2005;29(2):170-4. 
176. Deng J, Xia W, Hung MC. Adenovirus 5 E1A-mediated tumor suppression 
associated with E1A-mediated apoptosis in vivo. Oncogene 1998 Oct 29;17(17):2167-
75. 
177. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates 
selectively in p53-deficient human tumor cells. Science 1996;274:373-6. 
112 
 
178. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn 
DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis 
and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. 
Nat Med 1997 Jun;3(6):639-45. 
179. Heise CC, Williams AM, Xue S, Propst M, Kirn DH. Intravenous administration of 
ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer 
Res 1999;59(11):2623-8. 
180. Ganly I, Kirn D, Eckhardt G, et al. A phase I study of Onyx-015, an E1B 
attenuated adenovirus, administered intratumorally to patients with recurrent head and 
neck cancer. Clin Cancer Res 2000 Mar;6(3):798-806. 
181. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration 
of ONYX-015, a replication-selective adenovirus, in patients with refractory head and 
neck cancer. J Clin Oncol 2001 Jan 15;19(2):289-98. 
182. Khuri FR, Nemunaitis J, Ganly I, et al. a controlled trial of intratumoral ONYX-
015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil 
in patients with recurrent head and neck cancer. Nat Med 2000 Aug;6(8):879-85. 
183. Hecht JR, Bedford R, Abbruzzese JL, et al. A phase I/II trial of intratumoral 
endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in 
unresectable pancreatic carcinoma. Clin Cancer Res 2003 Feb;9(2):555-61. 
184. Morley S, MacDonald G, Kirn D, Kaye S, Brown R, Soutar D. The dl1520 virus is 
found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. 
Clin Cancer Res 2004 Jul 1;10(13):4357-62. 
185. Reid TR, Freeman S, Post L, McCormick F, Sze DY. Effects of Onyx-015 among 
metastatic colorectal cancer patients that have failed prior treatment with 5-
FU/leucovorin. Cancer Gene Ther 2005 Aug;12(8):673-81. 
186. Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an 
E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary 
carcinomas of the pancreas: a phase I trial. Gene Ther 2001 Feb;8(4):308-15. 
187. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 
mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with 
advanced head and neck cancer: a phase II trial. Cancer Res 2000 Nov 15;60(22):6359-
66. 
188. Goodrum FD, Ornelles DA. p53 status does not determine outcome of E1B 55-
kilodalton mutant adenovirus lytic infection. Journal of virology 1998 Dec;72(12):9479-
90. 
189. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H. 
Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 
status in tumor cells. Journal of virology 1998 Dec;72(12):9470-8. 
190. Edwards SJ, Dix BR, Myers CJ, et al. Evidence that replication of the antitumor 
adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor 
genes. Journal of virology 2002 Dec;76(24):12483-90. 
191. O'Shea CC, Johnson L, Bagus B, et al. Late viral RNA export, rather than p53 
inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004 Dec;6(6):611-23. 
192. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged 
approach to kill cancer cells selectively: concomitant viral, double suicide gene, and 
radiotherapy. Hum Gene Ther 1998 Jun 10;9(9):1323-33. 
193. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. 
Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective 
cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 
1997;57(13):2559-63. 
113 
 
194. DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-
competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent 
prostate cancer following radiation therapy. Cancer Res 2001 Oct 15;61(20):7464-72. 
195. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus 
type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor 
xenografts. Cancer Res 1999;59(17):4200-3. 
196. Dilley J, Reddy S, Ko D, et al. Oncolytic adenovirus CG7870 in combination with 
radiation demonstrates synergistic enhancements of antitumor efficacy without loss of 
specificity. Cancer Gene Ther 2005 Aug;12(8):715-22. 
197. Yu DC, Chen Y, Dilley J, et al. Antitumor synergy of CV787, a prostate cancer-
specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001 Jan 15;61(2):517-
25. 
198. Matsubara S, Wada Y, Gardner TA, et al. A conditional replication-competent 
adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an 
experimental model of androgen-independent prostate cancer bone metastasis. Cancer 
Res 2001;61(16):6012-9. 
199. Hsieh CL, Yang L, Miao L, et al. A Novel Targeting Modality to Enhance 
Adenoviral Replication by Vitamin D(3) in Androgen-independent Human Prostate 
Cancer Cells and Tumors. Cancer Res 2002 Jun 1;62(11):3084-92. 
200. Konety BR, Johnson CS, Trump DL, Getzenberg RH. Vitamin D in the prevention 
and treatment of prostate cancer. Semin Urol Oncol 1999 May;17(2):77-84. 
201. Getzenberg RH, Light BW, Lapco PE, et al. Vitamin D inhibition of prostate 
adenocarcinoma growth and metastasis in the Dunning rat prostate model system. 
Urology 1997 Dec;50(6):999-1006. 
202. Zhao XY, Feldman D. The role of vitamin D in prostate cancer. Steroids 2001 
Mar-May;66(3-5):293-300. 
203. Doronin K, Kuppuswamy M, Toth K, et al. Tissue-specific, tumor-selective, 
replication-competent adenovirus vector for cancer gene therapy. Journal of virology 
2001 Apr;75(7):3314-24. 
204. Banerjee NS, Rivera AA, Wang M, et al. Analyses of melanoma-targeted 
oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in 
submerged cells and organotypic cultures. Molecular cancer therapeutics 2004 
Apr;3(4):437-49. 
205. Li X, Zhang YP, Kim HS, et al. Gene Therapy for Prostate Cancer by Controlling 
Adenovirus E1a and E4 Gene Expression with PSES Enhancer. Cancer Res 2005 Mar 
1;65(5):1941-51. 
206. Harrison D, Sauthoff H, Heitner S, Jagirdar J, Rom WN, Hay JG. Wild-type 
adenovirus decreases tumor xenograft growth, but despite viral persistence complete 
tumor responses are rarely achieved--deletion of the viral E1b-19-kD gene increases the 
viral oncolytic effect. Hum Gene Ther 2001 Jul 1;12(10):1323-32. 
207. Sauthoff H, Hu J, Maca C, et al. Intratumoral spread of wild-type adenovirus is 
limited after local injection of human xenograft tumors: virus persists and spreads 
systemically at late time points. Hum Gene Ther 2003 Mar 20;14(5):425-33. 
208. Shen BH, Hermiston TW. Effect of hypoxia on Ad5 infection, transgene 
expression and replication. Gene Ther 2005 Feb 3. 
209. Lee CT, Park KH, Yanagisawa K, et al. Combination therapy with conditionally 
replicating adenovirus and replication defective adenovirus. Cancer Res 2004 Sep 
15;64(18):6660-5. 
  
114 
 
210. Li X, Raikwar SP, Liu YH, et al. Combination therapy of androgen-independent 
prostate cancer using a prostate restricted replicative adenovirus and a replication-
defective adenovirus encoding human endostatin-angiostatin fusion gene. Molecular 
cancer therapeutics 2006 Mar;5(3):676-84. 
211. Li X, Liu YH, Lee SJ, Gardner TA, Jeng MH, Kao C. Prostate-restricted 
replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting 
dramatic antitumor efficacy. Clin Cancer Res 2008 Jan 1;14(1):291-9. 
212. Kleinberger T, Shenk T. Adenovirus E4orf4 protein binds to protein phosphatase 
2A, and the complex down regulates E1A-enhanced junB transcription. Journal of 
virology 1993 Dec;67(12):7556-60. 
213. Huang MM, Hearing P. Adenovirus early region 4 encodes two gene products 
with redundant effects in lytic infection. Journal of virology 1989 Jun;63(6):2605-15. 
214. Fang B, Eisensmith RC, Wang H, et al. Gene therapy for hemophilia B: host 
immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX 
expression. Hum Gene Ther 1995 Aug;6(8):1039-44. 
215. Kay MA, Meuse L, Gown AM, et al. Transient immunomodulation with anti-CD40 
ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-
mediated gene transfer into mouse liver. Proc Natl Acad Sci U S A 1997 Apr 
29;94(9):4686-91. 
216. Poller W, Schneider-Rasp S, Liebert U, et al. Stabilization of transgene 
expression by incorporation of E3 region genes into an adenoviral factor IX vector and 
by transient anti-CD4 treatment of the host. Gene Ther 1996 Jun;3(6):521-30. 
217. Kuzmin AI, Finegold MJ, Eisensmith RC. Macrophage depletion increases the 
safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo. Gene 
Ther 1997 Apr;4(4):309-16. 
218. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGF-beta 
inhibitors. Invest New Drugs 2003 Feb;21(1):21-32. 
219. O'Riordan CR, Lachapelle A, Delgado C, et al. PEGylation of adenovirus with 
retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum 
Gene Ther 1999 May 20;10(8):1349-58. 
220. Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol 
modification of first-generation and helper-dependent adenoviral vectors to reduce 
innate immune responses. Mol Ther 2005 Jan;11(1):66-79. 
221. Croyle MA, Chirmule N, Zhang Y, Wilson JM. "Stealth" adenoviruses blunt cell-
mediated and humoral immune responses against the virus and allow for significant 
gene expression upon readministration in the lung. Journal of virology 2001 
May;75(10):4792-801. 
222. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of 
cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. 
Proc Natl Acad Sci U S A 1996 Mar 5;93(5):1831-5. 
223. Eastham JA, Chen SH, Sehgal I, et al. Prostate cancer gene therapy: herpes 
simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and 
human prostate cancer models. Hum Gene Ther 1996 Mar 1;7(4):515-23. 
224. Cheon J, Kim HK, Moon DG, Yoon DK, Cho JH, Koh SK. Adenovirus-mediated 
suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and 
animal models of human prostate cancer: changes in tumour cell proliferative activity. 
BJU Int 2000 Apr;85(6):759-66. 
225. Hall SJ, Mutchnik SE, Chen SH, Woo SL, Thompson TC. Adenovirus-mediated 
herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic 
activity against spontaneous and induced metastasis in an orthotopic mouse model of 
prostate cancer. Int J Cancer 1997 Jan 17;70(2):183-7. 
115 
 
226. Hinata N, Shirakawa T, Terao S, et al. Progress report on phase I/II clinical trial 
of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial 
experience at Kobe University. Int J Urol 2006 Jun;13(6):834-7. 
227. Ahn M, Lee SJ, Li X, et al. Enhanced combined tumor-specific oncolysis and 
suicide gene therapy for prostate cancer using M6 promoter. Cancer Gene Ther 2008 
Sep 5. 
228. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent 
adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent 
prostate cancer. Cancer Res 2002 Sep 1;62(17):4968-76. 
229. Freytag SO, Paielli D, Wing M, et al. Efficacy and toxicity of replication-
competent adenovirus-mediated double suicide gene therapy in combination with 
radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol 
Phys 2002 Nov 1;54(3):873-85. 
230. Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent 
adenovirus-mediated double-suicide gene therapy in combination with conventional-
dose three-dimensional conformal radiation therapy for the treatment of newly 
diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 2003 Nov 
1;63(21):7497-506. 
231. Bander NH, Yao D, Liu H, et al. MHC class I and II expression in prostate 
carcinoma and modulation by interferon-alpha and -gamma. Prostate 1997 Dec 
1;33(4):233-9. 
232. Kwon ED, Hurwitz AA, Foster BA, et al. Manipulation of T cell costimulatory and 
inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 1997 
Jul 22;94(15):8099-103. 
233. Sanda MG, Ayyagari SR, Jaffee EM, et al. Demonstration of a rational strategy 
for human prostate cancer gene therapy. J Urol 1994 Mar;151(3):622-8. 
234. Vieweg J, Rosenthal FM, Bannerji R, et al. Immunotherapy of prostate cancer in 
the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 1994 
Apr 1;54(7):1760-5. 
235. Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer 
antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor 
cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex 
vivo gene transfer. Cancer Res 1999 Oct 15;59(20):5160-8. 
236. Simmons SJ, Tjoa BA, Rogers M, et al. GM-CSF as a systemic adjuvant in a 
phase II prostate cancer vaccine trial. Prostate 1999 Jun 1;39(4):291-7. 
237. Simons JW, Nelson W, Nemunaitis J, et al. Phase II trials of a GM-CSF gene-
transduced prostate cancer cell vaccine (GVAX) in hormone refractory prostate cancer. 
Proc Am Soc Clin Oncol 2002;21:729A. 
238. Simons JW, Higano C, Corman J, et al. A phase I/II study of high dose allogeneic 
GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic 
hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 2003;22:166A. 
239. Tjoa B, Boynton A, Kenny G, Ragde H, Misrock SL, Murphy G. Presentation of 
prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. 
Prostate 1996 Jan;28(1):65-9. 
240. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell 
therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-
specific peptides from prostate-specific membrane antigen. Prostate 1996 
Dec;29(6):371-80. 
241. Tjoa BA, Erickson SJ, Bowes VA, et al. Follow-up evaluation of prostate cancer 
patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 
1997 Sep 1;32(4):272-8. 
116 
 
242. Tjoa BA, Simmons SJ, Elgamal A, et al. Follow-up evaluation of a phase II 
prostate cancer vaccine trial. Prostate 1999 Jul 1;40(2):125-9. 
243. Triest JA, Grignon DJ, Cher ML, et al. Systemic interleukin 2 therapy for human 
prostate tumors in a nude mouse model. Clin Cancer Res 1998 Aug;4(8):2009-14. 
244. Belldegrun A, Tso CL, Zisman A, et al. Interleukin 2 gene therapy for prostate 
cancer: phase I clinical trial and basic biology. Hum Gene Ther 2001 May 20;12(8):883-
92. 
245. Trudel S, Trachtenberg J, Toi A, et al. A phase I trial of adenovector-mediated 
delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene 
Ther 2003 Oct;10(10):755-63. 
246. Hu HM, Winter H, Ma J, Croft M, Urba WJ, Fox BA. CD28, TNF receptor, and IL-
12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells. 
J Immunol 2002 Nov 1;169(9):4897-904. 
247. Sunamura M, Sun L, Lozonschi L, et al. The antiangiogenesis effect of interleukin 
12 during early growth of human pancreatic cancer in SCID mice. Pancreas 2000 
Apr;20(3):227-33. 
248. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified 
system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 
1998;95(5):2509-14. 
249. Fallaux FJ, Kranenburg O, Cramer SJ, et al. Characterization of 911: a new 
helper cell line for the titration and propagation of early region 1-deleted adenoviral 
vectors. Hum Gene Ther 1996 Jan 20;7(2):215-22. 
250. Sramkoski RM, Pretlow TG, 2nd, Giaconia JM, et al. A new human prostate 
carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999;35(7):403-9. 
251. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic 
carcinoma. Cancer Res 1983 Apr;43(4):1809-18. 
252. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of 
androgen-independent human LNCaP prostatic cancer cell sublines: role of bone 
stromal cells. Int J Cancer 1994 May 1;57(3):406-12. 
253. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and 
characterization of a human prostatic carcinoma cell line (PC-3). Invest Urology 
1979;17:16-23. 
254. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human 
prostate carcinoma cell line (DU145). Int J Cancer 1978;21:274-81. 
255. Drewinko B, Yang LY, Barlogie B, et al. Further biologic characteristics of a 
human carcinoembryonic antigen-producing colon carcinoma cell line. J Natl Cancer Inst 
1978 Jul;61(1):75-83. 
256. Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H, Donner J. 
Established cell line of urinary bladder carcinoma (T24) containing tumour-specific 
antigen. Int J Cancer 1973 May;11(3):765-73. 
257. Moyer MP, Manzano LA, Merriman RL, Stauffer JS, Tanzer LR. NCM460, a 
normal human colon mucosal epithelial cell line. In Vitro Cell Dev Biol Anim 1996 
Jun;32(6):315-7. 
258. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical 
disease-free and cancer-specific survival following anatomic radical retropubic 
prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001 
Aug;28(3):555-65. 
259. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine 
compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N 
Engl J Med 2004 Oct 7;351(15):1513-20. 
117 
 
260. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or 
mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 Oct 
7;351(15):1502-12. 
261. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a 
new member of the TNF family that induces apoptosis. Immunity 1995 Dec;3(6):673-82. 
262. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction 
of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine 
family. J Biol Chem 1996 May 31;271(22):12687-90. 
263. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand 
TRAIL. Science 1997 Apr 4;276(5309):111-3. 
264. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and 
a death domain-containing receptor for TRAIL. Science 1997 Aug 8;277(5327):815-8. 
265. Kuang AA, Diehl GE, Zhang J, Winoto A. FADD is required for DR4- and DR5-
mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic 
fibroblasts. J Biol Chem 2000 Aug 18;275(33):25065-8. 
266. Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-
related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural 
killer cells. Nat Med 2001 Jan;7(1):94-100. 
267. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. 
The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated 
apoptosis, yet retains an incomplete death domain. Immunity 1997 Dec;7(6):813-20. 
268. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the 
cytotoxic ligand TRAIL. J Biol Chem 1998 Jun 5;273(23):14363-7. 
269. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated AKT 
activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J 
Biol Chem 2001 Apr 6;276(14):10767-74. 
270. Voelkel-Johnson C, King DL, Norris JS. Resistance of prostate cancer cells to 
soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by 
doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther 2002 
Feb;9(2):164-72. 
271. Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with 
chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. 
Prostate 2005 Feb 1;62(2):165-86. 
272. Shankar S, Singh TR, Srivastava RK. Ionizing radiation enhances the therapeutic 
potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. 
Prostate 2004 Sep 15;61(1):35-49. 
273. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant 
soluble Apo2 ligand. The Journal of clinical investigation 1999 Jul;104(2):155-62. 
274. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-
related apoptosis-inducing ligand in vivo. Nat Med 1999 Feb;5(2):157-63. 
275. Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes 
by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000 May;6(5):564-
7. 
276. Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of 
recombinant Apo2L/TRAIL versions. Nat Med 2001 Apr;7(4):383-5. 
277. Bruder JT, Appiah A, Kirkman WM, 3rd, et al. Improved production of adenovirus 
vectors expressing apoptotic transgenes. Hum Gene Ther 2000 Jan 1;11(1):139-49. 
278. Griffith TS, Broghammer EL. Suppression of tumor growth following intralesional 
therapy with TRAIL recombinant adenovirus. Mol Ther 2001 Sep;4(3):257-66. 
118 
 
279. Hu B, Zhu H, Qiu S, et al. Enhanced TRAIL sensitivity by E1A expression in 
human cancer and normal cell lines: inhibition by adenovirus E1B19K and E3 proteins. 
Biochem Biophys Res Commun 2004 Dec 24;325(4):1153-62. 
280. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen 
suppression and external irradiation in patients with locally advanced prostate cancer 
(an EORTC study): a phase III randomised trial. Lancet 2002 Jul 13;360(9327):103-6. 
281. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-
month androgen suppression plus radiation therapy vs radiation therapy alone for 
patients with clinically localized prostate cancer: a randomized controlled trial. Jama 
2004 Aug 18;292(7):821-7. 
282. Swanson GP, Thompson IM, Tangen C, et al. Phase III Randomized Study of 
Adjuvant Radiation Therapy versus Oservation in Patients with Pathologic T3 Prostate 
Cancer (SWOG 8794). Int J Radiat Oncol Biol Phys 2005;6(Supplement 1):S1. 
283. Kupelian P, Thames H, Levy L, et al. Year of treatment as independent predictor 
of relapse-free survival in patients with localized prostate cancer treated with definitive 
radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2005 Nov 1;63(3):795-9. 
284. Kupelian PA, Buchsbaum JC, Elshaikh M, Reddy CA, Zippe C, Klein EA. Factors 
affecting recurrence rates after prostatectomy or radiotherapy in localized prostate 
carcinoma patients with biopsy Gleason score 8 or above. Cancer 2002 Dec 
1;95(11):2302-7. 
285. Cooper JS, Ang KK. Concomitant chemotherapy and radiation therapy certainly 
improves local control. Int J Radiat Oncol Biol Phys 2005 Jan 1;61(1):7-9. 
286. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without 
concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 
2004 May 6;350(19):1945-52. 
287. Sause W, Kolesar P, Taylor SI, et al. Final results of phase III trial in regionally 
advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, 
Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000 
Feb;117(2):358-64. 
288. Pearcey R, Brundage M, Drouin P, et al. Phase III trial comparing radical 
radiotherapy with and without cisplatin chemotherapy in patients with advanced 
squamous cell cancer of the cervix. J Clin Oncol 2002 Feb 15;20(4):966-72. 
289. Kumar P, Perrotti M, Weiss R, et al. Phase I trial of weekly docetaxel with 
concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable 
localized adenocarcinoma of the prostate. J Clin Oncol 2004 May 15;22(10):1909-15. 
290. Perrotti M, Doyle T, Kumar P, et al. Phase I/II trial of docetaxel and concurrent 
radiation therapy in localized high risk prostate cancer (AGUSG 03-10). Urol Oncol 2008 
May-Jun;26(3):276-80. 
291. Gong B, Almasan A. Apo2 ligand/TNF-related apoptosis-inducing ligand and 
death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in 
leukemic cells. Cancer Res 2000 Oct 15;60(20):5754-60. 
292. Unnithan J, Macklis RM. TRAIL induction by radiation in lymphoma patients. 
Cancer investigation 2004;22(4):522-5. 
293. Finnberg N, Gruber JJ, Fei P, et al. DR5 knockout mice are compromised in 
radiation-induced apoptosis. Molecular and cellular biology 2005 Mar;25(5):2000-13. 
294. Wendt J, von Haefen C, Hemmati P, Belka C, Dorken B, Daniel PT. TRAIL 
sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent 
mitochondrial cell death pathway. Oncogene 2005 Jun 9;24(25):4052-64. 
  
119 
 
295. Abou El Hassan MA, Mastenbroek DC, Gerritsen WR, Giaccone G, Kruyt FA. 
Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of 
NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-
length TRAIL. British journal of cancer 2004 Jul 5;91(1):171-7. 
296. Wissink EH, Verbrugge I, Vink SR, et al. TRAIL enhances efficacy of 
radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. Radiother 
Oncol 2006 Aug;80(2):214-22. 
297. Chang JY, Zhang X, Komaki R, Cheung R, Fang B. Tumor-specific apoptotic 
gene targeting overcomes radiation resistance in esophageal adenocarcinoma. Int J 
Radiat Oncol Biol Phys 2006 Apr 1;64(5):1482-94. 
298. Zhang X, Cheung RM, Komaki R, Fang B, Chang JY. Radiotherapy sensitization 
by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-
small cell lung cancer. Clin Cancer Res 2005 Sep 15;11(18):6657-68. 
299. Kaliberov SA, Kaliberova LN, Stockard CR, Grizzle WE, Buchsbaum DJ. 
Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate 
cancer. Mol Ther 2004 Dec;10(6):1059-70. 
300. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to 
radiotherapy. Int J Radiat Oncol Biol Phys 2004 Jul 15;59(4):928-42. 
301. van Beusechem VW, van den Doel PB, Grill J, Pinedo HM, Gerritsen WR. 
Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic 
potency. Cancer Res 2002 Nov 1;62(21):6165-71. 
302. Hallenbeck PL, Chang YN, Hay C, et al. A novel tumor-specific replication-
restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene 
Ther 1999;10(10):1721-33. 
303. Mi J, Li ZY, Ni S, Steinwaerder D, Lieber A. Induced apoptosis supports spread 
of adenovirus vectors in tumors. Hum Gene Ther 2001 Jul 1;12(10):1343-52. 
304. Steinwaerder DS, Carlson CA, Otto DL, Li ZY, Ni S, Lieber A. Tumor-specific 
gene expression in hepatic metastases by a replication-activated adenovirus vector. Nat 
Med 2001 Feb;7(2):240-3. 
305. Qiu S, Ruan H, Pei Z, et al. Combination of Targeting Gene-ViroTherapy with 5-
FU enhances antitumor efficacy in malignant colorectal carcinoma. J Interferon Cytokine 
Res 2004 Apr;24(4):219-30. 
306. Dong F, Wang L, Davis JJ, et al. Eliminating established tumor in nu/nu nude 
mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic 
adenovirus. Clin Cancer Res 2006 Sep 1;12(17):5224-30. 
307. Ren XW, Liang M, Meng X, et al. A tumor-specific conditionally replicative 
adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma. 
Cancer Gene Ther 2006 Feb;13(2):159-68. 
308. Stevens CW, Zeng M, Cerniglia GJ. Ionizing radiation greatly improves gene 
transfer efficiency in mammalian cells. Hum Gene Ther 1996 Sep 10;7(14):1727-34. 
309. Zeng M, Cerniglia GJ, Eck SL, Stevens CW. High-efficiency stable gene transfer 
of adenovirus into mammalian cells using ionizing radiation. Hum Gene Ther 1997 Jun 
10;8(9):1025-32. 
310. Marini P, Jendrossek V, Durand E, Gruber C, Budach W, Belka C. Molecular 
requirements for the combined effects of TRAIL and ionising radiation. Radiother Oncol 
2003 Aug;68(2):189-98. 
311. Zhang J, Kabra NH, Cado D, Kang C, Winoto A. FADD-deficient T cells exhibit a 
disaccord in regulation of the cell cycle machinery. J Biol Chem 2001 Aug 
10;276(32):29815-8. 
120 
 
312. Alappat EC, Feig C, Boyerinas B, et al. Phosphorylation of FADD at serine 194 
by CKIalpha regulates its nonapoptotic activities. Molecular cell 2005 Aug 5;19(3):321-
32. 
313. Scaffidi C, Volkland J, Blomberg I, Hoffmann I, Krammer PH, Peter ME. 
Phosphorylation of FADD/ MORT1 at serine 194 and association with a 70-kDa cell 
cycle-regulated protein kinase. J Immunol 2000 Feb 1;164(3):1236-42. 
314. Shimada K, Nakamura M, Ishida E, Konishi N. Molecular roles of MAP kinases 
and FADD phosphorylation in prostate cancer. Histol Histopathol 2006 Apr;21(4):415-22. 
315. Kim M, Liao J, Dowling ML, et al. TRAIL inactivates the mitotic checkpoint and 
potentiates death induced by microtubule-targeting agents in human cancer cells. 
Cancer Res 2008 May 1;68(9):3440-9. 
 
 Curriculum Vitae 
 
 
 
Juan Antonio Jiménez 
 
Education: 
M.D.  (2010)  Indiana University School of Medicine, Indianapolis, IN. 
Ph.D.  2008  Indiana University, Indianapolis, IN. 
         Microbiology and Immunology 
B.S.  2002  Indiana University, Bloomington, IN. 
         Microbiology 
 
Professional Experience: 
2002 – present  Research Associate 
Department of Urology Research Laboratory, Indiana       
      University Medical Center, Indianapolis, IN. 
2005 – present Physician Extern, Chief 
         Department of Emergency Medicine, Henry County Hospital, 
         New Castle, IN. 
2005 (Fall)  Associate Instructor 
Department of Microbiology, Indiana University School of   
      Medicine, Indianapolis, IN. 
 
Awards: 
2008 – present NIH Medical Scientist Training Program, 1T32GM077229-01A1. 
2003 – 2008  NIH National Research Service Award Individual Fellowship, 
      NCI 1F31CA106215-01, Principle Investigator. 
2002   NIH Students in Health Professions, Short Term Training Grant, 
         T35HL07584-17. 
 
Publications: 
1. Jiménez, JA, Li, X, Zhang, YP, Bae, KH, Mohammadi, Y, Pandya, P, Kao, C and 
Gardner, TA: Antitumor activity of Ad-IU2, a prostate-specific replication-competent 
adenovirus encoding the apoptosis inducer, TRAIL. Cancer Gene Ther (Submitted). 
2. Jiménez, JA, Mohammadi, Y, Zhang, YP, Mendonca, MS, Ko, SC, Kao, C, Gardner, 
TA: Radio-sensitization of androgen-independent prostate cancer by TRAIL gene 
therapy. (In progress). 
3. Mellon MJ, Bae KH, Steding CE, Jiménez JA, Kao C and Gardner TA: Suppression 
of renal cell carcinoma growth and metastasis with sustained antiangiogenic gene 
therapy. Hum Gene Ther. 19: 487-95, 2008. 
4. Mellon MJ, Ahn M, Jiménez JA, Kao C and Gardner TA: Anti-angiogenic gene 
therapy for metastatic renal cell carcinoma produces tumor growth suppression in an 
athymic nude mouse model. J Urol. 179: 737-42, 2008. 
5. Ahn M, Lee SJ, Li X, Jiménez JA, Zhang YP, Bae KH, Mohammadi Y, Kao C and 
Gardner TA: Enhanced combined tumor-specific oncolysis and suicide gene therapy 
for prostate cancer using M6 promoter. Cancer Gene Ther, 2008. 
6. Jiménez, JA, Li, X, Gardner, TA, and Kao, C: Gene Therapy for Advanced Prostate 
Cancer. Prostate Cancer: Novel Biology, Genetics and Therapeutics. 2nd Edition. 
2007. 
 7. Li, X, Steding, CE, Jiménez, JA, Gardner, TA, and Kao, C: Development of prostate-
restricted replication-competent adenoviral vectors. Cancer and Gene Therapy, 
2007. 
8. Jiménez JA, Kao C, Raikwar S and Gardner TA: Current status of anti-angiogenesis 
therapy for prostate cancer. Urol Oncol. 24: 260-8, 2006. 
9. Desai P, Jiménez JA, Kao C and Gardner TA: Future innovations in treating 
advanced prostate cancer. Urol Clin North Am. 33: 247-72, viii, 2006. 
10. Jiménez, JA, Kao, C, Lee, SJ, Jung, C, and Gardner, TA:, Gene Therapy for 
Prostate Cancer.  Prostate Cancer: Basic Mechanisms and Therapeutic approaches. 
2005. 
11. Li X, Zhang YP, Kim HS, Bae KH, Stantz KM, Lee SJ, Jung C, Jiménez JA, Gardner 
TA, Jeng MH et al.: Gene therapy for prostate cancer by controlling adenovirus E1a 
and E4 gene expression with PSES enhancer. Cancer Res. 65: 1941-51, 2005. 
12. Gardner, TA, Jiménez, JA, Chung, LWK, and Kao, C: Antimetastatic Gene Therapy: 
Prostate Cancer Theory to Therapy. Cancer Gene Therapy. 2004. 
13. Cho YM, Woodard GL, Dunbar M, Gocken T, Jiménez JA and Foley J: Hair-cycle-
dependent expression of parathyroid hormone-related protein and its type I receptor: 
evidence for regulation at the anagen to catagen transition. J Invest Dermatol. 120: 
715-27, 2003. 
14. Foley J, King CS, Jiménez JA, Wysolmerski JJ and Philbrick WM: Activation of 
PTHrP gene expression in squamous carcinoma cell lines by mutant isoforms of the 
tumor suppressor p53. Oncol Res. 12: 71-81, 2000. 
 
Abstracts: 
1. American Society for Therapeutic Radiology and Oncology, Boston, MA, September 
2008.  Oral presentation. 
2. American Society of Gene Therapy, Boston, MA, May 2008.  Poster. 
3. American Urologic Association, Orlando, Fl, May 2008.  Poster. 
4. American Society of Clinical Oncology Genitourinary Cancers Symposium, San 
Francisco, CA, February 2008.  Poster. 
5. Department of Defense Innovative Minds in Prostate Cancer Today, Atlanta, GA, 
September, 2007.  Poster. 
6. American Society of Clinical Oncology Prostate Cancer Symposium, San Franscisco, 
CA, February 2007.  Poster. 
7. International Emerging Technologies in Drug and Gene-based Therapeutics 
Conference, Crete, Greece, September 2005. Oral presentation. 
